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Abstract
Clusterin (CLU) was the first described extracellular mammalian chaperone and can
interact with misfolded proteins to stabilise them in a soluble form, until the bound
protein can be re-folded or degraded. In the last twenty years there has been an interest
in using chaperones as adjuvants of the immune system. Numerous, mainly
intracellular, chaperones have been investigated in this context and some are able to
elicit a specific, cytotoxic T lymphocyte (CTL) response and in some cases a humoral
response against bound antigens.
The first aim of this project was to develop a chaperone-active form of recombinant
CLU (rCLU), as forms of rCLU described in published reports or currently
commercially available have not been thoroughly characterised or tested for chaperone
activity, and in many cases are impure. A bacterial expression system was first
investigated which yielded high molecular weight aggregates of rCLU; the protein was
not glycosylated or cleaved into α- and β-chains, and lacked chaperone activity. A
mammalian expression system was next trialled; previous attempts in our laboratory to
produce pure rCLU by mammalian expression failed due to the chaperone activity
of CLU resulting in it binding to misfolded proteins in the culture medium, which then
co-purified with the rCLU. Therefore an innovative approach was required to overcome
this problem, whereby a polyclonal culture of HEK293 cells expressing rCLU were
allowed to adhere to the surface of tissue culture flasks in medium containing foetal
calf serum (FCS), before replacement with FCS-free media. Under these conditions
cells remained attached to the flask surface and secreted rCLU into the medium until
dead. Using this approach, rCLU was successfully expressed and purified, and shown to
have chaperone activity comparable to that of wild type (wt)CLU; there were only
minor client protein-specific differences in activity between the rCLU and wtCLU that
may be attributable to differences in glycosylation between the two forms of CLU.
The mechanism by which chemically linked complexes formed between CLU and
ovalbumin (i.e. CLU-OVA) were bound and internalised by a range of cells was next
investigated. CLU-OVA and wtCLU showed significantly higher binding to murine
bone marrow derived macrophages, human granulocytes, monocytes and to a lower
extent lymphocytes, than OVA or control ligands. Confocal microscopy studies
indicated that CLU-OVA was rapidly internalised by murine bone marrow derived
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macrophages, in less than 15 min, and subsequently co-localised with both early
endosomes and lysosomes. The binding of CLU-OVA was inhibitable by fucoidan and
polyinosinic acid, implicating scavenger receptors in the uptake CLU-OVA into these
cell types.
The final aim of the project was to determine whether CLU could act as an adjuvant of
the immune system, to elicit both a CTL response and a humoral response when bound
to the model antigen OVA. The results obtained from an in vivo cytolysis assay suggest
that injection with CLU-OVA or CLU-OVA and a strong adjuvant (Complete Freund’s
Adjuvant; CFA) is able to stimulate an OVA-specific CTL response. Relative to mice
immunised with OVA or PBS alone, the levels of interleukin 2 and interferon gamma
contained within CD8+ T cells isolated from the draining lymph nodes and secreted
from cells obtained from the draining lymph nodes or spleen were significantly greater
in mice immunised with CLU-OVA + CFA, suggesting that the CD8+ T cells from this
treatment group were undergoing the highest levels of proliferation and had the highest
gain of (CTL) effector function. These experiments, however, need to be repeated with
more replicates to confirm these interpretations. Following immunisation with
CLU-OVA or CLU/OVA (complexes formed using the chaperone action of CLU), mice
mounted a mature immune response to OVA of a predominantly IgG1 isotype.
Immunisation with CLU-OVA and CLU/OVA also significantly enhanced the
production of OVA-specific IgM antibodies compared to mice immunised with OVA,
or other controls.
The results from this study provide a practical method to successfully express and
purify chaperone active, correctly post-translationally modified rCLU, thereby opening
the path for future studies to identify functional sites within CLU. It also provides a
theoretically unlimited supply of rCLU which may find future application in the
development of therapeutics. Similar to the results obtained for intracellular chaperones
that act as adjuvants of the immune system, CLU appears to direct bound proteins for
uptake by a wide range of cells via scavenger receptors. Further work is required to
definitively establish whether CLU can induce an antigen specific CTL response, as is
suggested by the results of this study. If CLU is able to activate both a CTL and an
antibody response to bound antigen, then CLU may provide a useful vector for the
development of vaccines to overcome the current limitations of vaccines based on the
use of intracellular chaperones.
v
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Chapter 1: Introduction

1 Roles of Chaperones in Proteostasis and
Immune Modulation
1.1

General Introduction

Clusterin (CLU) was the first described extracellular chaperone (EC) with an activity
similar to that of the intracellular small heat shock proteins (sHSPs) (Humphreys et al.
1999). Chaperones are proteins that are able to interact with partially unfolded (stressed,
non-native) proteins to stabilise their structure and hold them in a soluble state, until
the bound protein can be re-folded or degraded (Ellis 1987; Ellis 1996; Ellis 2000). In
the last twenty years there has been an interest in using chaperones as adjuvants of
the immune system. Numerous chaperones have been investigated in this context and
many are able to elicit a specific, cytotoxic T lymphocyte (CTL) response against
chaperoned client proteins. Therefore, they have therapeutic potential in that they could
be used to stimulate an immune response against tumour cells, or cells infected by
viruses or bacteria (Navaratnam et al. 2001; Zugel et al. 2001; Li et al. 2002). For
successful anti-cancer treatments, including vaccines, it is thought that the generation of
a CTL response is important (Boon et al. 1994). The majority of chaperones that have
been shown to stimulate CTL responses are normally found intracellularly, but many
have putative extra “moonlighting” functions in the extracellular space. This PhD
project includes an investigation of whether CLU is able to induce a humoral response
against bound peptides and, like other chaperones, can also stimulate a CTL response.
This chapter reviews the function of chaperones in the context of protein structure and
folding, and with respect to their recently discovered ability to manipulate the immune
system.
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1.2

Protein Structure and Folding

In order for proteins to function properly they must be correctly folded. It is the unique
3-dimensional structure of proteins that allows them to perform the vast array of
functions they undertake in the body. Consequently, many biological problems can arise
when proteins are incorrectly folded or partially unfold during conditions of stress.

1.2.1

Protein Structure

Protein structure can be categorised into four distinct levels; primary, secondary, tertiary
and quaternary, in order of increasing scale. The primary structure of a protein consists
of the amino acid sequence which is determined by the encoding gene. Each amino acid
has an inherent character determined by the nature of the side chain attached to the
alpha carbon. Some amino acids are inherently hydrophobic and therefore tend to be
located deep within the core of the protein. In contrast, hydrophilic amino acids are
often exposed on the surface of the protein where they are free to interact with the
surrounding aqueous environment. The side chains of amino acids can also help
determine the secondary structure of the protein. They may possess a negative or
positive charge which will repel similarly charged groups, or attract oppositely charged
groups. They may be bulky or rigid limiting the flexibility around the peptide bond or
creating physical distance from neighbouring amino acids (Lins and Brasseur 1995).
Together these properties help to dictate which portions of the amino acid sequence will
form particular secondary structures such as α-helices, β-sheets, β-turns or random-coil
regions. These inherent characteristics of the amino acids also influence the final
orientations of the secondary structures which in turn affect the tertiary (3-dimensional
shape) and quaternary structures of the protein (the latter involves the formation of
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multi-subunit complexes from multiple polypeptide chains). This means that ultimately
the amino acid sequence of the protein is able to dictate its final structure and function
(Anfinsen 1973).

1.2.2

Protein Folding

The native state of a protein generally corresponds to the most thermodynamically
stable structure, that which has the lowest energy (Anfinsen 1973). This structure
provides for stability and function in often crowded intracellular compartments and
‘stressful’ extracellular spaces. Some small and simple proteins, less than 100 amino
acid residues in length, are able to spontaneously fold via a 2-state folding pathway,
whereby there is a direct transition from a high energy state to a correctly folded, native,
low energy state (Jackson and Fersht 1991). This is generally quick and can occur in
less than 50 µs (Mayor et al. 2003; Yang and Gruebele 2003). In contrast, larger and
more complex proteins often fold by a slower 3-state folding pathway traversing a
molten-globule transition state (Hamada et al. 2000). The molten-globule transition
state contains secondary structures with substantial native-like local interactions, but
lacks tertiary and quaternary structures characteristic of the mature protein. The
formation of the molten globule is fast and usually occurs within a few milliseconds.
The second slower step, taking up to 1 s, is characterised by a gradual adoption of the
tertiary structure of the protein. During folding, some proteins may primarily occupy a
single transition state or utilise many alternative molten-globule structures (Anfinsen
1973; Dill 1990; Sali et al. 1994; Branden and Tooze 1999; Hartl et al. 2011).
Many proteins need the assistance of chaperones (which are discussed later) to
efficiently achieve their native conformation within a biologically relevant timescale
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(Ellis 1996; Radford 2000). Without assistance, many proteins would fail to
achieve their mature functional state (Hartl 1996). As all proteins are synthesised and
initially folded within the cell it is the intracellular chaperones that play a crucial role in
this process. During the transition between their unfolded and native states, proteins
progress through a funnel-shaped free energy landscape (Figure 1.1).

Figure 1.1 Folding funnel free-energy pathway of nascent/unfolded proteins. Proteins
pass along the free-energy surface as they head towards their native conformation (green)
by forming inter-molecular contacts. Proteins may accumulate in kinetically trapped
conformations and require the help of intracellular chaperones (in purple) to traverse
free-energy barriers and to reach a favourable downhill path. If many unfolded
intermediates are present in the same area, undesirable associations between protein
molecules may occur resulting in amorphous aggregates and amyloid fibrils (red). When
in sufficient amounts, molecular chaperones can prevent and/or limit these undesirable
inter-molecular associations. Modified from Hartl et al. 2011.(Hartl et al. 2011)
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Proteins can become trapped in partially folded states and this is one scenario in which
chaperones may act. Intracellular chaperones are able to provide energy and assistance
to proteins allowing them to overcome free-energy barriers and progress towards an
energetically favourable downhill path (Figure 1.1). Chaperones can also protect
proteins at risk of inappropriately interacting with other protein molecules and ‘rescue’
them from forming amorphous or amyloid aggregates (see next section).

1.2.3

Protein Unfolding and Misfolding

Under conditions of stress, proteins may unfold (lose structure) or misfold (adopt
incorrect structure) to expose previously hidden hydrophobic residues to the
surrounding aqueous environment. Stresses that may induce these changes include
elevated temperature, oxidative stress, changes in pH, and macromolecular crowding,
which ultimately destabilise the native conformation of proteins (Minton 1994; Stefani
and Dobson 2003). Proteins may encounter these stresses often, although extremes are
usually associated with various disease states, such as inflammation. Proteins may also
be misfolded if there are errors in the encoding gene, causing amino acid substitutions
which can result in altered structural characteristics or problems arising during
transcription and/or translation (Stefani and Dobson 2003). Evolution has selected
amino acid sequences in proteins that minimise the tendency to aggregate when not in
the native conformation. Protein database analyses indicate that sequences which would
favour aggregation, such as those containing alternating polar and non-polar amino acid
side chains or clusters of hydrophobic residues, occur less frequently than would be
expected on the basis of chance alone (Broome and Hecht 2000; Schwartz et al. 2001).
Various control mechanisms are in place both within the cell and in the extracellular
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space to help stabilise stressed proteins and minimise inappropriate interactions - these
include chaperones. When protein structure is destabilised, the exposure of hydrophobic
regions to the aqueous solvent increases the propensity of proteins to aggregate. If
this is not controlled, it can result in the deposition of insoluble protein aggregates in
various body tissues. These aggregates may either have an amorphous or amyloid-like
structure (Figure 1.2). Amorphous aggregates are characterised by an unstructured
amassing of unfolded and misfolded protein molecules, forming large irregular clusters
with a granular appearance when examined by transmission electron microscopy
(TEM). In contrast, amyloid aggregates contain highly ordered repeating β-sheet
units which are aligned in a plane perpendicular to the fibre axis. They display a
characteristic cross-β X-ray fibre diffraction pattern and, due to their high β-sheet
content, the formation of these aggregates may be monitored by the use of dyes such as
thioflavin T that fluoresce when bound to β-sheets. When examined by TEM, amyloid
aggregates typically display a thread like, filamentous structure. Once a critical size is
reached by either type of aggregate they become insoluble and may deposit inside the
cell or in the extracellular space (Figure 1.2).
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Figure 1.2 Pathways of protein unfolding and aggregation. Upon exposure to stress, native
proteins unfold to form non-native structures which may associate to form aggregates. As
the aggregates increase in size they decrease in solubility, eventually becoming insoluble
and may deposit either within the cell or in the extracellular space. TEM images of
aggregates kindly provided by Dr. Justin Yerbury (University of Wollongong, Australia).
Orange scale bars on the TEM images represent 500 nm.

These type of deposits are associated with many disease states collectively termed
protein conformational diseases (Thomas et al. 1995) which include, amongst many
others, Alzheimer’s disease, Parkinson’s disease, cataract, prion diseases and
Creutzfeldt-Jakob disease (Stefani and Dobson 2003).
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1.2.4

Protein Unfolding and Disease

Protein conformational diseases result from the deposition of insoluble aggregates
within various tissues in the body, either within the cell or in the extracellular space.
These protein aggregates may arise from (i) genetic errors - whereby mutations in the
gene encoding the protein prevent the protein from achieving its native conformation, or
(ii) conditions of stress in the body - which induce the unfolding and subsequent
aggregation of susceptible proteins. Incorrect folding of proteins can sometimes result
in a toxic gain of function, rather than a simple loss of normal function. Insoluble
aggregates generally result from the surface exposure of hydrophobic residues on
protein molecules and subsequent inter-molecular associations. As most protein
conformational diseases are age-related and late-onset (Carrell 2005), it has been
suggested that they result from protein aggregation processes overwhelming the
capacity of proteostasis (protein homeostasis) systems, which decline with age.
Some proteins are inherently stable and maintain native conformation even under the
most extreme of conditions; these proteins are unlikely to be involved in disease states.
On the other hand many other proteins are less stable and over time may accumulate
within the body to cause disease (Table 1.1).
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Table 1.1 Examples of protein conformational diseases and associated aggregate-forming
proteins (Thomas et al. 1995; Kelly 1996; Carrell and Lomas 1997; Hamidi Asl et al. 1997;
Carrell and Gooptu 1998; Soto 2001; Yerbury et al. 2005b; Asea and Brown 2008).
* Denotes extracellular location.

Disease

Protein

Age-related macular degeneration

62 different proteins *
Drusen *

Alzheimer’s disease

Amyloid-β (Aβ) *

Amyotrophic lateral sclerosis

Superoxide dismutase 1

Corneal dystrophy

Keratoepithelin *

Creutzfeldt-Jakob disease

Prion protein *

Dementia with Lewy bodies

α-Synuclein

Diabetes (Type 2)

Amylin *
Human islet amyloid
polypeptide *

Down’s syndrome

Aβ

Familial amyloid polyneuropathy

TTR *

Familial British dementia

ABri peptide *

Familial Danish dementia

ADan *

Haemodialysis-related amyloidosis

β2-Microglobulin *

Hereditary non-neuropathic systemic amyloidosis

Lysozyme *

Hereditary renal amyloidosis

Fibrinogen *

Huntington’s disease

Huntingtin

Non-amyloidotic monoclonal IgG deposition
disease

Immunoglobulin G *

Parkinson’s disease

α-Synuclein

Primary systemic amyloidosis

Immunoglobulin light chain *

Prion Diseases

PrP *

Pseudoexfoliation (PEX) syndrome

PEX components *

Reactive amyloidosis

Amyloid-α *

Renal disease

Tamm-Horsfall protein *
Osteopontin *

Secondary systemic amyloidosis

Serum-Aβ *
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1.3

Chaperones

1.3.1

Chaperone Function

The presence of non-native protein in the cell, including misfolded proteins and protein
aggregates, stimulates a complex biological response commonly referred to as the heat
shock response (Stefani and Dobson 2003; Richter et al. 2010) which stimulates
increased expression of chaperones (and other proteins). Chaperones are not only
involved in this heat shock response but also play a role in the normal ‘house keeping’
processes essential for the maintenance of healthy cells (Pelham 1986; Ellis et al. 1989).
‘Folding’ chaperones are able to actively assist misfolded proteins to regain their native
functional structure, utilising ATP as an energy source; these include members of the
heat shock protein (HSP) families HSP40, HSP60, HSP70 (where the indicated
numerals reflect the approximate molecular mass of each chaperone in kilodaltons).
Other ‘holding’ chaperones bind to misfolded proteins to stabilise them in a soluble
state and then, after the stress has passed, direct them to lysosomes or the proteasome
for intracellular degradation, or to ‘folding’ chaperones for refolding (Figure 1.3).
Members of the ‘holding’ chaperone family include the intracellular sHSPs and the ECs
CLU and α2-macroglobulin (α2m) (Poon et al. 2000; French 2008). Most of the
chaperones identified to date reside intracellularly, although abundant ECs have
recently been identified.
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Figure 1.3 Chaperone interactions with non-native protein. Following exposure to stress,
native proteins may unfold to generate a non-native form which can interact with folding or
holding chaperones. Holding chaperones may direct the bound client protein to sites of
intracellular degradation or transfer it to folding chaperones for subsequent refolding (using
ATP).

1.3.2

Intracellular Chaperones

Intracellular chaperones were first described decades prior to the discovery of ECs and
play a major role in maintaining protein homeostasis (proteostasis) within the cell. The
first chaperones to be described were the HSPs. As the name implies, HSPs were first
identified due to their up-regulated expression following elevated temperature (heat
shock) (Ritossa 1962; Ritossa 1996). The increased expression of HSPs enhances
cellular thermotolerance. The expression of HSPs has now also been shown to increase
following stresses other than heat shock (Mehlen et al. 1995; Preville et al. 1999). The
major families of heat shock proteins include HSP100, HSP90, HSP70, HSP60, HSP40
and the sHSPs. Another family of intracellular chaperones are the glucose regulated
proteins, including glucose regulated protein 96 (gp96). The expression of this protein is
up-regulated under a number of stress conditions, including low glucose levels,
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prolonged anaerobiosis, low extracellular pH, expression of mutated proteins and viral
infections (Kozutsumi et al. 1988). Although gp96 is often grouped with the HSPs it
is not up-regulated in response to heat shock due to its promoter lacking functional
heat-shock response elements (Maki et al. 1990).
Intracellular chaperones are found within many organelles, including the endoplasmic
reticulum and mitochondria, and the cytoplasm of eukaryotic cells and play an
important role in the folding of nascent polypeptide chains (Hartl 1996), helping to
facilitate membrane translocation of proteins, and in intracellular proteostasis (Vabulas
et al. 2010; Hartl et al. 2011; Kim et al. 2013). As sHSPs are ‘holding’ chaperones they
have no inherent refolding capabilities and act to stabilise misfolded or stressed proteins
in solution to allow for their subsequent degradation or re-folding by available ‘folding’
chaperones (Gething 1997).
Intracellular chaperones are normally retained within the cell but may be released into
the extracellular space under certain conditions. Several mechanisms have been
proposed to explain the presence of normally intracellular proteins bound to the outer
surface of the cell membrane or their release into the extracellular space. These include
non-specific release of intracellular chaperones after cell necrosis (Saito et al. 2005) but
not apoptosis (Basu et al. 2000), viral cell lysis, release of exosomes (Gastpar et al.
2005; Lancaster and Febbraio 2005), and other active release mechanisms (Johnson and
Fleshner 2006; Mambula and Calderwood 2006b; Mambula and Calderwood 2006a;
Asea 2007; Mambula et al. 2007; Merendino et al. 2010). It is likely that different
signalling pathways may lead to the secretion of intracellular chaperones (Lancaster and
Febbraio 2005) and the release of these proteins into the extracellular space may be
further enhanced by exogenous stress (Barreto et al. 2003). However, more work needs
to be done to definitively ascertain whether specific secretory pathways for intracellular
12
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chaperones exist as it has been argued that a non-specific mechanism of release, such as
necrosis, cannot account for the levels of intracellular chaperones found in the
extracellular space (Henderson 2010). Intracellular chaperones have been found in
human plasma and associated with the surfaces of cells, in particular cancer cells.
Numerous extracellular roles have been postulated for these chaperones, such as cancer
cell invasiveness (Eustace and Jay 2004; Eustace et al. 2004), neuroprotection (Luo et
al. 2012), and immune modulation (Basu et al. 2000; Feng et al. 2001; Jeffery 2003;
Tamura et al. 2012). These “moonlighting” functions for normally intracellular
chaperones may be very important. However, the low abundance of these chaperones in
extracellular fluids (low ng/mL), as well as the fact that many are functionally
dependent upon ATP (the extracellular concentration of which is low (Farias et al.
2005)), makes it unlikely that they could provide significant protection against high
levels of extracellular protein aggregation (Yerbury et al. 2005b; Wilson et al. 2008). It
is much more likely that this role is performed by the abundant ECs.

1.3.3

Extracellular Chaperones

The first reported abundant EC was CLU (Humphreys et al. 1999); since then a number
of other secreted proteins have been reported to have chaperone activity (Table 1.2).
CLU, α2m, and haptoglobin are amongst the best characterised ECs, with evidence
slowly emerging to support the existence of other ECs. These newly discovered ECs
need to be studied more extensively to determine their mechanisms of action and the
role they play in extracellular proteostasis. The growing number of ECs identified
suggests that ECs play an important role in the extracellular space to stabilise
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misfolding and unfolding proteins and inhibit their progression onto the amorphous or
amyloid aggregation pathways.
The extracellular environment is relatively harsh; here proteins can be exposed to shear
stress (Ubrich et al. 2000), oxidative conditions (Strocchi et al. 2006) and variations in
temperature and pH (Michel et al. 1997). All of these stress conditions can destabilise
proteins and cause them to expose usually hidden regions of hydrophobicity to the
surrounding aqueous solvent. ECs can bind to these regions of exposed hydrophobicity
to stabilise misfolded proteins in soluble complexes directing them towards mechanisms
of refolding or degradation.
The majority of ECs identified to date, and certainly the most abundant ones, are
‘holding’ chaperones which are unable to facilitate re-folding of proteins (Table 1.2). It
is thought that misfolded proteins bound by ECs are directed to cell surface receptors
for uptake and subsequent intracellular degradation.
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α2-macroglobulin

Clusterin

Chaperone

15

1 - 3.6 µg/mL
(CSF)

1.5 - 2 mg/mL
(blood plasma)

2 - 15 mg/mL
(seminal plasma)

1.2 - 3.6 µg/mL
(cerebrospinal
fluid (CSF))

35 - 105 µg/mL
(blood plasma)

Abundance

Holdase-type
chaperone activity
similar to sHSPs

Holdase-type
chaperone activity
similar to sHSPs

Chaperone
function

15

Able to stimulate a CTL response
against chaperoned peptides

Associated with extracellular deposits
in Alzheimer’s disease, dialysis
related amyloidosis and CreutzfeldtJakob disease

Genetic association with Alzheimer’s
disease

(Sottrup-Jensen 1989; Narita et al.
1997; Binder et al. 2001b; Fabrizi
et al. 2001; Mettenburg et al. 2002;
Motomiya et al. 2003; Binder
2004; Biringer et al. 2006; Adler et
al. 2007; Adler and Kryukov 2007;
French et al. 2008)

(Choi et al. 1990; French et al.
1992; Ghiso et al. 1993; Witte et
al. 1993; Matsubara et al. 1995;
Mackness et al. 1997; Michel et al.
1997; Humphreys et al. 1999;
Calero et al. 2000; Poon et al.
2000; Ubrich et al. 2000; Wilson
and Easterbrook-Smith 2000; Poon
et al. 2002; Sasaki et al. 2002;
Carver et al. 2003; Freixes et al.
2004; Loison et al. 2006; Harold et
al. 2009; Lambert et al. 2009;
Wyatt et al. 2009b)

Associated with extracellular deposits
including age related macular
degeneration, Creutzfeldt-Jakob
disease, atherosclerosis,
glomerulonephritis, Alzheimer’s
disease
Upregulated in experimental models of
stress

References

Disease association

Table 1.2 Overview of the currently known extracellular chaperones (ECs).
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Serum Amyloid P
Component
(SAP)

Apolipoprotein E

Haptoglobin

Chaperone

16

8.5 ng/mL (CSF)

40 µg/mL
(blood plasma)

1.8 - 5.7 µg/mL
(CSF)

4 - 6.4 µg/mL
(blood plasma)

0.5 - 2 µg/mL
(CSF)

0.3 - 2 mg/mL
(blood plasma)

Abundance

ATP-independent
refolding activity

Stabilises proteins in
solution

Holdase-type
chaperone activity
similar to sHSPs

Chaperone
function

16

Elevated SAP levels in CSF of
Alzheimer’s patients

Binds with high specificity to amyloid
and is universally found in amyloid
deposits

Co-localises with Alzheimer’s and
Creutzfeldt-Jakob plaques

Strong genetic association with
Alzheimer’s disease

Co-deposits with amyloid in senile
plaques, drusen with age-related
macular degeneration and in protein
deposits associated with chronic
glomerulonephritis

Upregulated during infection,
neoplasia, trauma, and other
inflammatory conditions

Disease association
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(Pepys et al. 1978; Breathnach et
al. 1981; Coria et al. 1988; Kalaria
et al. 1991a; Kalaria et al. 1991b;
Yang et al. 1992; Hutchinson et al.
1994; Tennent et al. 1995; Botto et
al. 1997; Coker et al. 2000;
Aquilina and Robinson 2003)

(Phillips et al. 1983; Namba et al.
1991; Corder et al. 1993;
Strittmatter et al. 1993; Strittmatter
et al. 1994; Landen et al. 1996;
Koistinaho et al. 2004)

(Baskies et al. 1980; Kurosky et al.
1980; Powers et al. 1981; Tomino
et al. 1981; Bowman and Kurosky
1982; Kliffen et al. 1995; Langlois
and Delanghe 1996; Pavlicek and
Ettrich 1999; Kristiansen et al.
2001; Yerbury et al. 2005a)

References
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Caseins

~ 80% of milk
protein

20 - 45 µg/mL
(blood plasma)

αEC-Fibrinogen

(Fibrinogen-420)

Abundance

Chaperone

αS1- and β-casein
have a holdase-type
chaperone activity
similar to sHSPs

Stabilises proteins in
solution

Chaperone
function

(Reid 1972; Nickerson 1987;
Claudon et al. 1998; Bhattacharyya
and Das 1999; Niewold et al. 1999;
Taniyama et al. 2000; Carver et al.
2003; Swaisgood 2003; Gruys
2004; Matsudomi et al. 2004;
Morgan et al. 2005; Zhang et al.
2005c; Hassanisadi et al. 2008;
Thorn et al. 2009)

Associated with amyloid-like deposits
in mammary tissue

17

(Grieninger 2001; Mosesson 2005;
Tang et al. 2009a; Tang et al.
2009b)

References

Plasma levels are elevated under
periods of stress

Disease association
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Following internalisation, chaperoned proteins are most likely directed to the lysosome
for degradation (Wyatt et al. 2011). Lysosomes are often involved in the break-down of
materials endocytosed from the extracellular environment and contain many lytic
enzymes including phosphatases, nucleases and proteases. It is also possible that
chaperoned proteins may be taken up by specialised cells such as antigen presenting
cells (APCs). Professional APCs include dendritic cells and macrophages and are
involved in the adaptive immune response. Following internalisation by APCs, ECs
may direct the peptides towards the lysosome (or other intracellular pathways) for
degradation and subsequent presentation of the resulting peptides on the cell surface in
association with class I and/or II major histocompatibility complex (MHC) antigens,
thereby modulating the immune system (Figure 1.4).
The EC CLU was the protein investigated during the course of this PhD, and
consequently the following section outlines relevant information from the literature
regarding this protein. Information regarding α2m follows this, as α2m was the first and
previously the only EC reported to be capable of modulating immune responses (Binder
et al. 2000b; Binder et al. 2001b; Binder 2004; Bowers et al. 2009; Bowers et al. 2012).
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Figure 1.4 Potential routes for internalisation of extracellular misfolded proteins. a) In
some cases, when present at low levels, misfolded proteins may be able to directly bind to
and be taken up by scavenger receptors which direct them for lysosomal degradation via an
endosomal route. b) When present at higher levels, it is likely that the bulk uptake of
misfolded proteins into the cell is facilitated by ECs that are able to stabilise them
in the form of soluble chaperone-client complexes, thereby inhibiting their aggregation
and deposition. c) Intracellular chaperones released from nearby cells or ECs may bind to
misfolded proteins and direct them to various receptors expressed on antigen presenting
cells which, following largely unknown intracellular processing mechanisms, can result in
re-presentation of immunogenic peptides complexed with MHC class I/II molecules.
Simultaneously, cytokine release is stimulated to result in a peptide specific immune
response. Modified from Dabbs et al. 2013. (Dabbs et al. 2013)
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1.3.3.1

Clusterin

CLU is a glycoprotein first isolated from ram testis fluid and was originally named for
its ability to cause cell clustering in vitro (Blaschuk et al. 1983). Expression of CLU
mRNA is near ubiquitous (Humphreys et al. 1999) and the mature CLU product is
usually found extracellularly (Carver et al. 2003). CLU is expressed as a secreted
58 - 62 kDa heterodimeric protein (Kapron et al. 1997) that migrates in SDS-PAGE
with an apparent mass of 75 - 80 kDa. Post-translational cleavage produces an α- and
β-chain that are linked by five disulphide bonds (Choi-Miura et al. 1992). A number of
intracellular “isoforms” of CLU have been reported (Reddy et al. 1996; Leskov et al.
2003; Pucci et al. 2004) but further work needs to be undertaken to characterise them to
ensure that they result from alternative transcription initiation or splicing, rather than
simply representing immature forms of CLU. Secreted CLU is heavily glycosylated
with ~ 30% of the mass comprised of N-linked carbohydrate (Kapron et al. 1997;
Wilson and Easterbrook-Smith 2000). The exact function of the extensive glycosylation
of CLU is unknown but it may assist in maintaining protein solubility (Stewart et al.
2007). Recently it has been shown that CLU retains its chaperone activity when
deglycosylated (Stewart et al. 2007) raising the possibility that a bacterial expression
system might be utilised to express functional recombinant CLU (rCLU).
Numerous biological functions have been proposed for CLU including roles in the
regulation of complement (Choi et al. 1989; Kirszbaum et al. 1989; Hochgrebe et al.
1999), sperm maturation (Blaschuk et al. 1983), programmed cell death (French et al.
1994) and lipid transport (Jenne et al. 1991). There have been many previous reports
proposing roles for CLU in apoptosis (Scaltriti et al. 2004; Zhang et al. 2005a;
Trougakos et al. 2009; Kim et al. 2010). However, many of these reports have been
conflicting and the question of whether CLU is pro- or anti-apoptotic remains unclear
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and may be cell context dependent (Trougakos and Gonos 2002; Debure et al. 2003;
Park et al. 2003).
CLU has a chaperone activity similar to that of the sHSPs - this was first described by
Humphreys et al. (1999). Alone, CLU is unable to promote the re-folding of stressed
client proteins but rather it stabilises aggregating proteins via hydrophobic interactions
to produce a soluble high molecular weight (HMW) complex (Humphreys et al. 1999;
Yerbury et al. 2005a). CLU has been shown to preferentially bind to protein
intermediate states that are slowly aggregating, long-lived and precipitation bound
(Poon et al. 2002). Furthermore, under conditions of endoplasmic reticulum (ER) stress,
CLU can retrotranslocate from the secretory pathway into the cytosol where it can also
contribute to the maintenance of intracellular proteostasis (Nizard et al. 2007; Li et al.
2013). Thus CLU is currently unique in that it is the only chaperone known to
participate in processes of both intra- and extracellular proteostasis.
Numerous receptors have been reported to bind CLU and facilitate its internalisation,
although some of these studies were undertaken using poorly characterised rCLU rather
than wild type (wt) CLU. Therefore, the results from the studies using rCLU must be
viewed cautiously. In the following discussion of earlier studies, the use of rCLU or
wtCLU is explicitly noted. The receptors previously identified are all members of the
low density lipoprotein receptor (LDLR) family. Although wtCLU (alone) is unable to
bind to the low density lipoprotein receptor related protein (LRP) 1 (LRP1/CD91/α2m
receptor) (Kounnas et al. 1995) multiple studies have identified LRP2 (glycoprotein
330/megalin) as a receptor for both wtCLU and rCLU (Kounnas et al. 1995; Mahon et
al. 1999; Lakins et al. 2002). As well as binding wtCLU in vitro, LRP2 has been shown
to mediate the endocytosis and subsequent lysosomal degradation of wtCLU by
various cell lines (Kounnas et al. 1995). rCLU was also shown to bind to two chicken
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oocyte-specific members of the LDLR family, the chicken homologue of the human
very low density lipoprotein receptor (VLDLR) and chicken LRP (Mahon et al. 1999).
LRP2 is also able to mediate uptake and lysosomal degradation of wtCLU bound to Aβ
(CLU-Aβ) (Hammad et al. 1997) or lipids (Calero et al. 1999), shows higher affinity for
CLU-Aβ and lipid-associated wtCLU than wtCLU alone, and mediates the cellular
uptake of CLU-Aβ and its transport across the blood-brain barrier (Zlokovic et al.
1996). Other receptors identified as binding murine rCLU complexed to leptin include
human VLDLR and the murine apolipoprotein receptor type 2 (Bajari et al. 2003).
Binding and internalisation of rCLU (secreted from Madine-Darby canine kidney cells
in serum free media) by LRP1, LRP2, and an as a yet to be determined mechanism, is
enhanced in the presence of cell debris (Bartl et al. 2001) suggesting a clearance
mechanism in which rCLU facilitates the internalisation and removal of cell debris via
receptor mediated endocytosis.

1.3.3.2

α2Macroglobulin

α2M is a widely distributed glycoprotein that was recently shown to act as an EC
with an action similar to that of CLU (French et al. 2008). α2M is comprised of ~ 10%
by mass of carbohydrate linked to four identical 180 kDa subunits which form a
720 kDa tetramer (Jensen and Sottrup-Jensen 1986). α2M is best known for its
ability as a unique protease inhibitor that ‘traps’ proteases within its core, making
this the first identified mammalian dual-action chaperone and protease inhibitor (French
et al. 2008). Internal proteolytic cleavage of α2m induces a major conformational
change irreversibly trapping the protease (Sottrup-Jensen 1989). This trapping
mechanism excludes large protease substrates from the active site of the enzyme
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but allows low-molecular weight substrates to be hydrolysed (Travis and Salvesen
1983a; Travis and Salvesen 1983b; Borth 1992). The persistence of the catalytic
activity of the trapped protease (assessed using small substrates able to diffuse into the
α2m-protease steric cage) makes α2m a unique protease inhibitor (Travis and Salvesen
1983a; Travis and Salvesen 1983b; Borth 1992). The major conformational change
induced by protease trapping exposes a recognition site for LRP1, facilitating the
clearance of α2m bound ligands (Barrett and Starkey 1973; Strickland et al. 1991).
Aside from the protease trapping mechanism, α2m is also able to bind to and promote
receptor-mediated clearance of a wide range of dissimilar proteins including growth
factors, apolipoprotein E, cytokines, leptin and Aβ (Borth 1992; Gonias et al. 2000).

1.4

The Adaptive Immune System

The adaptive immune system plays a crucial role in the body’s fight against invading
pathogens. It comprises two main arms, the humoral/antibody and cell mediated
systems; these branches of the adaptive immune response are mediated by B and T cells
respectively. A critical difference between B cell and T cell responses is how the cells
recognise an antigen. B cells recognise antigens in their native form, compared to
T cells which require processing of an antigen into antigenic peptides and subsequent
presentation in association with MHC molecules. Prior research has examined the roles
that chaperones play in modulating the cell based arm of the adaptive immune response,
specifically the ability of chaperones to stimulate a CTL response against chaperoned
peptides. Comparatively little work has been undertaken to examine the potential of
chaperones to stimulate a humoral immune response.
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Activation of the T cell limb of the adaptive immune response requires the recognition
of MHC-bound peptides on plasma membranes. This can occur via two distinct
pathways whereby antigenic peptides are either presented on the surface by MHC
class I or MHC class II molecules. MHC I molecules are predominately responsible for
displaying endogenous antigens whereas MHC II molecules predominately associate
with antigens originally sourced from the extracellular milieu (Figure 1.5).
Typically, cytosolic proteasomes are the primary producers of antigenic peptides for
presentation by MHC I molecules (Goldberg and Rock 1992; Monaco 1992). The
peptides are then transported across the ER membrane by the transporter associated
with antigen processing (TAP) (Ortmann et al. 1994; Suh et al. 1994; Grandea et al.
1995; Sadasivan et al. 1996). Once within the ER lumen these peptides bind to nascent
MHC I heavy chain-β2-microglobulin complexes and subsequently pass through the
secretory pathway for presentation on the cell surface (Figure 1.5) (Pamer and
Cresswell 1998; Cresswell et al. 2005). It is here that the peptides interact with CD8+ T
cell receptors on CTLs which activate them to kill foreign or infected cells.
In contrast, peptides that associate with the MHC II molecule are sourced from various
endosomal compartments and MHC II molecules are predominately found only in
professional APCs such as B cells, dendritic cells and macrophages. Following
internalisation of antigens, these endosomal compartments are acidified by the action
of proton pumps. These compartments then fuse with lysosomes to generate a
phagolysosome - the acidic nature of this compartment allows for the action of pH
dependent hydrolases and proteases to generate antigenic peptides (Harding and Geuze
1992; Harding 1995; Watts 2012). The antigenic peptides then associate with MHC II
molecules and are carried to the cell surface by out-going vesicles (Geuze 1998), where
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interactions with helper T cells can occur (Cresswell 1994a; Cresswell 1994b; Wubbolts
et al. 1997) (Figure 1.5). Once activated, helper T cells then stimulate B cells to produce
soluble antibodies against the presented antigen (Martinez and Coutinho 1981).

Figure 1.5 MHC class I and MHC class II trafficking. Classically, MHC class I molecules
and MHC class II molecules are thought to associate with intracellular and extracellular
antigens respectively. Intracellular antigens are typically digested in the proteasome and
transported across the endoplasmic reticulum (ER) membrane by the transporter associated
with antigen processing (TAP). Once inside the ER they are bound by MHC I molecules
and transported through the secretory pathway via the golgi to the cell surface. Extracellular
antigens are internalised via endocytosis, the endocytic vesicle fuses with the lysosome
creating the phagolysosome where antigen processing occurs. MHC II molecules are
assembled in the ER and transported through the golgi to form MHC II vesicles. These
vesicles fuse with the phagolysosome to allow loading of antigenic peptides and subsequent
transport to the cell surface.

It was originally thought that MHC class I molecules could only present peptides
derived from endogenous antigens. However, in some circumstances cross-presentation
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may occur, whereby peptides derived from exogenous antigens may be presented on
MHC I molecules (Bevan 1976; Heath and Carbone 2001). If a CD8+ T cell response
is stimulated this is called cross-priming (Heath and Carbone 1999; Shen and Rock
2006) and is important for raising an appropriate immune response to viral infections
and tumours (den Haan and Bevan 2001; Basta and Alatery 2007; Allan 2008). If
cross-presentation of self-antigens occurs, autoreactive T cells can be deleted; this is
deemed cross-tolerance (Kurts et al. 1997a; Kurts et al. 1997b; Heath et al. 1998).
Tolerance may also occur if the antigens are cross-presented in the absence of
immunostimulatory signals (Rock and Shen 2005).
Four general pathways have been identified to describe how exogenous material is
loaded onto MHC I molecules. (i) Direct injection of antigenic material by pathogens
into the cytosol of APCs, these pathogens include viruses (Yewdell et al. 1988) and
some strains of bacteria (Finelli et al. 1999). This allows normal processing to then
occur as described above. (ii) Peptide antigens contained within endosomes may be
‘regurgitated’ onto the cell surface where they may then associate with pre-formed
MHC I molecules (Harding 1995). (iii) Cytosolic diversion may occur, whereby
peptides contained within endosomal compartments including phagosomes may be
diverted to the cytosol for subsequent processing by the traditional MHC I pathway
(Heath and Carbone 2001; Burgdorf et al. 2008). (iv) Antigen is cleaved into peptides
by endosomal proteases and bound by MHC I molecules within the endosome itself
(Rock and Shen 2005).
Antigen uptake may occur via receptor mediated endocytosis (Rodriguez et al. 1999;
Singh-Jasuja et al. 2000b), phagocytosis (Kovacsovics-Bankowski and Rock 1995) or
macropinocytosis (Norbury et al. 1995; Norbury et al. 1997), although uptake via
mechanisms other than receptor mediated endocytosis require higher levels of antigen
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and are likely to be less relevant in vivo. Receptor mediated endocytosis has been
reported to be essential for cross-presentation in some circumstances (Singh-Jasuja et
al. 2000b).

1.5

Chaperones and the Immune System

Intracellular chaperones released into the extracellular environment often carry with
them chaperoned peptides; the intracellular chaperone-peptide complex may then be
internalised by another cell, often an APC. The processed peptides may be presented on
either MHC class I or II molecules and recognised by CD8+ or CD4+ T lymphocytes,
respectively. In addition to inducing a cytotoxic immune response, intracellular
chaperones are also able to provide maturation signals to APCs (Binder et al. 2000a;
Singh-Jasuja et al. 2000a), inducing the expression of cytokines that co-stimulate
T lymphocytes to ensure a robust immune response (Chen et al. 1999; Mellman and
Steinman 2001).

1.5.1

Discovery of the Immune Modulatory x
Capabilities of Intracellular Chaperones

Many previous studies have examined whether intracellular chaperones can direct
tumour peptides/antigens into APCs to generate a tumour-specific immune response,
thereby acting as anti-cancer vaccines. One of the first such studies was by Srivastava
and colleagues in the 1980s. They demonstrated that tumour resistance could be induced
when a gp96 fraction isolated from a tumour cell lysate was administered to the
mice from which the original tumour was sourced (Srivastava et al. 1986). It was
proposed that the response was due to tumour-derived peptides being chaperoned
by gp96 to APCs, as removal of bound peptides from gp96 resulted in a loss of the
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immune response (Udono and Srivastava 1993). Subsequent similar work with other
intracellular chaperones was undertaken to show that they can also induce protective
immunity against tumours or virus infected cells (Srivastava et al. 1986; Udono and
Srivastava 1993; Udono et al. 1994; Udono and Srivastava 1994; Arnold et al. 1995;
Feldweg and Srivastava 1995; Nieland et al. 1996; Castellino et al. 2000; Singh-Jasuja
et al. 2000b). HSP-peptide complexes generated in vitro can also stimulate this response
(Blachere et al. 1997; Suzue et al. 1997; Moroi et al. 2000). Therefore, intracellular
chaperone-peptide complexes may play a role in the immunosurveillance of tumours.
Moreover, it has been shown that these complexes can be used for anti-cancer
immunotherapy in mice (Udono and Srivastava 1993; Suto and Srivastava 1995; Basu
and Srivastava 1999) and humans (Rivoltini et al. 2003; Lewis 2004; Pilla et al. 2006;
Maki et al. 2007; Testori et al. 2008).

1.5.2

Receptors Involved in the Cellular Uptake of
Normally Intracellular Chaperones

The method by which chaperone-antigen complexes induce cross-presentation is
still not clear in all cases, although internalisation is believed to be by receptor
mediated endocytosis (Arnold-Schild et al. 1999; Singh-Jasuja et al. 2000b; Basu et al.
2001; Thériault et al. 2005; Thériault et al. 2006; Gong et al. 2009a). Intracellular
chaperones do not bind to a single specialised cell surface receptor but instead bind
to a variety of rather promiscuous receptors such as LRP1 and scavenger receptors
(Facciponte et al. 2005; Calderwood et al. 2007b). HSP60, HSP70, HSP90, gp96
and calreticulin bind to LRP1 (Binder et al. 2000b; Basu et al. 2001; Binder and
Srivastava 2004); HSP110 (Facciponte et al. 2007), gp96 and calreticulin are bound
and internalised by scavenger receptor AI (SR-AI) (Berwin et al. 2003; Berwin et al.
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2004); the scavenger receptor expressed by endothelial cells 1 (SREC-1) binds
to calreticulin (Berwin et al. 2004), HSP110 (Facciponte et al. 2007), mediates
HSP70-peptide immunity (Thériault et al. 2006; Calderwood et al. 2007b; Gong et al.
2009a), HSP90-ovalbumin (OVA) cross-presentation (Murshid et al. 2010) and
facilitates the uptake of intracellular chaperone-peptide complexes into the MHC II
pathway (Gong et al. 2008); Lectin-like oxidised low density lipoprotein receptor-1
(LOX-1) internalises HSP70 and can mediate cross-presentation (Delneste et al. 2002;
Thériault et al. 2005); and HSP70 binds to and is internalised by fasciclin,
epidermal growth factor-like, laminin-type epidermal growth factor like, and link
domain-containing scavenger receptor-1 (FEEL-1) (Thériault et al. 2006).
HSP60, HSP70 and gp96 have also been shown to bind toll-like receptor (TLR) 2 and 4,
the latter either alone or in combination with CD14 (Asea et al. 2000; Vabulas et al.
2001; Vabulas et al. 2002; Ramirez et al. 2005). Some reports suggest that TLR
signalling is required for anti-tumour immunity to be developed (Gong et al. 2009a).
This may be due to TLR signalling being involved in dendritic cell maturation (Takeda
et al. 2003), and/or this signalling may stimulate the expression of scavenger receptors
including SREC-1 (which is involved in binding HSP70-peptide complexes to facilitate
cross-priming (Gong et al. 2009a)).
With the wide range of receptors identified it seems likely that more than one receptor
is involved in the uptake process, and depending on which receptor is utilised it
may mediate different immune responses. For instance, binding to SR-AI is
immunosuppressive whereas LOX-1 mediates HSP70 immunogenicity and antigen
cross-presentation (Wang et al. 2007).
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1.5.3

Contention
Regarding
the
Action
of
Intracellular Chaperones in the Extracellular
Space

Currently immunobiologists studying the effects of intracellular chaperones in the
extracellular space are divided into two broad groups: (i) those who consider
intracellular chaperones as potent stimulators of the inflammatory response and
indicators of pathological events, and (ii) those who believe intracellular chaperones
have mainly anti-inflammatory properties (Pockley et al. 2008). Due to this contention,
much more work needs to undertaken in this area to ascertain whether in fact these
proteins have multiple and often seemingly opposing functions or whether inherent
differences between studies explain the sometimes apparently contradictory results.
Another school of thought proposes that the apparent immunological functions of
intracellular chaperones is not due to their inherent chaperone activity but rather is due
to microbial contaminants such as lipopolysaccharide (LPS)/endotoxin (Medzhitov and
Janeway 2000) or flagellin. Much work has been done to defend the research which
supports the role of intracellular chaperones as adjuvants of the immune system and
there are many reviews (Quintana et al. 2004; Gastpar et al. 2005; Pockley et al. 2008;
Henderson et al. 2010) outlining the controls have been put in place to increase the
validity of the research.

1.5.4

Chaperones as Immune Modulators

Most of the previous work has examined the immunomodulatory role of intracellular
chaperones acting in the extracellular space. As many of these chaperones mediate
responses via interactions with LRP1 (Binder et al. 2000b; Basu et al. 2001; Binder and
Srivastava 2004) the ability of α2m to do the same was examined and it has been shown
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to elicit a similar (chaperoned peptide specific) CD8+ T cell response to that produced
by gp96 (Binder et al. 2001b; Binder et al. 2002; Bowers et al. 2009). All studies using
intracellular chaperones and α2m show an enhancement of antigen specific
cross-priming when chaperones are bound to the antigens, compared to injection of
antigen alone (Srivastava et al. 1994; Udono and Srivastava 1994; Suto and Srivastava
1995; Blachere et al. 1997; Basu and Srivastava 1999; Binder et al. 2001a; Binder et al.
2002; Li et al. 2002). Furthermore, heat stressing tumours prior to the preparation of
HSP70-peptide vaccines also enhances cross-priming (Shi et al. 2006), implicating
chaperones in the delivery of peptides to MHC I via cross-presentation.
Currently, little is known about the intracellular trafficking route(s) utilised for
cross-presentation. However, one study has shown that once HSP70 is bound to a
receptor(s) on the surface APCs cross-presentation on MHC I molecules may occur
via two distinct routes: (i) a cytosolic route, involving proteasomes and TAP, or (ii) an
endosomal route, independent of proteasomes and TAP. The preferred processing route
appeared to be antigen dependent and ultimately resulted in HSP70 mediated
cross-priming (Castellino et al. 2000).
HSPs (when complexed to antigen) may mediate either a pro- or anti-inflammatory
(tolerogenic) immune response. Induction of tolerance is important to protect against
autoimmune diseases whereas the production of a pro-inflammatory response is needed
to protect against infections and cancer (Kaul and Thippeswamy 2011). It is likely that
the type of response generated may be dependent on the type of immune cells
interacting with the chaperone-peptide complexes and the presence of any inflammatory
or anti-inflammatory molecules in the local environment.

31

Chapter 1: Introduction
Although most previous work has focussed on the immunomodulatory potential
of intracellular chaperones, it is likely that ECs have a similar activity. This is
supported by the demonstration that α2m can elicit a chaperoned peptide specific
CTL response (Binder et al. 2001b; Binder et al. 2002; Bowers et al. 2009). The
current project investigates the potential of CLU to stimulate an immune response
against a protein (OVA) physically associated with CLU both via the MHC class I
cross-presentation pathway to elicit a CTL response, and via the MHC class II
presentation pathway to stimulate a humoral immune response.

1.6

Aims

The specific experimental aims of this study were to:
1) Produce a chaperone active recombinant form of CLU.

2) Test the binding and internalisation of CLU and CLU chemically linked to
OVA to a variety of cells, to elucidate potential receptors involved.
3) Study the ability of CLU to stimulate a both a CTL and humoral immune
response against the model antigen OVA in a mouse model.
This study will help to further our knowledge of the immunomodulatory abilities of
CLU and establish which receptors may be involved in this process.
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2 Methods
2.1

Materials

Antibodies used in this study are detailed in Tables 2.1, 2.2 and 2.3. Buffer
salts and H2O2 were purchased from Crown Scientific (Melbourne, Vic, Australia).
Ampicillin (Ap), bicinchoninic acid (BCA) solution, bromophenol blue, bovine
serum albumin (BSA), casamino acids, casein, citrate synthase (CS) from porcine
heart, complete Freund’s adjuvant (CFA), creatine phosphokinase (CPK) from
rabbit muscle, cytochalasin D (cytoD), deoxymethylsulphoxide (DMSO), dithiothreitol
(DTT), ethylene diamine tetraacetic acid (EDTA), 5-(N-Ethyl-N-isopropyl)amiloride
(EIPA),

Ex-Cell®

293

medium,

fucoidan,

glycerol,

horseradish

peroxidase

(HRP), human serum albumin (HSA), iodoacetic acid (IAA), iodoacetamide
(IAM), isopropyl-β-D-thio-galactoside (IPTG), LPS, lysozyme, mannan from
Saccharomyces

cerevisiae,

methyl-beta-cyclodextrin

(mβCD),

murine

serum

albumin (MSA), N-ethylmaleimide (NEM), o-phenylenediamine dihydrochloride
(OPD),

paraformaldehyde

(PFA),

phenylmethylsulfonyl

fluoride

(PMSF),

polyinosinic acid (polyI), propidium iodide (PI), saponin, sodium azide (Az), sodium
citrate,

sodium

dodecyl

sulphate

(SDS),

streptavidin

(SA),

thimerosal,

N,M,N’,N’-tetramethylethylenediamine (TMED), yeast extract and 2-mercaptoethanol
were all obtained from Sigma-Aldrich (St. Louis, MO, USA). Acrylamide and tryptone
were from Amresco (Solon, OH, USA). Brefeldin A and FcBlock were from
eBioscience (San Diego, CA, USA). PD10 columns were from GE Healthcare (Chalfont
St

Giles,

UK).

Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate

(SMCC) crosslinker and biotinylated HRP (bHRP) were from Pierce (now Thermo
Scientific; Rockford, IL, USA). Complete® Protease Inhibitor Cocktail, DNase I and
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Triton X-100 (Tx-100) were from Roche Diagnostics Australia (Castle Hill, NSW,
Australia). Lyophilised, endotoxin-free OVA was kindly provided by Jeannin et al.
(INSERM, Angers, France). The molecular weight markers used were PageRuler™
Unstained Protein Ladder and PageRuler™ Plus Prestained Protein Ladder (Fermentas,
Burlington, Canada), and Precision Plus Protein™ unstained standards and Precision
Plus Protein™ Dual Color Standards (Bio-Rad, Hercules, CA, USA). The restriction
enzyme EcoRI and corresponding buffer were also from Fermentas. Alexa Fluor® 488
5-TFP ester, CD293 medium, 5-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl
Ester (CFDA-SE), Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12
(DMEM:F-12), GIBCO® trypsin/EDTA, L-glutamine, pDEST42, RPMI 1640 medium,
and SA-ALEXA488 were from Invitrogen (now Life Technologies™; Carlsbad, CA,
USA). Foetal calf serum (FCS) was from Bovogen (East Keilor, VIC, Australia).
Nitrocellulose membrane used for Western blotting was from Pall Corporation
(Pensacola, FL, USA). Guanidine hydrochloride (GdHCl) was from ICN Biochemicals
(Irvine, CA, USA), geneticin (G418 Sulfate) was from Promega (Madison, WI, USA).
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Table 2.1 List of isotype control antibodies used in this study.
Antibody

Form

Supplier

Goat IgG

Purified

Millipore (Billerica, MA, USA)

Mouse IgA

Purified

Immunology Consultants
Laboratory Inc. (ICL)
(Portland, OR, USA)

Mouse IgE

Purified

ICL

Mouse IgG1

Purified

ICL

Mouse IgG2a

Purified

ICL

Mouse IgG2b

Purified

ICL

Mouse IgG3

Purified

ICL

Mouse IgM

Purified

ICL

Mouse-anti-human CLU
(G7)

Purified

Wilson and Easterbrook-Smith,
1992(Wilson and Easterbrook-Smith 1992)

Rabbit-anti-dinitrophenyl

Purified

Dako (Glostrup, Denmark)

Rat IgG1

Phycoerythrin (PE)
labelled

BD Biosciences

Rat IgG2a

Biotinylated

BD Biosciences

Rat IgG2a

Allophycocyanin
labelled

BD Biosciences
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Table 2.2 List of primary antibodies used in this study.
Target protein
of interest

Form

Host species

Supplier

CD14

FITC labelled
monoclonal

Mouse

Millipore

CD45.2 (mouse)

Biotinylated,
monoclonal

Rat

eBioscience

Clusterin
(human)

G7 and 41D
hybridoma
supernatant

Mouse

In house production of
supernatant as previously
described (Wilson and
Easterbrook-Smith 1992;
Humphreys et al. 1997)

EEA1
(early endosome
marker)

Immunogen affinity
purified, polyclonal

Rabbit

Millipore

Interferon
gamma (IFNγ)

PE labelled

Rat

BD Biosciences (San
Diego, CA, USA)

Interleukin 2
(IL-2)

Allophycocyanin
labelled

Rat

BD Biosciences

Lamp 1
(lysosome
marker)

Immunoglobulin G
(IgG) fraction,
monoclonal

Mouse

Millipore

Ovalbumin

IgG fraction,
polyclonal

Rabbit

Sigma-Aldrich

Mouse IgA

Purified, polyclonal

Goat

ICL

Mouse IgE

Purified, polyclonal

Goat

ICL

Mouse IgG1

Purified, polyclonal

Goat

ICL

Mouse IgG2a

Purified, polyclonal

Goat

ICL

Mouse IgG2b

Purified, polyclonal

Goat

ICL

Mouse IgG3

Purified, polyclonal

Goat

ICL

Mouse IgM

Purified, polyclonal

Goat

ICL
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Table 2.3 List of secondary antibodies used in this study.
Antibody

Form

Dilution or
concentration
used

Supplier

Goat-anti-mouse Ig

1:1,000

HRP conjugate

Millipore

Goat-anti-mouse Ig

2.5 µg/mL

CF633 conjugate

Biotium (Hayward,
CA, USA)

Goat-anti-rabbit Ig

2.5 µg/mL

CF633 conjugate

Biotium

Rabbit-anti-goat IgG

1:20,000

Biotin conjugate

Millipore

Mouse-anti-goat Ig

1:30,000

HRP conjugate

Sigma-Aldrich

Sheep-anti-mouse Ig

1:1,000

HRP conjugate

Millipore

Sheep-anti-rabbit Ig

1:1,000

HRP conjugate

Millipore

2.2

Protein Quantification

Estimations of protein concentration were performed by measuring the absorbance
at 280 nm (A280) in a quartz cuvette in a WPA Biowave S2100 Diode Array
Spectrophotometer (Biochrom, Cambridge, UK), using the appropriate extinction
coefficient for each protein. Alternatively, for solutions containing more than one
protein BCA assays were carried out. If the sample contained a reducing agent, a
Bradford assay (Sigma-Aldrich) was used instead.
Briefly, the BCA assay was undertaken in a 96 well plate, utilising 25 µL of protein
solution/well. BCA working reagent was made by adding 50 parts reagent A (BCA
solution) to 1 part reagent B (copper sulphate pentahydrate 4% (w/v) solution) and
adding 200 µL/well. The plate was covered and incubated at 60 °C for 15 min before
absorbance readings were taken on a Spectra Max Plus 384 plate reader (Molecular
Devices, Sunnyvale, CA, USA) at 562 nm. Protein solutions of unknown concentrations
were compared to a set of BSA standards (0 - 1 mg/mL) prepared in the same buffer as
the unknown sample.
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The Bradford assay was also undertaken in a 96 well plate, using 5 µL protein
sample/well. The Bradford reagent was then added (250 µL/well) and the plate shaken.
The plate was incubated at room temperature for 10 - 20 min and absorbance
subsequently read as above at 595 nm. Protein solutions of unknown concentrations
were compared to a set of BSA standards (0 - 1 mg/mL) prepared in the same buffer as
the unknown sample.

2.3

SDSPAGE Electrophoresis

The purity and molecular weight of protein samples were assessed using SDS-PAGE.
Samples were prepared in 1X sample buffer (60 mM Tris pH 6.8, 1% (w/v) SDS, 10%
(v/v) glycerol, 0.01% (w/v) bromophenol blue) and heated at 100 °C in either a water
bath or heating block for 5 min prior to loading on the gel. Unless otherwise specified, a
10% (v/v) resolving acrylamide gel and a 5% (v/v) stacking gel was made, at a
thickness of either 0.75 or 1.5 mm depending on the amount of sample to be resolved.
The acrylamide gel was poured and placed in a HoeferTM SE 250/260 SDS-PAGE
apparatus (GE Healthcare) with SDS running buffer (96 mM glycine, 25 mM Tris-Base,
0.1% (w/v) SDS, pH 8.25) before samples were loaded. Samples were electrophoresed
at a constant 120 V and subsequently stained in Coomassie Blue (0.2% (w/v)
Coomassie Blue R250, 40% (v/v) methanol, 10% (v/v) glacial acetic acid in distilled
water (dH2O)) and destained in 40% (v/v) methanol, 10% (v/v) glacial acetic acid and
50% (v/v) dH2O. If Coomassie staining was not adequately sensitive, the gel was
subsequently stained using ImperialTM Protein Stain (Quantum Scientific, Sydney,
Australia) followed by destaining in MilliQ water. Unstained molecular weight markers
were used for routine SDS-PAGE analysis, either PageRuler™ Unstained Protein
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Ladder or Precision Plus Protein™ unstained standards. For SDS-PAGE gels for
subsequent use in Western blotting, prestained markers were used to assess the transfer
efficiency and estimate the molecular weight of protein bands detected. The prestained
markers used were either PageRuler™ Prestained Protein Ladder or Precision Plus
Protein™ Dual Colour Standards.

2.4

Western Blotting

Protein transfer was undertaken using a Trans-blot (Bio-Rad) apparatus. The trans-blot
apparatus was placed in the buffer chamber of a Mini-Protean II electrophoresis cell
(Bio-Rad) and the apparatus filled with Western transfer buffer (25 mM Tris base,
192 mM glycine, 20% (v/v) methanol, pH 8.3). The transfer was performed at 100 V for
1 h at 4 °C with stirring. The efficiency of the transfer as well as the approximate
protein size was determined by using prestained molecular weight markers, as indicated
above, on the gel. Following protein transfer, the nitrocellulose membrane was blocked
overnight at 4 °C in HDC (1% (w/v) heat denatured casein + 0.01% (w/v) thimerosal in
phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 7.9 mM Na2HPO4,
1.5 mM KH2PO4, pH 7.4)).
After blocking the membrane, the appropriate primary antibody was diluted (Table 2.2)
in HDC or added undiluted in the case of hybridoma tissue culture supernatants. The
membrane was heat sealed with the antibodies in a plastic bag to reduce the volume of
antibody required to cover the membrane. The membrane was then incubated for 1 h at
37 °C with shaking prior to washing. Between each incubation the membrane was
washed with 0.1% (v/v) Triton X-100 in PBS three times followed by a rinse with PBS.
An appropriate HRP labelled secondary antibody (Table 2.3) was used and incubated as
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above followed by development as per the manufacturer’s protocol using an enhanced
chemiluminescence detection (ECL) kit (Supersignal Western Pico substrate working
solution; Thermo Scientific). Amersham Hyperfilm ECL (GE Healthcare) was then
placed over the membrane in a Kodak X-Omatic cassette. Once exposed the film was
removed from the cassette and developed using Kodak Developer and Fixer (Kodak,
Sydney, Australia).

2.5

Clusterin Purification

Blood was collected as a kind donation from Wollongong hospital (Wollongong
hospital pathology unit, NSW, Australia). To prepare plasma, blood containing 10 mM
sodium citrate was poured into 50 mL tubes and centrifuged at 2,500 rpm in a Heraeus
Megafuge 1.0R benchtop centrifuge (Heraeus, Hanau, Germany) for 30 min at 4 °C.
The plasma was then removed and frozen at - 20 °C until required. After quickly
thawing frozen plasma in a 37 °C water bath, Complete® protease inhibitor was added
and the plasma filtered through a GFC glass fibre filter (MicroAnalytic Products Inc.,
Mountain Lakes, NJ, USA) to remove any large debris and clots that may have formed.
Plasma was then filtered through a 0.45 µm cellulose nitrate filter (Sartorius Stedim
Biotech, Goettingen, Germany). Two 5 mL immunoaffinity columns, each bearing
~ 25 mg of bound anti-CLU monoclonal antibody (MAb) (G7 MAb on one column,
41D MAb on the other (Wilson and Easterbrook-Smith 1992)) were connected in
tandem to an Econopump system (Bio-Rad) and equilibrated in filtered PBS/Az. The
plasma was then pumped over the columns (at 0.5 mL/min or less) to allow CLU to
bind, followed by washing with (i) ~ 50 mL PBS/Az, then (ii) ~ 50 mL PBS/0.5% (v/v)
Tx-100, pH 7.4 (to remove any bound lipids), before re-equilibrating in PBS/Az. Next
200 mM sodium acetate, 0.5 M NaCl, pH 5 was passed over the columns to remove
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non-specifically bound material. Finally, specifically bound material was eluted using
2 M GdHCl in PBS, pH 7.4. Once the A280 had returned to base line the columns were
immediately re-equilibrated with PBS/Az for storage at 4 °C. Fractions containing the
GdHCl eluate were combined and dialysed against two changes of 20 mM Tris, pH 8.
A Q-Sepharose anion exchange column (4.2 mL) was equilibrated in 20 mM Tris, pH 8
and the dialysed eluate loaded. The bound material was eluted with a NaCl gradient of
0 to 1 M (in 20 mM Tris, pH 8) over 20 column volumes. Eluted peaks were analysed
by SDS-PAGE and fractions deemed to contain pure CLU were pooled. Alternatively,
the GdHCl eluate fractions were combined and dialysed against two changes of 20 mM
MES, pH 6.0. A 1 mL HiTrap™ SP XL cation exchange column (GE Healthcare) was
equilibrated in 20 mM MES, pH 6.0, the dialysed fraction loaded and the flow-through
collected. The flow through contains the CLU as at pH 6.0 CLU remains negatively
charged and doesn’t bind to the cation exchanger. The bound ‘contaminating’ proteins,
typically > 250 kDa in size were eluted from the column with 20 mM MES + 1 M NaCl,
pH 6.0. CLU purity was subsequently tested via SDS-PAGE analysis. If required, the
sample was then concentrated using a Vivaspin20 concentrator (30 kDa molecular
weight cut off; GE Healthcare).

2.6

Chaperone Assays

Protein precipitation assays were performed in order to test whether recombinant forms
of CLU were chaperone active. Client proteins were either induced to amorphously
precipitate by heat stress or reductive stress in a FLUOstar OPTIMA plate reader
(BMG Labtech; Ortenberg, Germany). Glutathione-S-transferase (GST) (500 µg/mL)
was heated to 60 °C in PBS/Az for 3 - 4 h; CS (200 µg/mL) was heated to 43 °C in
TE buffer (50 mM Tris, 2 mM EDTA, pH 8) with 3 s double orbital shaking (1 mm
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shaking width, 600 rpm) after each read (reads taken every minute) for 3 - 4 h; CPK
(1.12 mg/mL) was heated to 43 °C in PBS/Az with 10 s double orbital shaking (1 mm
shaking width, 600 rpm) after each read (reads taken every minute) for 3 - 4 h. BSA
(1.5 mg/mL) was induced to precipitate by incubation in PBS/Az containing 20 mM
DTT (at 37 °C) without shaking for 16 h. In all cases, assays were performed in flat
bottomed 384 well plates (Greiner Bio-One; Kremsmunster, Austria) with a final
volume of 50 - 100 µL/well. Protein precipitation was measured as turbidity
(absorbance at 360 nm (A360)). The putative chaperone proteins being tested were added
at different concentrations to determine whether they could rescue the client protein
from precipitation. BSA was used as a non-chaperone control protein in the GST
precipitation assay; OVA was used as a non-chaperone control protein in the remaining
assays.

2.7

Size Exclusion Chromatography (SEC)

Unless specified otherwise, a SuperoseTM 6 10/300 column (GE Healthcare) was
equilibrated in PBS/Az at room temperature. All samples were filtered through a
Minisart RC15 0.45 µm syringe filter (Sartorius Stedim Biotech) or through an
Ultrafree® 0.45 µm centrifugal filter unit (Millipore) before being loaded onto the
column using an ÄKTA FPLC (GE Healthcare). Protein was passed over the column at
0.3 mL/min and the A280 of the eluate monitored continuously. If a preparative run was
performed, the eluate was collected using the Frac-950 ÄKTA fraction collector.
Molecular mass standards (HMW Gel Filtration Calibration Kit, Amersham Pharmacia
Biotech, Piscataway, NJ, USA) were used to calibrate the column and allow estimation
of the sizes of proteins in solution.
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2.8

Circular Dichroism Spectroscopy

A Jasco Model J-810 (Jasco, Easton, MD, USA) spectropolarimeter linked to a
CDF-426S/L Peltier system (Jasco) was used to acquire circular dichroism (CD) data.
Far-UV (180 - 250 nm) CD studies were undertaken to compare the secondary structure
of proteins. Samples were analysed using a 1 mm CD cell, acquiring spectra at room
temperature with a sensitivity of 100 millidegrees and a bandwidth of 1 nm. The
scanning mode was continuous at 50 nm/min and 6 data sets were accumulated before
the average was displayed.

2.9

Making Chemically Linked Protein
Conjugates

x

CLU, MSA and HSA were coupled individually to OVA using the chemical cross linker
SMCC to generate CLU-OVA, MSA-OVA and HSA-OVA respectively. OVA was
reduced using 20 mM DTT in conjugation buffer (5 mM EDTA in PBS, pH 7.2) for
2 h at room temperature. At the same time the protein to be conjugated to OVA was
reacted in conjugation buffer with a 20 - fold molar excess of SMCC for 2 h at
room temperature. DTT and excess SMCC were removed from the mixtures by
fractionating over separate PD10 desalting columns equilibrated in conjugation
buffer. SMCC derivatised proteins and reduced OVA were combined at a molar ratio
of 1.5:1 respectively and shaken for 2 h at room temperature, then overnight at 4 °C.
Unconjugated proteins were removed by SEC on a SuperoseTM 6 10/300 column
equilibrated in PBS, and the HMW reaction products concentrated using a Vivaspin 20
(30 kDa molecular weight cut off) if required.
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2.10

Production of CLU/OVA Complexes

As CLU is a chaperone protein it is able to bind destabilised proteins in solution.
Numerous conditions to destabilise OVA and allow CLU to form soluble complexes
with it were investigated. It was found that when 10 mg/mL OVA in PBS was incubated
at 37 °C with 400 mM DTT, extensive protein precipitation occurred. Under these
conditions, 1 mg/mL CLU was able to inhibit some of this precipitation and soluble
HMW complexes of CLU/OVA were detected by SDS-PAGE and SEC. As not all
OVA precipitated, SEC using a SuperoseTM 6 10/300 column equilibrated in PBS was
used to separate free OVA from HMW CLU/OVA complexes.

2.11

Endotoxin Removal

Endotoxin was removed from samples using EndoTrap® red (Hyglos, Bernried,
Germany) following the manufacturer’s protocol. Samples were applied twice to the
EndoTrap® column to ensure efficient removal and rather than using the equilibration
buffer provided, a “half strength” PBS solution was created by diluting the protein (in
1X PBS) into an equivalent volume of endotoxin free water. This is recommended by
the manufacturer as an alternative to the equilibration buffer if the equilibration buffer is
not suited to downstream uses of the protein.

2.12

Standard Tissue Culture Techniques

2.12.1

Tissue Culture

Cells were routinely cultured in medium consisting of DMEM:F-12 supplemented with
10% (v/v) FCS and incubated in a Heraeus HERAcell humidified incubators at 37 °C
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and 5% (v/v) CO2. All tissue culture was undertaken using sterile techniques in a
laminar flow biohazard hood. All solutions used for tissue culture were sterile and
pre-warmed to 37 °C before use.

2.12.2

Retrieving Cells from Frozen Stocks

Cryovials containing the desired cells were removed from storage in liquid nitrogen and
placed in a pre-warmed (37 °C) container of ethanol ensuring the seal of the vial was
not submerged. The container was swirled until the majority of the cell suspension was
defrosted. The cell suspension was placed in a sterile 50 mL tube and topped up with
DMEM:F-12 medium. The tube was then centrifuged at 300 x g for 5 min at 22 °C to
wash the cells, the medium removed and the cell pellet resuspended in DMEM:F-12
medium supplemented with 10 - 20% (v/v) FCS and placed in a 25 cm2 tissue culture
flask.

2.12.3

Passaging of Mammalian Cells

2.12.3.1

Adherent Cell Lines

Passaging of adherent cell lines involved the culture medium being removed and the
cell monolayer being washed with DMEM:F-12 to remove traces of FCS. The cells
were then incubated with a sufficient volume of trypsin/EDTA to cover the base of the
flask and incubated for 3 - 4 min in a Heraeus HERAcell humidified incubator at
37 °C and 5% (v/v) CO2 until the monolayer was no longer attached to the flask. The
cells were poured into either a 15 mL or 50 mL centrifuge tube, the flask washed with
DMEM:F-12 and this then placed into the same tube, before centrifugation as above.
The cell pellet was subsequently resuspended in 1 - 2 mL of culture medium and the
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flask re-seeded (or a new flask seeded) with 1/10 to 1/3 the number of cells (depending
on the cell line, confluency required and health of the cells).

2.12.3.2

Suspension Cell Lines

Culture (containing suspended cells) was placed into a sterile 15 mL tube and
centrifuged as above. The supernatant was removed and the pellet resuspended in
1 - 2 mL of culture medium. This suspension was then used to seed flasks at the
required density.

2.12.4

Cryogenic Storage of Cell Lines

Cells were removed from the flasks as indicated above but rather than the cell pellet
being resuspended in culture medium they were resuspended in ice cold freeze mix
(50% (v/v) FCS, 10% (v/v) DMSO and 40% (v/v) DMEM:F-12). Aliquots (1 mL)
were dispensed into sterile cryovials and placed in a pre-chilled Cryo 1 °C Freezing
Container (Nalgene, Sydney, NSW, Australia) which was then stored in a - 80 °C
freezer overnight to achieve a - 1 °C/min rate of cooling. The vials were then transferred
to liquid nitrogen for long term storage.

2.13

Bacterial Culture Methods

2.13.1

Bacterial Strains and Culture Methods

Escherichia coli was routinely cultured in Luria Bertani (LB) broth (10 g/L tryptone,
5 g/L yeast extract, 171 mM NaCl in dH2O), or on LB agar (LB broth supplemented
with 15 g/L agar) plates. When the E. coli had been transformed with plasmids
encoding antibiotic resistance, the media and/or agar was supplemented with the
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appropriate selection antibiotic, typically 100 µg/mL Ap unless otherwise specified.
Bacteria were cultured overnight at 37 °C. Liquid suspensions were created by
inoculating LB broth with a single colony of bacteria and incubated overnight at 37 °C
with shaking (220 rpm).

2.13.2

Making Electrocompetent Cells

A single colony of E. coli (BL21 (DE3) for expression, or DH5α as a maintenance
strain) was used to inoculate 5 mL of LB broth (starter culture) followed by overnight
incubation at 37 °C with shaking (220 rpm). The starter culture was then added to
95 mL of pre-warmed LB broth. The cultures were grown under standard conditions
until an optical density at 600 nm (OD600) of 1.0 was reached. The cells were then
centrifuged in chilled centrifuge bottles at 5,000 x g for 15 min at 4 °C. All following
steps were performed on ice using sterile, ice cold buffers to ensure the cells remained
cold. To minimise the conductivity of the cell suspension, the cell pellet was first
washed in 100 mL of dH2O (centrifuging as above), followed by another wash with
50 mL dH2O. The dH2O washes were followed by a wash in 20 mL of 10% (v/v)
glycerol in dH2O, and the pellet finally resuspended in 500 µL 10% (v/v) glycerol,
aliquoted into sterile microcentrifuge tubes (40 µL/tube) and stored at - 80 °C until
required.

2.13.3

Transformation into Competent E. coli Strains

2.13.3.1

Transformation into Electrocompetent E. coli

A 40 µL aliquot of electrocompetent E. coli was mixed with ~ 50 ng DNA (in between
1 and 4 µL of water) and transferred to a 2 mm gap electroporation cuvette (Astral
Scientific, Caringbah, NSW, Australia). Transformation by electroporation occurred in
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a Bio-Rad Gene Pulser at 2.5 KV, 25 µFD and 200 Ω and the cells then transferred to
500 µL of pre-warmed LB broth and incubated at 37 °C for 1 h with shaking. The
bacteria were then plated on LB agar plates containing an appropriate selection agent.
All plates were incubated overnight at 37 °C.

2.13.3.2

Transformation into Chemically Competent E. coli

Chemically competent cells were kindly provided by Dr. Jake Matic (University of
Wollongong, NSW, Australia) and thawed on ice before transformation. Approximately
50 ng of DNA was added to the cells and gently mixed, the cells incubated on ice for
30 min followed by ‘heat shock’ at 42 °C for 45 s. The cells were placed on ice for
2 min before adding them to 500 µL pre-warmed LB broth and incubation at 37 °C for
1 h with shaking. The bacteria were then plated and incubated as above.

2.13.4

Making Glycerol Stocks of Transformed xxx
Bacteria

Bacterial glycerol stocks were created for long term storage of bacterial strains and
transformed bacteria. In the case of transformed bacteria the plasmids were placed into
the maintenance strain DH5α for long term storage. A single colony was used to streak
an entire agar plate to promote as much growth as possible. All bacteria from the plate
were collected using a sterile inoculating loop and placed in 1 mL sterile glycerol
storage buffer (20% (v/v) glycerol, 1% (w/v) casamino acids in dH2O), vigorously
mixed to create a homogenous suspension and frozen at - 80 °C.

48

Chapter 2: Methods

2.13.5

E. coli Plasmid DNA Extraction

Plasmid DNA was extracted from E. coli cultures using the Wizard® Plus SV
Minipreps DNA Purification System (Promega). A culture was prepared by inoculating
5 mL LB broth (containing the appropriate antibiotic) with a single E. coli colony and
grown overnight at 37 °C with shaking. This culture was then centrifuged at 10,000 x g
for 5 min and the pellet processed according to the manufacturer’s instructions, except
DNA was incubated in 50 µL nuclease-free water for 5 min prior to elution.

2.14

Agarose Gel Electrophoresis

DNA was resolved on a 1% (w/v) TAE agarose gel by electrophoresis at 60 V in a
Bio-Rad MinisubTM using 1X TAE (400 mM Tris Base, 10 mM EDTA, 1.142% (v/v)
glacial acetic acid, pH 8) electrophoresis buffer. DNA was visualised by ethidium
bromide staining and recorded using an EC3 Darkroom W/Gel HR camera gel
documentation system (UVP BioImaging Systems, Upland, CA, USA).
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3 Production of Chaperone Active
Recombinant Clusterin
3.1

Introduction

The production of a recombinant form of CLU would be advantageous for many
purposes. For example, it would allow for mutagenesis studies to be performed, which
could help identify the specific residues of CLU directly involved in its chaperone
action. It could also provide a source of CLU to undertake structural studies such as
crystallisation, or to use in the development of CLU as a therapeutic. For these and
related reasons many research groups have previously attempted to produce rCLU,
although none of the previous products were tested for chaperone activity, and most
were poorly characterised. Developing a functionally active form of rCLU is predictably
challenging because the molecule contains 5 disulfide bonds and, before secretion is
normally proteolytically processed into an α- and β-chain, and highly and variably
glycosylated to between 17 and 27% of the total mass of the molecule (Kapron et al.
1997). These post-translational modifications suggest that using a eukaryotic expression
system may be the best approach to produce rCLU. However, CLU was shown to retain
its chaperone action following deglycosylation (Stewart et al. 2007), which raises the
possibility of expressing functional rCLU in bacteria.
Many approaches have been trialled in the past. Expression of rCLU in an insect based
expression system resulted in rCLU that was not proteolytically cleaved into α- and
β-chains, variable levels of glycosylation and low yield (Dawes 2002). Other studies
using a baculovirus expression system in an insect cell line resulted in the production of
under-glycosylated, non-secreted rCLU that had not been post-translationally cleaved
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into mature α- and β-chains (Bajari et al. 2003), indicating that this may be a common
problem when trying to express rCLU in a insect based system. A study using a yeast
expression system (Pichia pastoris) indicated that a glycosylated, disulfide-bonded
heterodimeric form of rCLU can be produced; however, it was partially proteolytically
degraded (Lakins et al. 2002).
Other groups have expressed rCLU in E. coli (Heller et al. 2003), yeast (Hakkoum et al.
2008) and various mammalian cell lines (Boggs et al. 1996; Guan et al. 2012). In these
studies rCLU was not well characterised; typically a Western blot was performed to
verify the identity of the product (although in some cases this is not shown), and in most
cases SDS-PAGE analyses are not shown nor is the purity of the sample even
commented on. Methods used to purify rCLU are also poorly described in these
publications, making it hard to reproduce and/or validate the methods. Furthermore,
none of these previous studies attempted to verify that the product was chaperone
active.
Earlier work in this laboratory established the difficulties of producing pure rCLU from
cultured mammalian cells. One major problem with this expression system was the
formation of HMW complexes between secreted CLU and misfolding proteins in the
culture medium (Stewart 2007). Collectively, the available information raises serious
questions about whether any of the published studies cited above have in fact produced
‘pure’ rCLU, or indeed a functionally active product.
Several companies currently sell rCLU ranging in price from US$2,900 to US$5,500
for 1 mg. These products are generally not well characterised and the purity of the
samples is unclear. In some instances an SDS-PAGE image showing both reduced and
non-reduced samples is made available, although often only one or the other, or none at
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all is shown. For example, Figure 3.1 shows an SDS-PAGE analysis of rCLU (provided
from the supplier; BioVendor), in which the protein purity is clearly poor.

1
97
66
45
31

2

3
Figure 3.1 SDS-PAGE analysis of rCLU available for
purchase from BioVendor. Lane 1: Molecular weight
markers, sizes indicated in kDa. Lane 2: Shows a 5 µg sample
of reduced and heated HEK293 derived rCLU. Lane 3: Shows
a 5 µg sample of non-reduced and heated HEK293 derived
rCLU.
Image obtained from

21
14

http://www.biovendor.com/country281/product/proteins/
clusterin-human-hek293

The current study explored many routes, including both bacterial and mammalian
expression systems, to obtain a source of pure and chaperone-active rCLU.
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3.2

Methods

Bacteria are fast and inexpensive to grow and often produce high yields of recombinant
protein. They cannot, however, glycosylate proteins nor can they perform proteolytic
processing. It has been shown that the chaperone action of CLU is maintained following
enzymatic deglycosylation (Stewart et al. 2007), indicating that the conjugated sugars
are not required for chaperone activity. Furthermore, it is not yet known whether the
post-translational proteolytic cleavage to produce the α- and β-chains of CLU is
required for chaperone activity. Therefore, considering all the available information, a
bacterial expression system was thought to be worthy of initial investigation.

3.2.1

Bacterial Expression System

Human CLU cDNA was cloned in to a pDEST42 expression vector, to yield
pDEST42-CLU, by a previous Masters student in this laboratory (Yvonne Gonzales,
University of Wollongong). However, a stop-codon had been included in the sequence
prior to the vector-encoded C-terminal His-tag so it was not possible to use Ni-NTA
affinity chromatography to purify the bacterially expressed rCLU (b-rCLU). In the
literature there are a number of reported methods used for the production of soluble
recombinant proteins in bacteria. It was unknown which of these methods would work
and therefore many methods were trialled in attempts to purify a chaperone active form
of rCLU expressed in bacteria (i.e. b-rCLU).

3.2.1.1

Purification of brCLU from Inclusion Bodies

Electrocompetent BL21star E. coli were transformed with pDEST42-CLU as outlined in
section 2.13.3.1. Plasmid DNA was extracted from the bacteria (section 2.13.5) to
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confirm the purity and presence of the desired plasmid. Extracted plasmids were
digested with EcoRI (5 µL DNA, 1 µL EcoRI, 2 µL EcoRI buffer, 12 µL dH2O)
overnight at 37 °C before analysis of both digested and undigested plasmid by agarose
gel electrophoresis (section 2.14). Plasmids should only linearise if the CLU sequence
is present because the EcoRI recognition sequence is not present in pDEST42. Two
E. coli clones identified as containing pDEST42-CLU were subsequently prepared for
storage at - 80 °C (section 2.13.4) and tested for protein expression.
Two 15 mL starter cultures (one for each clone) were inoculated with a single colony
and grown overnight at 37 °C. The starter culture was used to inoculate 1 L of
pre-warmed LB broth containing 100 μg/mL Ap. The culture was grown until an OD600
of 0.8 was reached before inducing expression with 0.3 mM IPTG and shaking
at 200 rpm overnight at 24 °C. Samples (1 mL) were taken before induction, and at
1, 2, 3 and 4 h, as well as after the overnight incubation. Samples were centrifuged at
10,000 x g for 5 min to pellet cells and resuspended in 60 µL PBS before being
sonicated using a Branson Sonifier® 250 (Branson, Danbury, CT, USA; two 10 s bursts
keeping cells on ice in between bursts, output 6, constant duty cycle). The sonicated cell
suspensions were further disrupted by adding 60 μL of cracking buffer (120 mM Tris
pH 6.8, 2% (w/v) SDS, 20% (v/v) glycerol, 0.02% (w/v) bromophenol blue, 10% (v/v)
2-mercaptoethanol) and boiling in a water bath for 5 min. SDS-PAGE (section 2.3)
showed higher expression levels in one clone than the other, so this clone was used for
all following experiments.
Determination of whether b-rCLU was contained within the soluble or inclusion body
fraction was determined in subsequent experiments using the cOmplete Lysis-B (2x),
EDTA-Free Kit (Roche Diagnostics, Australia) as per the manufacturer’s directions.
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To extract b-rCLU from inclusion bodies, the thawed bacterial culture pellet was
resuspended in 5 mL lysis buffer (300 mM NaCl, 46.6 mM Na2HPO4, 3.4 mM
NaH2PO4, 0.75 mg/mL lysozyme, 10 U/mL DNase 1, 1 mM PMSF; pH 8.0) per gram
of bacterial pellet. During resuspension a Complete® Protease Inhibitor Cocktail tablet
was added. The suspension then underwent three freeze/thaw cycles using liquid
nitrogen and a 37 °C water bath respectively. The solution was pelleted at 10,000 x g
for 30 min and the supernatant discarded. The pellet was resuspended in 25 mL of wash
buffer (300 mM NaCl, 46.6 mM Na2HPO4, 3.4 mM NaH2PO4, 0.5% (v/v) Tx-100;
pH 8.0) and centrifuged at 25,000 x g for 30 min, this step was repeated four times to
wash away any proteins that may have non-specifically adsorbed onto the hydrophobic
inclusion bodies (Clark 1998) and maximise purity. The pellet was then resuspended in
5 mL of solubilisation buffer (300 mM NaCl, 46.6 mM Na2HPO4, 3.4 mM NaH2PO4,
8 M urea, 10 mM DTT; pH 8.0). Due to the gelatinous nature of the pellet, once the
majority had been resuspended, the solution was gently shaken at 4 °C overnight to
dissolve the remainder of the pellet. The supernatant was then clarified by
centrifugation for 30 min at 25,000 x g prior to further use.

3.2.1.2

SEC Purification

A Superose™ 6 10/300 column was equilibrated in solubilisation buffer and solubilised
inclusion bodies were loaded and fractionated as detailed in section 2.7. Alternatively,
solubilised inclusion bodies that had been dialysed down a urea step gradient (see
section 3.2.1.5) into PBS containing 5 mM DTT (to maintain reducing conditions) were
separated using a Superose™ 6 10/300 column equilibrated in PBS containing 5 mM
DTT (detailed in section 2.7).
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Fractions identified by non-reducing SDS-PAGE as containing b-rCLU (migrating at an
apparent mass of ~ 50 kDa), with minimal contamination by HMW aggregate, were
combined for further use. To confirm the presence of b-rCLU, Western blot analysis
(section 2.4) was undertaken using undiluted G7 and 41D hybridoma supernatants as
the primary antibody (Table 2.2), and either sheep-anti-mouse Ig-HRP conjugate or
goat-anti-mouse Ig-HRP conjugate as the secondary antibody (Table 2.3).

3.2.1.3

Direct Dilution

Direct dilution of b-rCLU into a refolding buffer was trialled on a small scale to
determine efficacy. A volume of 200 µL b-rCLU in solubilisation buffer was added
dropwise to 1 mL refolding buffer (50 mM NaH2PO4, 300 mM NaCl, 1 mM DTT,
10% (v/v) glycerol, 0.1% (w/v) Az; pH 8.0). This resulted in essentially all the protein
precipitating, and hence this method was not pursued further.

3.2.1.4

“Fast” Dialysis

A small sample of b-rCLU in solubilisation buffer was dialysed against PBS
supplemented with 5 mM DTT. This gave similar results to the direct dilution method,
and so a slower method of dialysis was subsequently trialled.

3.2.1.5

Urea Step Gradient Dialysis

Solubilised b-rCLU (after SEC, section 3.2.1.2) was dialysed against a urea step
gradient. This gradient was created by either making new buffers at the desired urea
concentration in PBS or by removing a certain volume of dialysis buffer and replacing it
with PBS to create the new desired concentration of urea; this reduced the cost of
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dialysis especially at higher concentrations of urea. The urea concentration was reduced
three times a day (approximately every 4 h) stepping down in 1 M increments from 6 M
to 1 M urea (i.e. 5 changes), followed by dialysis against 0.5 M, then 0.25 M urea in
PBS before dialysis against 3 changes of PBS/Az.
In one case urea gradient dialysis was undertaken prior to SEC (see section 3.2.1.2)
maintaining a concentration of 5 mM DTT at all times. Relative to the samples
containing both 8 M urea and 5 mM DTT, when analysed by SEC, the fully dialysed
samples contained a higher proportion (~ 70%) of material eluting at a position
corresponding to the size exclusion limit of the column (4 x 107 Da). This indicates that
b-rCLU formed HMW aggregates in the absence of urea, even when 5 mM DTT was
present.
Following removal of DTT via dialysis, b-rCLU samples obtained from SEC (migrating
at an apparent mass of ~ 75 kDa, with minimal contamination by HMW aggregate)
began to form HMW aggregates presumably forming inappropriate inter-molecular
disulphide bonds. Nevertheless, this step gradient dialysis method produced b-rCLU
that remained soluble and this product was used in subsequent experiments.

3.2.1.5.1

Reduction and Alkylation

As stated above, the urea solubilised b-rCLU subsequently subjected to step gradient
dialysis into PBS/Az contained HMW aggregates, suggesting that it had incorrectly
refolded. A range of treatment conditions were tested for their ability to stably disrupt
the HMW aggregates formed. Following treatment, samples were analysed by SEC on a
BIOSEP™-SEC-4000 column (Phenomenex, Torrance, CA, USA; 50 µL loaded and
run at 0.5 mL/min). It was found that reducing 1 mL (4 mg) of b-rCLU with 50 mM
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DTT for 18 h gave over 80% non-aggregated b-rCLU. Following reduction, the sample
was passed over a PD10 column equilibrated with PBS + 3 mM EDTA to remove DTT,
and fractionated into a quartz 96 well plate. The wells with the highest A280 values were
pooled and alkylated with 50 mM IAM overnight at 37 °C with shaking. It was
subsequently discovered that these conditions were inadequate to fully alkylate the
reduced clusterin as SEC showed that the protein once again formed HMW aggregates.
Subsequently, different alkylating and capping agents were trialled; alkylating agents
irreversibly modify cysteine residues within the protein by the addition of an alkyl
group, whereas ‘capping’ with cysteine forms cysteine-cysteine bonds between cysteine
groups of the protein and free cysteine groups in solution. After reduction and removal
of DTT as above, free thiol groups were modified with either a 100-fold molar excess of
L-cysteine (cysteine; a ‘capping’ agent) or 50 mM of the alkylating reagents NEM and
IAA. All reactions were carried out overnight at 37 °C with shaking.

3.2.1.5.2

Binding to Monocyte Derived Macrophages

Binding of b-rCLU both in a non-reduced form and reduced and alkylated with IAM
(even though it was not fully alkylated; see above) were tested for binding to human
monocyte derived macrophages by our French collaborators (Jeannin et al. INSERM,
Angers) and compared with wtCLU purified from human plasma and flagellin as a
negative control. Differences between the results were assessed for statistical
significance using un-paired student’s t-test analysis.
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3.2.1.5.3

Circular Dichroism Spectroscopy

CD analysis was undertaken as described in section 2.8 on non-reduced b-rCLU,
b-rCLU that had been alkylated with IAM or reduced and capped with cysteine, and
compared with analyses of wtCLU.

3.2.1.5.4

Chaperone Assay

To determine whether b-rCLU had chaperone activity a chaperone assay (section 2.6)
was undertaken to compare the respective activities of wtCLU, b-rCLU, b-rCLU
alkylated with IAM and the non-chaperone control protein BSA.

3.2.1.6

Refolding Assay

As the step gradient method of refolding b-rCLU produced HMW aggregates,
alternative refolding methods were trialled. To optimise refolding of b-rCLU, various
additives and concentrations of b-rCLU were investigated in a refolding assay
performed in a multiwell plate format. Initially b-rCLU (3 mg/mL) in 4 M urea/PBS/Az
containing 5 mM DTT (a buffer which prevented the formation of HMW aggregates)
was binary diluted across a 96 well plate in either (i) PBS/Az, (ii) PBS/Az + 400 mM
L-arginine, (iii) PBS/Az + 2 mM reduced glutathione, or (iv) PBS/Az + 400 mM MgCl2
and 400 mM CaCl2, and incubated at 4 °C overnight. These samples, and the starting
material, were then analysed by non-reducing SDS-PAGE to determine whether any of
the additives were able to promote the correct refolding of b-rCLU to produce b-rCLU
that in the absence (or at reduced levels) of reducing agents remained free of HMW
aggregates. The presence of L-arginine in the samples resulted in the formation of
HMW aggregates regardless of dilution factor, whereas the samples diluted into buffers
containing reduced glutathione or MgCl2 and CaCl2 appeared the same as the starting
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material on SDS-PAGE (data not shown); in these experiments, however, some
precipitation of Ca and Mg salts (attributable to Ca/Mg-phosphate formed with the
phosphate buffer in PBS) was noted.
A HEPES buffer lacking DTT was next used to avoid the previously observed
precipitation of Ca/Mg-phosphate salts. DTT was removed from the sample by rapid
buffer exchange over a PD10 column equilibrated in 10 mM HEPES buffer containing
4 M urea, pH 7.4, and the protein was binary diluted across a 96 well plate in 10 mM
HEPES buffer, pH 7.4, containing either (i) 4 M urea, (ii) 2 M urea, (iii) 1 M urea,
(iv) 4 M urea + 400 mM MgCl2 and 400 mM CaCl2, (v) 2 M urea + 400 mM MgCl2
and 400 mM CaCl2, or (vi) 1 M urea + 400 mM MgCl2 and 400 mM CaCl2. Samples
were incubated overnight at 4 °C. SDS-PAGE analysis indicated that compared to
b-rCLU in 4 M urea alone, the addition of 400 mM MgCl2 and 400 mM CaCl2
minimised the formation of HMW aggregates (data not shown). The same samples were
analysed by SDS-PAGE five days later to determine whether this effect was maintained
over time. Samples of b-rCLU in 10 mM HEPES containing 4 M urea, 400 mM MgCl2
and 400 mM CaCl2 were subsequently dialysed against PBS.

3.2.1.7

Use of a pET32a Plasmid for the Expression of brCLU

A different vector (pET32a) was then trialled for the expression of b-rCLU as this
plasmid had previously been used to express soluble recombinant disulphide-bonded
proteins in bacteria (LaVallie et al. 1993; Carrick et al. 2001; Kuang et al. 2006). The
pET32a plasmid produces a thioredoxin fusion protein in which the thioredoxin moiety
enhances the solubility of the fusion partner, promoting the correct formation of
disulphide bonds and minimising the formation of inclusion bodies (LaVallie et al.
1993; Stewart et al. 1998). Contract cloning of human CLU cDNA into pET32a was
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performed by Genscript (Piscataway, NJ, USA) to yield pET32a-CLU. This plasmid
was transformed into electrocompetent BL21star E. coli (section 2.13.3.1) and a starter
culture inoculated with one of the resulting colonies. The overnight starter culture was
used to inoculate pre-warmed LB broth containing 100 μg/mL Ap. The culture was
grown until an OD600 of 0.6 was reached before inducing expression with 1 mM IPTG
and overnight shaking at 18 °C and 200 rpm. The cells were pelleted at 5,000 x g for
5 min before being resuspended in 2.5 mM EDTA, 20 mM Tris, pH 7.4, 100 µg/mL
lysozyme and sonicated using a Branson Sonifier® 250 (output 6, constant duty cycle)
for three 30 s intervals on ice. A quick method to determine whether b-rCLU was
contained within the soluble or inclusion body fraction of the bacterial cell pellet
involved centrifugation of the lysate at 10,000 x g for 10 min. Samples of the
supernatant and the pellet (solubilised in 8 M urea) were then loaded onto a SDS-PAGE
gel; b-rCLU was found exclusively in the inclusion body fraction (data not shown),
therefore this vector was not used in further experiments.

3.2.2

Mammalian Expression System

Ultimately, the bacterial expression system did not produce a functionally active form
of b-rCLU (see results). Therefore, a mammalian expression system using human
embryonic kidney 293 (HEK293) cells was subsequently used.

3.2.2.1

Transfection of HEK293 Cells

HEK293 cells were used to express mammalian recombinant CLU (m-rCLU) as they
are easily transfected and thus commonly used to express recombinant proteins, serum
and protein free media specifically developed for these cells are commercially available,
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and they had not previously been assessed in this laboratory for the expression of
m-rCLU.
To determine the appropriate concentration of geneticin to use when chemically
selecting transfectants, the toxicity of a range of geneticin concentrations (0 - 800 µM)
to HEK293 cells was tested. Geneticin was added into the growth medium and cell
proliferation and viability visually assessed using light microscopy over a period of
7 days. The lowest concentration of geneticin that caused cell death of was determined
(600 µM) and subsequently used to select transfected HEK293 cells.
For transfection, cells were seeded into a sterile 24 well plate at a range of
concentrations in DMEM:F-12 with 10% (v/v) FCS so that the well would be
approximately 80% confluent the following day. These cells were allowed to adhere to
the plate overnight in a tissue culture incubator under standard conditions. To generate
the transfection mixture, lipofectamine (2 µL) was added to 48 µL DMEM:F-12
medium, mixed gently and incubated for 5 min at room temperature, this was then
combined with 0.8 µg pRcCMV-CLU (kindly provided by Prof. Wilson, University of
Wollongong) in 50 µL DMEM:F-12 medium and incubated for 20 min at room
temperature; a mock transfection mixture was created without the addition of plasmid
DNA. Approximately 24 h after seeding, two wells were carefully washed 3X with
DMEM:F-12 and then each covered with 500 µL DMEM:F-12. Each well was the
supplemented with either the transfection mixture or the mock transfection mixture, and
incubated for 5 h under standard conditions before then adding 1.5 mL of DMEM:F-12
containing 10% (v/v) FCS to each well. The following day the medium was replaced
with DMEM:F-12 containing 20% (v/v) FCS and 600 µM geneticin. The media was
replaced when required (every 2 - 3 days) until all the cells in the mock transfected well
were dead. Supernatant was then collected from the transfected cells to test for
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expression of m-rCLU using an immuno dot blot procedure (section 3.2.2.2). Once
expression had been confirmed, cells were removed from the plate by vigorous pipetting
and transferred into a 25 cm2 flask containing DMEM:F-12 medium supplemented with
20% (v/v) FCS and 600 µM geneticin.

3.2.2.2

Determining the Expression of mrCLU

The expression of m-rCLU by transfected cells was tested using both immunoblot and
immuno dot blot procedures. For immunoblotting, supernatant was collected from
transfected cells and electrophoresed on a SDS-PAGE gel (section 2.3) followed by
protein transfer and immuno blotting (section 2.4); the blot gave an indication of
the purity of m-rCLU. In the case of the immuno dot blot procedure, a binary dilution
series of the transfected cell tissue culture supernatant was generated and each of the
dilutions individually spotted onto nitrocellulose membrane. For comparison, known
concentrations of wtCLU were also spotted onto the membrane, and the spots on the
membrane were thoroughly air dried. The membrane was then blocked and probed as
outlined in section 2.4, and gave an indication of the concentration of m-rCLU present
in the supernatant. In both cases the primary antibodies used were a 1:1 mixture of
undiluted G7 and 41D hybridoma culture supernatants (Table 2.2) followed by either
goat-anti-mouse-HRP or sheep-anti-mouse-HRP as the secondary antibody (Table 2.3).

3.2.2.3

Cloning by Limiting Dilution

To establish a high expressing clone of transfected HEK293 cells, cells were removed
from a flask as outlined in section 2.12.3.1, resuspended in 1 mL DMEM:F-12
supplemented with 20% (v/v) FCS and 600 µM geneticin, and counted using a
haemocytometer. Cells were then diluted to 20 cells/mL, 10 cells/mL, 5 cells/mL and
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2.5 cells/mL and each dilution plated into a 96 well plate. The plates were sealed with
masking tape to reduce evaporation and incubated under standard conditions. Cells not
used in the cloning were cryogenically stored (section 2.12.4). After one week, plates
were examined by light microscopy for wells containing growing cells. Cloning by
serial dilution relies upon the theory that if less than 1/3 of wells contain cells there is a
95% probability that the growth in any well is derived from a single cell (and therefore
represents a clone) (Lefkovits and Waldmann 1999). Once wells had reached between
50 and 100% confluence, they were screened for m-rCLU expression using the immuno
dot blot procedure (section 3.2.2.4). The three clones secreting the highest levels of
m-rCLU (between 10 and 15 µg/mL) were expanded in culture and used to seed
individual 25 cm2 flasks containing DMEM:F-12 supplemented with 20% (v/v) FCS
and 600 µM geneticin.

3.2.2.4

Weaning of Cells into Protein Free Media

Both untransfected and transfected HEK293 cells were progressively weaned from
DMEM:F-12 containing 20% (v/v) FCS and 600 µM geneticin into Ex-Cell® 293
medium or CD293 medium which are both protein free. This was done by progressively
diluting DMEM:F-12 with different concentrations of the protein free media, whilst
reducing the amount of FCS in the cultures until the cells were in only either Ex-Cell®
293 or CD293 media. As these media do not support the growth of adherent HEK293
cells (the cells grow as a suspension), gentle shaking of the cells was trialled to compare
growth with static cultures, and in all cases media was replaced every 48 h. Cell
proliferation, under all protein free conditions tested, was very low and therefore it was
not possible using this approach to produce the large volumes of culture required to
generate good yields of m-rCLU.
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3.2.2.5

Optimised Method for the Production of mrCLU

Three high expressing clones stably transfected with pRcCMV-CLU were investigated
for their ability to proliferate and maintain viability over a number of passages,
compared to a polyclonal population that had not been cloned by limiting dilution. The
polyclonal population grew faster in culture and with higher cell viabilities; cell
viability was monitored by light microscopy, and the dead cells were visible as
non-adherent, granulated cells and cell bodies in the culture medium (data not shown).
The polyclonal population yielded between 7.5 and 10 µg/mL of m-rCLU (as
determined by immuno dot blot; data not shown) and was subsequently used to produce
m-rCLU.
The polyclonal transfected culture was maintained in DMEM:F-12 containing
10% (v/v) FCS and 600 µM geneticin and routinely passaged when ~ 95% confluence
was reached (section 2.12.3.1). For expression, 175 cm2 flasks were seeded to
50% confluency in 35 mL DMEM:F-12 medium supplemented with 5% (v/v) FCS for
16 - 24 h to allow cells to adhere to the flask. Cells typically reached 60 - 80%
confluence during this time period and showed characteristic adherent morphology. The
medium containing FCS was subsequently removed, the cell monolayer gently rinsed
twice with DMEM:F-12 to remove any remaining traces of FCS, and 35 - 50 mL of
DMEM:F-12 was added to the flask. Following FCS removal, cells remained adherent
but appeared to round up slightly and form stronger associations with neighbouring
cells. Cells were allowed to die and the supernatant harvested by centrifugation after
7 - 10 days. The supernatant was filtered through a 0.45 µm cellulose nitrate filter, then
loaded onto a G7 anti-CLU mAb column and m-rCLU purified as detailed for plasma
derived CLU (section 2.5). After antibody affinity chromatography was undertaken,
cation exchange chromatography was used to further purify the recombinant product
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akin to what is used to purify plasma derived CLU (section 2.5). An additional ‘cleanup’ step of SEC on a Superose™ 6 10/300 column was undertaken to remove remaining
HMW contaminating proteins. The recombinant product was then tested for purity by
SDS-PAGE (section 2.3), secondary structure content (CD analysis, section 2.8) and
chaperone function (section 2.6).
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3.3

Results

3.3.1

Bacterial Expression System

Using the expression vector pDEST42 in BL21star E. coli, b-rCLU was contained
within the insoluble inclusion body fraction (Figure 3.2). SDS-PAGE analysis showed
the presence of two major bands at ~ 45 kDa and ~ 35 kDa (Figure 3.2), which were
both detected by Western blot analysis using anti-CLU antibodies (data not shown). The
calculated theoretical mass of mature, unglycosylated CLU is ~ 50 kDa (Swiss Institute
of Bioinformatics, ExPASy; CLUS_HUMAN; p10909), however, b-rCLU migrates at
an apparent mass of ~ 45 kDa, similar to that of deglycosylated wtCLU published by
Stewart et al. (2007) suggesting that when un- or deglycosylated, CLU migrates in
SDS-PAGE at an apparent mass slightly less than its actual mass. The band at ~35 kDa
most likely represents a cleavage product of b-rCLU, which is not uncommon using
bacterial expression systems. Using pET32a for the expression of b-rCLU also resulted
in it being contained within the insoluble inclusion body fraction (data not shown).
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Figure 3.2 Non-reducing SDS-PAGE analysis of soluble and inclusion body fractions from
BL21star E. coli transformed with pDEST42-CLU. Lane 1: Precision Plus Protein™
unstained standards with size indicated in kDa. Lane 2: Soluble fraction. Lane 3: Insoluble
fraction.
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Subsequent results shown are for b-rCLU expressed in E. coli transformed with
pDEST42-CLU. Work with pET32a-CLU was undertaken concurrently with work on
the mammalian expression system; as the use of pET32a-CLU also resulted in insoluble
b-rCLU contained within the inclusion body fraction, further work was not undertaken
with this vector.
In order to generate pure b-rCLU that was chaperone active many attempts were made
to correctly refold b-rCLU after solubilisation of the inclusion bodies with urea and
reducing agents. In many cases, attempts to remove the reducing agents resulted in the
precipitation of b-rCLU (Figure 3.3). Urea extraction of b-rCLU from inclusion bodies
produced a yield of between 100 and 120 mg/L bacterial culture, with a 95% recovery
of soluble product when using a step gradient dialysis method (3.2.1.5). However,
subsequent analyses indicated that this product was chaperone-inactive.
SDS-PAGE analysis of the sample containing 8 M urea and 5 mM DTT showed a major
species migrating ran at ~ 45 kDa (Figure 3.4a), corresponding to the expected size of
uncleaved, unglycosylated CLU, similar to the apparent mass of deglycosylated wtCLU
in SDS-PAGE (Figure 3.4c). However, once the urea and DTT were removed from the
samples, HMW aggregates began to form (Figure 3.4b) presumably due to the
progressive generation of inappropriate inter-molecular disulphide bonds between
b-rCLU molecules. A minor band at ~ 35 kDa was also detected by SDS-PAGE and
Western blot analysis using anti-CLU antibodies, suggesting that this band may
represent a cleavage product of b-rCLU, which is not uncommon using bacterial
expression systems. This cleavage product was not further characterised as b-rCLU was
not functional.
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Bacterial Expression System

pET32a‐CLU

Inclusion bodies

pDEST42‐CLU

Inclusion bodies

SEC chromatography

Direct Dilution

Direct Dialysis

Refolding Assay

Urea Gradient
Dialysis

Urea Gradient
Dialysis

SEC chromatography

Dialysis
Protein Soluble
Protein Precipitates
Out of Solution
Reduction and Alkylation

Chaperone Assay

Binding to Monocyte
Derived Cells

CD Analysis

Figure 3.3 Outline of the methods attempted to purify b-rCLU and the outcomes obtained.
Red crosses indicate where b-rCLU precipitated from solution. Further tests (indicated),
were undertaken with soluble b-rCLU by urea step gradient dialysis of solubilised inclusion
bodies.
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Figure 3.4 SDS-PAGE analyses of b-rCLU and deglycosylated wtCLU. Blue arrows
indicate bands corresponding to the predicted size of b-rCLU. Green arrows indicate a
putative cleavage product of b-rCLU (detectable via Western blot using anti-CLU
antibodies). a) Lane 1: PageRuler™ Unstained Protein Ladder molecular weight markers
with size indicated in kDa. Lane 2: Sample of b-rCLU after SEC purification in
solubilisation buffer containing 8 M urea and 5 mM DTT. b) Lane 1: PageRuler™
Unstained Protein Ladder molecular weight markers with size indicated in kDa. Lane 2:
Sample of b-rCLU after SEC purification in solubilisation buffer and urea gradient dialysis
into PBS/Az. Red arrow with black border indicates aggregated protein sitting at the base of
the well and the orange arrow indicates protein > 250 kDa sitting at the interface between
the 5% stacking and 10% resolving gel. c) Lane 1: PageRuler™ Unstained Protein Ladder
molecular weight markers with size indicated in kDa. Lane 2: Sample of deglycosylated
wtCLU, obtained from, and SDS-PAGE analysis undertaken by N. Farrawell (University of
Wollongong, 2012).
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Reduction and alkylation, or cysteine-capping, of b-rCLU was undertaken to inhibit the
formation of HMW aggregates following removal of urea and DTT. SEC analyses of
non-reduced b-rCLU showed HMW weight aggregates; after the use of strong reducing
conditions, capping with cysteine resulted in b-rCLU migrating at an apparent mass of
less than 70 kDa. Using the same reducing conditions, subsequent alkylation of b-rCLU
with IAM failed to prevent the subsequent formation of HMW aggregates in solution
(Figure 3.5).
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Figure 3.5 SEC analysis of b-rCLU before reduction, and after reduction and subsequent
capping with cysteine or alkylation with IAM; analysis was performed using a
BIOSEP™-SEC-4000 column equilibrated in PBS/Az. Protein elution was monitored using
an ÄKTA FPLC system UV monitor at 280 nm. The positions and masses (in kDa) of the
molecular weight markers are indicated by labelled arrows; the column exclusion limit (Vo)
≥ 1.5 x 106 Da.

A sample of b-rCLU alkylated with IAM or capped with cysteine was examined by CD
and compared to wtCLU and b-rCLU that had not been reduced or alkylated. Although
b-rCLU ran as HMW aggregates in solution when analysed by SEC, it showed similar
secondary structure to wtCLU as determined by CD analysis. Both alkylation with IAM
and cysteine capping of b-rCLU altered the secondary structure content (Figure 3.6).
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Figure 3.6 Circular dichroism analysis of b-rCLU. a) Comparison between wtCLU,
b-rCLU and IAM alkylated b-rCLU. b) Comparison between wtCLU, b-rCLU and cysteine
capped b-rCLU. Plots represent mean molar ellipticity of 6 acquisitions.

Binding of wtCLU, b-rCLU that had not been reduced or alkylated, and b-rCLU
reduced and alkylated with IAM, to human monocyte derived macrophages was tested
(Figure 3.7). Both wtCLU and b-rCLU show significantly increased binding to human
monocyte derived macrophages compared to the negative control (flagellin). However,
wtCLU shows significantly higher binding than b-rCLU (p = 0.016). Reduction and
alkylation of b-rCLU with IAM resulted in significantly lower binding than flagellin
(p = 0.0003).
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Figure 3.7 Binding of b-rCLU to human monocyte derived macrophages, as measured by
flow cytometry. Binding of b-rCLU and b-rCLU reduced and alkylated with IAM was
compared to wtCLU and flagellin as a negative control and reported in arbitrary
fluorescence units (AFU) (mean ± standard deviation; n = 4). * Significantly increased
binding compared to the negative control (flagellin) at (p < 0.05). § Significantly increased
binding compared to non-reduced and alkylated b-rCLU at (p < 0.02). ŧŧ Significantly lower
binding than the negative control (flagellin) at (p < 0.001), as determined by un-paired
student’s t-test.

The chaperone activity of b-rCLU was tested against two client proteins using either
heat (GST) or reductive stress (BSA) (Figure 3.8). Under both conditions, all forms of
b-rCLU tested lacked any detectable chaperone activity. In contrast, wtCLU dose
dependently inhibited protein precipitation. For the GST precipitation assay, BSA was
used as a non-chaperone control protein (Figure 3.8a). Not all concentrations of b-rCLU
and CLU tested are shown in the figure.
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Figure 3.8 Protein precipitation assays to test the chaperone activity of b-rCLU against two
client proteins. a) GST was heated at 60 °C; BSA (negative control), wtCLU (positive
control), b-rCLU and IAM alkylated b-rCLU were tested at the concentrations indicated.
The turbidity at 360 nm was recorded every 2 min, but for clarity only every 6 min is
plotted (mean ± standard deviation; n = 3). b) BSA was reduced with 20 mM DTT; wtCLU
(positive control) and non-reduced and alkylated b-rCLU were tested at the concentrations
indicated. The turbidity at 360 nm was recorded every 2 min, but for clarity only every
12 min is plotted (mean ± ½ range; n = 2).

As the bacterial expression system was unable to produce a chaperone-active form of
rCLU, a mammalian expression system was next trialled.
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3.3.2

Mammalian Expression System

The expression of m-rCLU by transfected HEK293 cells was confirmed by Western
blot analysis. Once expression of m-rCLU with a mass similar to that of wtCLU was
confirmed by both reducing and non-reducing SDS-PAGE and Western blot analysis,
these cells underwent cloning by limiting dilution in order to generate a high expressing
clone. Expression in the clonal wells was determined by immuno dot blot analysis of
culture supernatants, to easily distinguish between clones (Figure 3.9). Three highly
expressing clones were chosen for further testing.

10F8
5H11
10D9

Figure 3.9 Immuno dot blot of tissue
culture supernatant from wells
containing growing cell clones,
testing for m-rCLU expression.
Clones used for further use are
indicated in purple boxes and are
designated 5H11, 10D9 and 10F8, the
plate well coordinates from which
they were obtained. Spots correspond
to supernatants binary diluted from
left to right.

Following multiple passages, it was determined that clone 5H11 grew the most
vigorously and this was used for subsequent experiments. Expression of m-rCLU
in media containing FCS resulted in the presence of HMW contaminants that
co-purified with m-rCLU after affinity and subsequent chromatography steps. These
HMW bands were shown to contain m-rCLU as determined by Western blot analysis,
and may represent non-covalent complexes formed between m-rCLU and misfolded
media proteins. To reduce the production of these HMW complexes, numerous attempts

75

Chapter 3: Production of Chaperone Active Recombinant Clusterin

were made to grow m-rCLU expressing HEK293 cells in protein free media. In all
cases, cells showed low viability and proliferated poorly (data not shown).
The following method of m-rCLU production proved successful. Uncloned HEK293
cells stably transfected with pRcCMV-CLU were cultured in DMEM:F-12 containing
10% (v/v) FCS and 600 µg/mL geneticin; for expression, cells were seeded to
50% confluency and allowed to adhere for 16 - 24 h before being rinsed and the
medium replaced with FCS-free DMEM:F-12. The cells were then incubated under
standard conditions for 7 - 10 days, and the culture supernatant harvested once the cells
had died. The absence of FCS in the culture medium dramatically reduced the levels of
HMW contaminants in the purified sample. Low levels of HMW material were detected
in the purified m-rCLU by non-reducing SDS-PAGE, but this was comparable to
analyses of wtCLU purified from human plasma (Figure 3.10a).
Non-reducing SDS-PAGE analysis of m-rCLU detected a major band at ~ 75 kDa and a
minor band at ~ 53 kDa, compared to wtCLU which showed a major band at ~ 85 kDa
(Figure 3.10a). Reducing SDS-PAGE detected a band at ~ 30 kDa for m-rCLU and at
~ 35 kDa for wtCLU; in both cases these bands correspond to the co-migrating α- and
β-chains of CLU, indicating that m-rCLU was correctly post-translationally cleaved.
The differences in mass between m-rCLU and wtCLU are most likely due to lower
levels of glycosylation of m-rCLU by HEK293 cells. In both reduced samples minor
bands between 50 and 85 kDa were present, which may represent incompletely reduced
forms and/or minor uncleaved species (Figure 3.10b).
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Figure 3.10 Images of a) non-reducing and b) reducing SDS-PAGE analyses of m-rCLU
and wtCLU. In both images, Lane 1: PageRuler™ Unstained Protein Ladder molecular
weight markers with size indicated in kDa; Lane 2: Sample of purified m-rCLU; Lane 3:
Sample of wtCLU.

CD analysis of m-rCLU showed comparable molar ellipticity to that of wtCLU (Figure
3.11) indicating that they contain similar secondary structure content.
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Figure 3.11 Circular dichroism analysis of m-rCLU compared to wtCLU. Plots represent
mean molar ellipticity of 6 acquisitions.

Size exclusion analysis of m-rCLU on a Superose™ 6 10/300 column showed that it
migrated as a broad peak between 7 and 15 mL, with a maximum pea at 11.7 mL
(Figure 3.12). In contrast wtCLU showed several peaks between 10 and 15 mL with a
maximum absorbance at 13.6 mL. Another minor peak was also detected for both types
of CLU, with maxima at 15.5 mL (wtCLU) or 15.9 mL (m-rCLU) (Figure 3.12). Thus
both m-rCLU and wtCLU spanned the same size range of species in solution but
m-rCLU is biased more towards larger species than wtCLU.
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Figure 3.12 SEC analysis of wtCLU and m-rCLU using a Superose™ 6 10/300 column
equilibrated in PBS/Az. Protein elution was monitored by an ÄKTA FPLC system at
280 nm. The positions and masses (in kDa) of the molecular weight markers are indicated
by labelled arrows; the exclusion limit (Vo) ≥ 4 x 107 Da. The m-rCLU trace is purposely
vertically offset to more clearly display the results.

The chaperone activity of m-rCLU was subsequently tested at a range of concentrations
against 3 client proteins (OVA was used as a non-chaperone control protein in these
assays). Similarly to wtCLU, m-rCLU dose dependently inhibited the reduction-induced
precipitation of BSA; a concentration of 0.2 mg/mL (corresponding to a mass ratio of
chaperone to client of 1:7.5) fully inhibited precipitation of BSA (Figure 3.13).
Concentrations up to 0.75 mg/mL m-rCLU and wtCLU were tested, but as 0.2 mg/mL
m-rCLU was able to fully inhibit precipitation of BSA the higher concentrations are not
shown. OVA at 0.75 mg/mL was unable to inhibit precipitation of BSA. Under these
conditions, m-rCLU showed comparable chaperone activity to wtCLU at all
concentrations tested (Figure 3.13).
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Figure 3.13 Protein precipitation assays to test the chaperone activity of m-rCLU using
bovine serum albumin (BSA) as the client protein. DTT was used to induce the precipitation
of BSA. The turbidity at 360 nm was recorded every 5 min, but for clarity only every
30 min is plotted (mean ± standard deviation; n = 3). a) BSA ± DTT, wtCLU at the
concentrations indicated and OVA (at the highest concentration of CLU tested) as a
negative control. b) BSA ± DTT, m-rCLU at the concentrations indicated and OVA (at the
highest concentration of CLU tested) as a negative control.

In a second series of chaperone assays, like wtCLU, m-rCLU dose dependently
inhibited heat-induced CS precipitation, though complete inhibition was not seen even
at a 1:1 molecular mass ratio between m-rCLU and CS. Although m-rCLU was able to
inhibit aggregation of CS, it was not as effective as wtCLU against this client protein
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(Figure 3.14). At 0.2 mg/mL wtCLU inhibited end-point precipitation of CS by 93%
compared to 72% by m-rCLU; at 0.1 mg/mL wtCLU inhibited precipitation of CS by
83% compared to 29% by m-rCLU; and at 0.05 mg/mL wtCLU inhibited precipitation
of CS by 46% compared to 15% by m-rCLU.

a)
Absorbance (360 nm)

1.1

CS
1

CS + 0.05 mg/mL
mg/ml
wtCLU
CS + 0.1 mg/mL
mg/ml
wtCLU
CS + 0.2 mg/mL
mg/ml
wtCLU
CS + 0.2 mg/mL
mg/ml
OVA

0.9
0.8
0.7
0.6
0

50

100

150

Time (min)

Absorbance (360 nm)

b)

1.1

CS
1

CS + 0.05 mg/mL
mg/ml
m-rCLU
CS + 0.1 mg/mL
mg/ml
m-rCLU

0.9
0.8

CS + 0.2 mg/mL
mg/ml
m-rCLU
CS + 0.2 mg/mL
mg/ml
OVA

0.7
0.6
0

50

100

150

Time (min)
Figure 3.14 Protein precipitation assays to test the chaperone activity of m-rCLU using
citrate synthase (CS) as the client protein. CS heated at 43 °C to induce precipitation; the
turbidity at 360 nm was recorded every minute, but for clarity only every 5 min is plotted
(mean ± standard deviation; n = 3). a) CS ± wtCLU at the concentrations indicated and
OVA (at the highest concentration of CLU tested) as a negative control. b) CS ± m-rCLU at
the concentrations indicated and OVA (at the highest concentration of CLU tested) as a
negative control.
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A third series of chaperone assays were performed using CPK as the client protein
(Figure 3.15). Like wtCLU, m-rCLU dose dependently inhibited CPK precipitation. At
0.5 mg/mL a mass ratio of m-rCLU to CPK of 1:5.6, m-RCLU fully inhibited the
precipitation of CPK and was able to do this at a chaperone : client mass ratio
approximately half that required for wtCLU (1:5.6 versus 1:2.24, respectively).

Absorbance (360 nm)

a)

1.2

CPK
1.1

CPK + 0.2 mg/mL
mg/ml
wtCLU
CPK + 0.5 mg/mL
mg/ml
wtCLU
CPK + 1.12
mg/ml wtCLU
mg/mL
wtCLU
CPK + 1.12
mg/ml OVA
mg/mL
OVA

1
0.9
0.8
0.7
0

50

100

150

200

250

Time (min)
b)
Absorbance (360 nm)

1.2

CPK

1.1

CPK + 0.2 mg/mL
mg/ml
m-rCLU
CPK + 0.5 mg/mL
mg/ml
m-rCLU
CPK + 1.12
mg/mLm-rCLU
m-rCLU
mg/ml
CPK + 1.12
mg/mLOVA
OVA
mg/ml

1
0.9
0.8
0.7
0.6
0

50

100

150

200

250

Time (min)
Figure 3.15 Protein precipitation assays to test the chaperone activity of m-rCLU using
creatine phosphokinase (CPK) as the client protein. Precipitation of CPK was induced with
heat (43 °C) and measured as turbidity at 360 nm (mean ± standard deviation; n = 3).
a) CPK ± wtCLU at the concentrations indicated and OVA (at the highest concentration of
CLU tested) as a negative control. b) CPK ± m-rCLU at the concentrations indicated and
OVA (at the highest concentration of CLU tested) as a negative control.
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3.4

Discussion

Previously reported forms of rCLU are typically not well characterised and levels of
purity are highly variable, this is both in the literature and from commercially available
sources that charge up to $5,500 for 1 mg (Table 3.1). Therefore it is important to
identify a reliable method to generate rCLU that is correctly folded, pure and
functionally active. If this can be achieved it opens up new areas of research, including
the identification of functional residues / regions within the molecule, and it could also
provide a source of CLU to undertake structural studies such as X-ray crystallography,
or to use in the development of CLU as a therapeutic.
Bacterial expression systems typically produce high levels of recombinant products and
are frequently used for the expression of proteins. Therefore, a pDEST42-CLU vector
was initially used for expression as it had already been produced in our laboratory
(Gonzales, University of Wollongong). The recombinant protein product had not,
however, been fully characterised. Even though low concentrations of IPTG and low
temperatures were used during expression b-rCLU was contained within the insoluble
inclusion body fraction of the bacterial pellet (Figure 3.2). Reducing the amount of
IPTG used for initiation of expression has previously been reported to enhance the
solubility of recombinant proteins expressed in bacteria (Galloway et al. 2003; Li and
Cheng 2009). Lowering the temperature used during expression is also meant to
maximise solubility of recombinant products and limit inclusion body formation
(Schein and Noteburn 1988; Vera et al. 2007).
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Table 3.1 Characteristics of (human) rCLU described in previous studies, and commercially
available (human) rCLU products.
Expression System

Quality Assessment

Reference

Yeast (Pichia
pastoris)

• Glycosylated
• Disulfide-bonded heterodimers
• Proteolytically degraded

(Lakins et al. 2002)

Yeast (Pichia
pastoris)

• Western blot showing β-chain of CLU

(Hakkoum et al.
2008)

Insect Sf9 cells

• Low level expression
• Not cleaved into α- and β-chains
• Structurally different to serum CLU

(Dawes 2002)

Mammalian
(CHO cells)

• Glycosylated
• Cleaved into α- and β-chains

(Dawes 2002)

Mammalian
(HEK293 cells)

• None shown
• Claims Western blot analysis shows full
length secreted heterodimer

(Guan et al. 2012)

Mammalian
(AV12-664 cells)

• Western blot of reduced and non
reduced samples of “conditioned media”
• Cleaved into α- and β-chains

(Boggs et al. 1996)

E. coli (MBP-tag)

• None shown

(Heller et al. 2003)

Mammalian
(HEK293 cells)

• Low purity detected by SDS-PAGE

BioVender
catalogue number
RD172034100

Mammalian
(HEK293 cells)

• None shown

Neuromics
catalogue number
PR27111

E. coli (His-tag)

• ~ 45 kDa band detected by
SDS-PAGE
• Incomplete SDS-PAGE gel shown

Enzo Life Sciences
catalogue number
ALX-201-355

Mammalian
(NSO murine
myeloma cell line)

• None shown
• Cleaved into α- and β-chains

R&D Systems
catalogue number
2937-HS

Mammalian
(cell line not
specified)

• Reducing SDS-PAGE shows > 92%
purity

Sino Biological Inc.
catalogue number
11297-H08H

Mammalian
(HEK293 cells)

• None shown
• > 95% purity specified

PROSPEC Bio
catalogue number
CYT-278
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Due to the high level of expression of b-rCLU and the ease of production, attempts to
solubilise and refold b-rCLU were undertaken. Direct dilution into a refolding buffer
that had previously been successful for refolding CLU domains expressed in bacteria
(Stewart 2007) resulted in the gross precipitation of b-rCLU. Direct one-step dialysis of
b-rCLU in solubilisation buffer (containing 8 M urea and 10 mM DTT) against PBS
also resulted in gross precipitation of the protein. Subsequently, dialysis over 2 - 3 days
against a series of buffers containing progressively less urea (7 changes of buffer to
reduce the concentration of urea from 8 M to zero) resulted in a soluble product. SEC
(data not shown) and SDS-PAGE (Figure 3.4) analysis of this product showed that
HMW aggregates had been formed. Whilst in solubilisation buffer, SDS-PAGE analysis
showed that the majority of b-rCLU (> 95%) migrated at the expected size of
deglycosylated CLU with minimal HMW species present, suggesting that following
removal of urea and DTT the undesired inter-molecular association between b-rCLU
molecules occurred to form HMW complexes, the exact nature of these interactions was
not investigated.
The use of a number of refolding agents was also trialled including arginine (Chen et al.
2008), reduced glutathione (Clark 1998), MgCl2 and CaCl2 (Simons et al. 2002;
Yazdanparast and Khodarahmi 2005; Zhang et al. 2005b) in various concentrations of
urea and at various protein concentrations (lower concentrations of protein during
refolding often minimises unfavourable interactions). SDS-PAGE analyses indicated
that in the presence of 4 M urea, MgCl2 and CaCl2 appeared to reduce the formation of
HMW species when DTT was removed from the sample; however, following dialysis
into PBS/Az the overwhelming majority of b-rCLU precipitated from solution (Figure
3.3).
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Various conditions to dissociate aggregated b-rCLU formed after the step gradient
dialysis into PBS were examined. Quite harsh conditions (50 mM DTT, 18 h) were
required to achieve this. Once reduced, various alkylation reagents (IAA, IAM and
NEM) were examined for their ability to maintain b-rCLU free of HMW aggregates,
although none of the reagents tested were able to do this. There have been previous
reports in the literature that cysteine alkylation by maleimide derivatives (which
includes IAM and NEM) is inefficient (Galvani et al. 2001; Luche et al. 2004; Smejkal
et al. 2006) which may account for these results. The effects of cysteine as a ‘capping’
agent, where free cysteine was able to reversibly interact with the cysteine residues
within the protein to ‘cap’ them, was also examined. Cysteine was able to interact
with the free sulphydryl groups on b-rCLU and stop the subsequent formation of HMW
aggregates (Figure 3.5).
CD analysis of b-rCLU (still in HMW form) showed a similar secondary structure
content to wtCLU (Figure 3.6). Following reduction and alkylation with IAM or
capping of free sulphydryl groups with cysteine, the secondary structure content
changed. This is perhaps not surprising as in its native conformation CLU contains
5 disulphide bonds which could be disrupted by both alkylating agents and free
cysteine. The exposure of b-rCLU to harsh reducing conditions prior to alkylation or
capping may also play a role in altering its structure. The HMW aggregates of b-rCLU
may contain both normal disulphide bonds as well as inappropriate disulphide bonds
between molecules. Although b-rCLU was not cleaved into α- and β-chains, the CD
analyses indicated that its secondary structure content was similar to wtCLU, suggesting
that cleavage into α- and β-chains is not required to form the normal secondary
structures, although it may be required for aspects of the mature tertiary and quaternary
structure. When tested in two different chaperone assays, however, b-rCLU had no
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measurable chaperone activity (Figure 3.8). This lack of activity may result from it
being in the form of inappropriately disulphide-bonded HMW aggregates, from its lack
of proteolytic cleavage into α- and β-chains, or both.
Both wtCLU and b-rCLU that had not been reduced or alkylated showed significant
binding to human monocyte derived macrophages, however, wtCLU bound to the same
cells to a greater extent. Reduced and IAM alkylated b-rCLU showed the least binding
of all ligands tested, including the negative control (Figure 3.7). As b-rCLU that had not
been reduced or alkylated appears to show similar secondary structure to wtCLU this
may explain why some binding occurs. However, as this form of b-rCLU primarily
consists of HMW aggregates (> 50% by SDS-PAGE, 100% by SEC) it is likely that
some receptor binding sites are obstructed or altered, resulting in reduced binding
compared to wtCLU. Considering the altered secondary structure, and the lack or
chaperone activity of reduced and alkylated b-rCLU it is not surprising that it is unable
to bind to these cells. This means that b-rCLU is unlikely to be useful for the
development of a therapeutic as it would not be able to bind to misfolded extracellular
proteins and facilitate their clearance, which is thought to be an important role for CLU
in the body (Wyatt et al. 2009a; Wyatt et al. 2011; Dabbs et al. 2013).
The expression vector pET32a-CLU was tested after the experiments using the
pDEST42-CLU vector were undertaken, and whilst work was being undertaken using
the mammalian expression system. This vector produces a thioredoxin fusion protein
which has previously been shown to increase the solubility of the co-expressed
recombinant protein (Carrick et al. 2001; Kuang et al. 2007). As b-rCLU was still
contained within the insoluble inclusion body fraction of the bacterial pellet, and the
work with m-rCLU was beginning to look promising, no further work was undertaken
with this product.
87

Chapter 3: Production of Chaperone Active Recombinant Clusterin

As expression of a chaperone-active form of rCLU in bacteria was unsuccessful a
mammalian expression system was subsequently trialled. Previous work has shown that
obtaining a pure product from these systems is difficult (Stewart 2007). Culture media
proteins are subjected to sustained elevated temperature (37 °C) and shear stress if the
cultures are agitated. These conditions result in a progressive misfolding of some of the
proteins used to supplement the medium. As CLU is a chaperone it will bind to these
misfolded proteins to form soluble HMW complexes. In the body these complexes are
rapidly cleared (Wyatt et al. 2011), but in cell culture these clearance mechanisms
aren’t available, meaning that the HMW complexes remain in the medium and co-purify
with m-rCLU. Previously, separating the HMW complexes from non-complexed
m-rCLU has proved difficult, and the yield was low (Stewart 2007).
Cloning of transfected HEK293 cells by limiting dilution was undertaken to produce a
high expressing clone. One clone, 5H11, grew the most vigorously and this was used for
subsequent experiments. To minimise unfavourable interactions with proteins in the
culture medium two commercially available protein free media were tried, however the
cells grew poorly in these media. An alternative approach was next trialled in which a
polyclonal culture of HEK293 cells was maintained in culture medium containing 10%
(v/v) FCS, in which they grew satisfactorily and remained viable. For expression, the
cells were first passaged into DMEM:F-12 containing 5% (v/v) FCS to allow adherence
to the tissue culture flask, before being rinsed and placed in FCS-free DMEM:F-12
medium, and the culture supernatant collected after 7 - 10 days. Under these conditions
between 7.5 and 10 µg/mL m-rCLU was recovered from the culture supernatant
(estimated by a semi quantitative immuno dot blot). After 3-step purification (using
G7 anti-CLU mAb affinity chromatography, cation exchange chromatography and
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SEC) and concentration, 1 L of tissue culture supernatant yielded ~ 4.5 mg of pure,
chaperone active m-rCLU.
Non-reducing SDS-PAGE analysis showed that m-rCLU migrated as a lower mass
species than wtCLU (~ 75 kDa versus ~ 85 kDa, respectively). The apparent molecular
weight of the α- and β-chains under reducing conditions was also smaller for m-rCLU
(~ 30 kDa) than wtCLU (~ 35 kDa) (Figure 3.10). This demonstrates that, like wtCLU,
HEK293 expressed m-rCLU is a disulphide-bonded heterodimer comprised of α- and
β-chains, and suggests that HEK293 cells glycosylate m-rCLU to a lesser extent than
wtCLU. There was a minor band (constituting < 5 %) in the non-reduced m-rCLU
sample at ~ 50 kDa which may correspond to an unglycosylated form of m-rCLU or a
minor proteolytic fragment (Figure 3.10a). The molecular masses, determined by mass
spectrometry, of glycosylated and deglycosylated human wtCLU are 58 - 62 kDa and
~ 50 kDa, respectively (Kapron et al. 1997; Stewart et al. 2007).
CLU typically exists in physiological solution as a mixture of oligomers (Humphreys et
al. 1999); this characteristic of polydispersity is shared by a number of chaperones
including the sHSPs (Carver et al. 2003). As has been previously shown by Stewart et
al. (2007) and in this study (Figure 3.12), when analysed by SEC a small fraction
of wtCLU ran at the size exclusion limit of the column (≥ 4 x 107 Da), and a major
peak was detected at ~ 400 kDa. In this study, compared to wtCLU, the forms of
m-rCLU in solution were biased towards higher molecular weight species.
Deglycosylated CLU has previously been shown to migrate in SEC as a major peak at
~ 900 kDa (Stewart et al. 2007). Thus, the lower levels of glycosylation of m-rCLU,
relative to wtCLU, may have the effect of increasing the mean size of oligomers in
solution, but this remains to be definitively established. In the body wtCLU is produced
by many different types of tissues/cells and typically blood from more than one donor is
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pooled and used to purify wtCLU, leading to a sample with heterogeneous glycosylation
levels.
Mass spectrometry has previously shown molecular heterogeneity of wtCLU with
between 17 and 27% attached carbohydrate by weight. This was determined by
calculating the difference between the observed mass and the predicted molecular mass
of CLU based on the gene sequence (Kapron et al. 1997). This analysis could be
performed on m-rCLU to determine the exact glycosylation state and to establish the
variability of glycosylation using this production method. CLU has, however, been
shown to retain its chaperone activity following complete enzymatic deglycosylation
(Stewart et al. 2007). CD analysis showed that m-rCLU had similar secondary structure
content to wtCLU (Figure 3.11), as expected. It was previously shown that
deglycosylated CLU has a similar secondary structure content to wtCLU (Stewart et al.
2007).
HEK293 expressed m-rCLU was chaperone active against all three client proteins
tested. Depending on the individual client protein, m-rCLU showed either the same,
increased or decreased ability to inhibit precipitation compared to wtCLU. These client
protein-dependent differences in relative chaperone activity may relate to differences in
glycosylation and/or solution size between m-rCLU and wtCLU, although further work
would be required to confirm this. Further characterisation of m-rCLU could include
determination of its exact glycosylation state, the localisation of sugar groups on the
molecule, mass spectrometry to establish the precise molecular mass, and chaperone
assays using amyloid forming client proteins.
As m-rCLU is chaperone active, cleaved into α- and β-chains (SDS-PAGE analysis),
glycosylated (SDS-PAGE and SEC analysis) and has similar secondary structure
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content (CD analysis) to wtCLU, this now provides a viable route for the further study
of CLU. This may include: (i) The production of rCLU as a therapeutic agent for the
treatment of a wide range of protein deposition diseases, or as an adjuvant of the
immune system. (ii) The production and characterisation of CLU mutants, to identify
residues important in structure and function. Previous studies have identified that CLU
has at least three distinct binding sites for (a) unstressed ligands, (b) chaperone binding
site for stressed protein ligands and (c) binding site/s for the LRP2 and other cell surface
receptors (Lakins 1998; Lakins et al. 2002). The precise locations of these sites within
the CLU molecule have not been identified, however, using m-rCLU, site directed
mutagenesis may be undertaken on residues/regions potentially involved in these
interactions to identify those that are important. (iii) Other CLU mutants may also be
generated to determine if the chaperone efficiency of CLU and/or the clearance of CLU
bound to misfolded proteins can be increased, which could be valuable therapeutically.
It is thought that a primary physiological role for CLU is as an extracellular chaperone
which stabilises misfolded extracellular proteins and facilitates their clearance from the
body. The development of a valid source of correctly processed, functional rCLU opens
the door to increased understanding of how CLU performs its physiological roles and
potentially gives us the ability to develop this new knowledge towards an outcome that
will enhance human health.

91

Chapter 4: Binding and Internalisation of CLU and CLU-OVA

4 Binding and Internalisation of CLU and
CLUOVA
4.1

Introduction

In the literature there are many different cellular mechanisms reported to play a role in
the uptake of exogenous antigens, chaperones and chaperone-antigen complexes. The
method by which chaperone-antigenic peptide complexes induce cross-presentation
(where exogenously derived peptides are presented on MHC class I molecules) and
subsequent cross-priming (resulting CTL response to exogenously derived antigen
presented on MHC class I molecules) is still not clear in all cases; some studies have
shown that activation of the CTL response in vitro is dependent upon macropinocytosis
or phagocytosis (Kovacsovics-Bankowski et al. 1993; Norbury et al. 1995; Norbury et
al. 1997). However, the large amount of antigen required in order for these pathways to
give rise to a CTL response may limit their relevance in vivo (Heath and Carbone 1999).
Many groups instead have shown that internalisation via receptor-mediated endocytosis
is

important

for

cross-presentation

and

cross-priming

both

in

vitro

and

in vivo (see section 1.5.2) (Arnold-Schild et al. 1999; Singh-Jasuja et al. 2000b; Basu et
al. 2001; Thériault et al. 2005; Thériault et al. 2006; Gong et al. 2009a).
Preliminary work in our laboratory and by our collaborators has shown that scavenger
receptors may mediate the binding of CLU to human monocyte derived macrophages
and dendritic cells. Work by Wyatt et al. has also shown the involvement of scavenger
receptors in the binding of CLU-client-protein complexes to a rat yolk sac cell line
(BN), peripheral human monocytes and rat hepatocytes (Wyatt et al. 2011). However,
no previous work examined the mechanism by which CLU-OVA is taken up by APCs
or any other cell type.
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This study therefore sought to: (i) determine if CLU-OVA shows greater binding
and internalisation than either CLU or OVA alone; (ii) investigate the mechanism by
which CLU-OVA is internalised by APCs and other white blood cells using specific
inhibitors; and (iii) identify which intracellular compartments CLU-OVA is directed to
by confocal microscopy. Understanding the mechanism of uptake and intracellular
trafficking route taken by CLU-OVA may help to elucidate how CLU can modify
specific immune responses to OVA, which in turn might aid in the development a
CLU-based chaperone-peptide vaccine system.
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4.2

Methods

Three sources of cells were used for this study. These included an immortalised mouse
leukaemic monocyte-macrophage cell line (RAW 264.7), mouse bone marrow derived
macrophages, and human white blood cells. This (i) avoided any potential limitations
associated with the use of only immortalised cell lines; (ii) enabled the study of an
important murine APC, and (iii) sought to identify circulating human blood cell
populations that play a role in the uptake of CLU and CLU-OVA complexes.

4.2.1

RAW 264.7 Cells

RAW 264.7 cells were routinely cultured in DMEM:F-12 containing 10% (v/v) FCS.
When ~ 95% confluence was reached, the cell monolayer was rinsed with DMEM:F-12
to remove any dead cells or cellular debris and the adherent cells then removed using a
cell scraper (Greiner Bio-One), passaged at a 1:10 dilution and incubated under standard
conditions as outlined in section 2.12.3.1.
When being used for binding or internalisation assays, the cell monolayer was washed
in ice cold 1% (w/v) BSA/PBS, the cells harvested by scraping and washed twice in ice
cold 1% BSA/PBS by centrifugation at 300 x g for 5 min at 4 °C.

4.2.2

Bone Marrow Derived Macrophages

Murine bone marrow derived macrophages were derived from C57BL/6 mice. Mice that
were no longer required for other experimentation were euthanised by CO2 asphyxiation
by Tracy Maddocks (Animal House Manager, University of Wollongong) and the
femurs and tibias excised. Excess tissue was removed from the bones before they were
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soaked in 70% ethanol for 5 min to sterilise and subsequently allowed to air dry. The
ends of the bones were then removed with a sharp scalpel blade and the bone marrow
flushed out using DMEM:F-12 and a 25 gauge syringe. The suspension was then
homogenised by repeated aspiration and expulsion through the needle, and the cells then
pelleted by centrifugation at 300 x g for 5 min at 4 °C. Red blood cells were removed
from the sample by osmotic lysis. Cells were resuspended in 3 mL of 0.2% NaCl for
15 s followed by 3 mL of 1.6% NaCl to return the solution to an isotonic state. The tube
was topped up with DMEM:F-12 and centrifuged as above. Cells were resuspended
in macrophage complete medium (20% (v/v) L929 culture supernatant, 10% (v/v)
FCS, 50 U/mL penicillin, 50 µg/mL streptomycin in DMEM:F-12) and plated in
6 well plates at 5 x 105 cells/well in 3 - 4 mL medium. L929 cells secrete macrophage
colony-stimulating factor which is required for the differentiation of monocytes into
macrophages (Weischenfeldt and Porse 2008). L929 culture supernatant was generated
by the routine culture of the L929 cell line in DMEM:F-12 supplemented with 20%
(v/v) FCS; when the culture reached between 90 and 100% confluency the supernatant
was taken, filtered through a 0.22 µm sterile filter and stored at 4 °C until required for
the generation of macrophage complete medium. On day 3 the medium was removed
and replaced with fresh macrophage complete medium. Cells were used for binding
and internalisation experiments between days 5 and 7. Cell monolayers were washed in
1% BSA/PBS and cells removed by gentle scraping using the plunger of a 1 mL syringe
and washed twice in ice cold 1% BSA/PBS by centrifugation at 300 x g for 5 min at
4 °C.
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4.2.3

Purification of White Blood Cells

Fresh blood was collected from individuals using the University of Wollongong
phlebotomy services and heparin (2,500 U/mL of blood) added to prevent clotting.
Blood was centrifuged for 30 min at 3,000 rpm in a Heraeus Megafuge 1.0R benchtop
centrifuge at 4 °C to pellet the cells. The majority of the plasma was removed leaving
5 - 10 mL above the cell pellet. The buffy coat containing white blood cells was then
removed from the red blood cell pellet by pipetting with a plastic Pasteur pipette, placed
into a 50 mL tube and the tube topped up with PBS and centrifuged for 5 min at 300 x g
to wash the cells. Contaminating red blood cells were removed from the sample using
an osmotic lysis method; the cell pellet was resuspended in 5 mL of 0.2% NaCl for 30 s,
followed by the addition of 5 mL 1.6% NaCl to return the solution to an isotonic state.
The tube was then topped up with PBS and centrifuged as above to wash the cells. Cells
were then washed twice in 1% BSA/PBS prior to subsequent experimentation.

4.2.3.1

Determining Cell Type by Flow Cytometry

White blood cells obtained as detailed in section 4.2.3 were suspended in PBS and
analysed using a LSRII flow cytometer (BD Biosciences), examining forward scatter
(size) and side scatter (granularity). CD14 expression was also analysed; CD14 is
strongly expressed on monocytes, expressed at a medium level on granulocytes and at a
low level on lymphocytes (Antal-Szalmas et al. 1997). Samples of white blood cells
were incubated with mouse-anti-human CD14-FITC (10 µL/test) in 100 µL of
1% BSA/PBS (or in the same buffer in the absence of the antibody) for 30 min on ice.
Cells were then washed in PBS, resuspended in PBS and analysed by flow cytometry.
Populations gated on the basis of size and granularity were examined for CD14
expression to confirm their identity.
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4.2.4

Fluorescent Labelling of Ligands

Ligands were dialysed into 0.1 M sodium bicarbonate buffer pH 8.3 at a concentration
between 2 and 5 mg/mL. Alexa Fluor® 488 5-TFP ester was dissolved in DMSO to a
final concentration of 10 mg/mL and briefly vortexed to homogenise the solution. Alexa
Fluor® 488 5-TFP ester (100 µg/mg ligand) was slowly added to the ligand solution
with stirring. Reaction tubes were wrapped in foil and incubated for 2 h at room
temperature with shaking. Ligands labelled with Alexa Fluor® 488 (Alexa-488) were
then extensively dialysed against PBS to remove any unbound dye, aliquoted and stored
at - 20 °C until use.

4.2.5

Ligand Binding to Cells

Cells were obtained as described in sections 4.2.1, 4.2.2 and 4.2.3 and ~ 2 x 106 cells
added per tube. Ligand binding experiments were conducted on ice and in
the presence of 0.1% (w/v) Az to minimise endocytosis. Cells were pelleted by
centrifugation at 300 x g for 5 min at 4 °C, the supernatant removed, and the cells
drained by inversion onto a paper towel. Pellets were resuspended in 100 µg/mL ligand
(AcLDL, CLU, OVA, CLU-OVA, HSA or BSA all labelled with Alexa-488 as detailed
in section 4.2.4) in ice cold 1% BSA/PBS/Az (50 µL/tube) and incubated on ice for
30 min. Negative control cells were resuspended in ice cold 1% BSA/PBS/Az and
incubated under the same conditions. Cells were then washed in ice cold PBS by
centrifugation and resuspended in PBS. Immediately prior to analysis by flow
cytometry, PI (10 µg/mL) was added to assess cell viability.
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4.2.6

Time Course for Internalisation of CLUOVA

Cells were obtained as described in sections 4.2.1, 4.2.2 and 4.2.3 and ~ 6 x 106 cells
added per tube. Cells were pelleted by centrifugation at 300 x g for 5 min at 4 °C,
the supernatant removed, and the tubes drained by inversion onto a paper towel.
Pellets were resuspended in 100 µg/mL CLU-OVA labelled with Alexa-488
(CLU-OVAAlexa-488) in 1% BSA/PBS and incubated at 37 °C. Negative control cells
were resuspended in 1% BSA/PBS and incubated under the same conditions. At the
appropriate time points a sample of cells was taken from each tube and immediately
washed with PBS to remove any unbound CLU-OVAAlexa-488. Samples were then
immediately fixed in 4% (w/v) PFA in PBS for 15 min at room temperature with
shaking, washed in PBS and kept at 4 °C for no longer than 3 days until analysis using a
Leica TCS SP5 Advanced System confocal microscope (Leica Microsystems, Wetzlar,
Germany).

4.2.6.1

Staining of Cellular Compartments

To examine co-localisation of internalised CLU-OVAAlexa-488 with early endosomes or
lysosomes, intracellular staining with specific antibodies was undertaken. Cells that
had been incubated with CLU-OVAAlexa-488, fixed and washed in PBS (section 4.2.6)
were permeabilised with 0.5% (v/v) Tx-100/PBS for 15 min on ice. After
permeabilisation, cells were washed in PBS by centrifugation at 2,000 rpm for 10 min
in a Heraeus Megafuge 1.0R benchtop centrifuge at 4 °C. All subsequent centrifugation
steps were undertaken under these conditions to ensure the cells pelleted. The
supernatant was removed and the tubes inverted on a paper towel to drain. To minimise
non-specific binding, the Fc receptors of cells were blocked by incubation with
0.5 mg/mL goat IgG for 30 min on ice, followed by washing in PBS as above.
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Rabbit-anti-EEA1, mouse-anti-Lamp1 or isotype controls rabbit-anti-dinitrophenyl and
mouse-anti-(human)CLU (G7) were added to the cells at 5 µg/mL in 1% BSA/PBS and
incubated for 30 min at room temperature, as per the manufacturer’s instructions. Cells
were washed in 1% BSA/PBS and the secondary antibodies added. For cells originally
incubated with rabbit-anti-EEA1 or rabbit-anti-dinitrophenyl, goat-anti-rabbit-CF633
was added at 2.5 µg/mL in 1% BSA/PBS for 1 h on ice. For cells originally incubated
with mouse-anti-Lamp1 or mouse-anti-(human)CLU (G7), goat-anti-mouse-CF633 was
added at 2.5 µg/mL in 1% BSA/PBS for 1 h on ice. After incubation, cells were washed
in PBS and kept at 4 °C for no longer than 3 days until analysis by confocal
microscopy.

4.2.7

Inhibition of Binding and Internalisation

For inhibition studies cells were pre-incubated with either: 100 µg/mL unlabelled
CLU, 25 µg/mL cytoD, 100 µM EIPA, 500 µg/mL fucoidan, 100 µg/mL of a fusion
protein of GST and receptor associated protein (GST-RAP), 50 µg/mL LPS, 500 µg/mL
mannan, 10 mM mβCD, 50 µg/mL polyI or 1% BSA/PBS as the no inhibitor control.
All inhibitors, or the no inhibitor control, were incubated with cells in 50 µL
1% BSA/PBS for 30 min on ice before adding 50 µL of 100 µg/mL CLU-OVAAlexa-488
in 1% BSA/PBS/Az for 30 min on ice (binding experiments) or at 37 °C
(internalisation). The inhibitors selected are known to inhibit multiple binding and
internalisation pathways in cells (Table 4.1).
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Table 4.1 The inhibitors used in this study and the binding and internalisation processes
they affect.
Inhibitor

Process involved

References

CLU

Should inhibit CLU-OVA binding if
CLU specific binding is utilised.

-

cytoD

Disrupts the actin cytoskeleton of cells
to inhibit endocytosis and phagocytosis.

(Mimura and Asano 1976;
Schliwa 1982; Valentijn et al.
1999; Herre et al. 2004; Shoji et
al. 2012)

EIPA

Inhibits macropinocytosis.

(Koivusalo et al. 2010; Hussain
et al. 2011)

fucoidan

Inhibits binding to class A, C, E, F and
H scavenger receptors but not class B
scavenger receptors.

(Acton et al. 1994; Fluiter and
van Berkel 1997; Gough and
Gordon 2000; Peiser and
Gordon 2001)

GST-RAP

RAP inhibits binding to LRP1, LRP2
and VLDLR.

(Willnow et al. 1996; Andersen
et al. 2000)

LPS

Inhibits binding to CD14, β2 integrins
and TLR4 signalling.

(Fenton and Golenbock 1998;
Triantafilou and Triantafilou
2002; Triantafilou and
Triantafilou 2005)

mannan

Inhibits binding to mannose receptors.

(Kery et al. 1992; Sheng et al.
2006)

mβCD

mβCD is a cyclic oligosaccharide that
sequesters cholesterol to deplete
membrane cholesterol and therefore
disrupt lipid rafts, and may also inhibit
the formation of clathrin-coated
endocytic vesicles.

(Kilsdonk et al. 1995; Rodal et
al. 1999)

polyI

PolyI is a non-specific inhibitor of
scavenger receptors and TLR3, though
it is also reported not to bind to class B
scavenger receptors.

(Brown et al. 1980; Pearson et
al. 1993; Fluiter and van Berkel
1997; Peiser and Gordon 2001;
Marshall-Clarke et al. 2007).
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4.3

Results

For all the following results, ligands were directly labelled with Alexa-488, this enabled
the binding and internalisation of a wide range of ligands by cells to be easily monitored
without the need for multi-stage permeabilisation and staining procedures. RAW 264.7
cells were initially used to test binding and internalisation of CLU and CLU-OVA. The
positive control (AcLDL) showed the highest binding to RAW 264.7 cells. CLU and
CLU-OVA showed similar levels of binding (Figure 4.1) that were significantly higher
than the negative controls as determined by one-way ANOVA (p = 0.000, f = 42.61).
Post-hoc un-paired student’s t-test analysis showed that binding of AcLDL, CLU and
CLU-OVA was significantly higher than OVA, BSA or HSA (p < 0.01).
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Figure 4.1 Binding of ligands to RAW 264.7 cells as assessed by flow cytometry and
reported in arbitrary fluorescence units (AFU; mean ± standard deviation; n = 3).
* Significantly higher than OVA, HSA or BSA at (p < 0.01), as determined by un-paired
student’s t-test.

CLU binding to the entire surface of RAW 264.7 cells was visible at 15 and 30 min
(Figure 4.2). After 1 h incubation, binding to the cell surface was still visible, however,
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punctate regions of fluorescence were also now visible within the cells, suggesting some
internalisation had occurred. Greater internalised fluorescence was seen at 2 h (Figure
4.2). At 15 min, CLU-OVA showed a similar pattern of binding to CLU, with the
majority of the protein localised at the RAW 264.7 cell surface (Figure 4.2). At all other
time points monitored, some CLU-OVA appeared to be internalised as evidenced by the
presence of punctate fluorescence within the cells (Figure 4.2). OVA showed less
binding than CLU or CLU-OVA at 15 min, with only faint fluorescence visible at the
cell surface; at the remaining time points tested OVA appeared to be internalised by
RAW 264.7 cells (Figure 4.2). HSA and BSA showed similar patterns of binding; at
15 min only low levels of binding were detectable and at all other time points tested the
binding and internalisation remained low compared to CLU, CLU-OVA and OVA with
both diffuse and punctate intracellular fluorescence evident (Figure 4.2). The negative
control showed minimal fluorescence and is representative of the autofluorescence of
RAW 264.7 cells under the conditions used in this experiment (Figure 4.2).

Confocal microscopy gave similar results to those obtained by flow cytometric analysis
of ligand binding to RAW 264.7 cells. Using both approaches, at the 15 min time point,
CLU and CLU-OVA showed the highest level of binding to the cell surface, while
OVA, HSA and BSA showed much less (Figure 4.1 and 4.2).
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30 min

1h

2h

NEG

BSA

HSA

OVA

CLU-OVA

CLU

15 min

Figure 4.2 Time course of internalisation of ligands into RAW 264.7 cells as monitored by
confocal microscopy. RAW 264.7 cells were incubated with Alexa488-labelled CLU,
CLU-OVA, OVA, HSA or BSA and samples taken at 15 min, 30 min, 1 h and 2 h,
immediately washed to remove any unbound ligand and kept at 4 °C until analysis. The
negative control had no added ligand and indicates autofluorescence. Yellow scale bars at
the bottom right of each image represent 10 µm. Images shown are representative of
between 50 and 100 cells examined in each case.
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The concentration dependence of the binding of CLU and CLU-OVA to RAW 264.7
cells was examined and did not show saturable binding at the concentrations tested
(between 20 and 225 µg/mL; data not shown) suggesting that a receptor based system
was not involved in the binding and internalisation of CLU and CLU-OVA. Previous
work undertaken by our lab and our French collaborators has implicated scavenger
receptors in the internalisation of CLU and CLU complexes by macrophages and
dendritic cells (personal communications). Hence, it was expected that RAW 264.7
cells would bind CLU and CLU-OVA via scavenger receptors. Therefore a panel
of inhibitors was tested to examine the mechanism by which these ligands were taken
up by RAW264.7 cells. When compared to the PBS control, none of the inhibitors
tested showed a significant inhibition of CLU-OVA binding (Figure 4.3a) as assessed
by one-way ANOVA (p = 0.053, f = 2.475). However, when looking at total
cell-associated fluorescence (surface bound and internalised ligand), although in all
cases the levels of inhibition were low, one-way ANOVA showed that the results
contained a significant difference (p = 0.01, f = 3.684). Only mβCD showed a small
(< 20%) but significant inhibition of total cell-associated CLU-OVA compared to the
PBS control as assessed by an un-paired student’s t-test (p = 0.021; Figure 4.3b).
Although not significant (p = 0.1), fucoidan also appeared to inhibit total cell associated
CLU-OVA, though polyI which is also a scavenger receptor inhibitor did not (Figure
4.3b).
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Figure 4.3 Inhibition of a) binding and b) total cell-associated CLU-OVA to RAW 264.7
cells. Unlabelled CLU, EIPA, fucoidan, GST-RAP, LPS, mannan, mβCD and polyI were
used as inhibitors of a variety of receptors and cellular uptake mechanisms. Binding is
reported in arbitrary fluorescence units (AFU; mean ± standard deviation; n = 3).
* Significantly higher inhibition than the no inhibitor control at (p < 0.05), as determined by
un-paired student’s t-test.

To avoid potential artifacts sometimes associated with immortalised cell lines, the
binding and internalisation of CLU and CLU-OVA by primary murine bone marrow
derived macrophages was subsequently investigated. CLU and CLU-OVA showed
significantly higher binding to these cells than the negative controls (Figure 4.4) as
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determined by one-way ANOVA (p = 0.000, f = 1445). Post-hoc un-paired student’s
t-testing showed that in all cases CLU and CLU-OVA had significantly higher binding
than OVA, BSA or HSA (p < 0.0001). Compared to CLU alone, CLU-OVA showed
approximately two-fold greater binding (Figure 4.4; p < 0.0001).
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Figure 4.4 Binding of ligands to bone marrow derived macrophages as assessed by flow
cytometry and reported in arbitrary fluorescence units (AFU; mean ± standard deviation;
n = 3). * Significantly higher than OVA, HSA and BSA at (p < 0.0001), as determined by
un-paired student’s t-test.

Bone marrow derived macrophages and RAW 264.7 cells both show high red
autofluorescence in the 550 nm to 650 nm range when excited by the 488 nm laser or
the 561 nm laser. Unfortunately this meant that due to the configuration of the confocal
system available, only green (excitation 488 nm, detection 520 nm) and far red
(excitation 633 nm, detection 650 nm) fluorescence could be measured. Hence
co-localisation of CLU-OVA with early endosomes and lysosomes were conducted
separately.
Internalisation

of

CLU-OVA

by

bone

marrow

derived

macrophages

and

co-localisation with early endosomes was examined (Figure 4.5). CLU-OVA appeared
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to be taken up into bone marrow derived macrophages very rapidly with intracellular
CLU-OVA detectable at 15 min (Figure 4.5). Overlay of the images showed a clear
overlap of fluorescence corresponding to early endosomes and CLU-OVA (Figure 4.5;
see yellow regions of overlap), indicating that CLU-OVA enters the early endosome
compartment in bone marrow derived macrophages. Similar patterns were seen at
30 min and 1 h (Figure 4.5). However, in some cells, green punctate bodies representing
intracellular CLU-OVA are distinct from the labelled early endosomes. This suggests
that in these cells CLU-OVA may be present within another cellular compartment than
the early endosome. In addition, some other cells were detected showing either low
level staining of early endosomes or low levels of internalisation of CLU-OVA (Figure
4.5). Low staining of early endosomes may be due to incomplete permeabilisation of the
cell membrane prior to antibody staining. Low levels of CLU-OVA uptake in some
cells may be due to the stage of the cell cycle stage they are in. The negative control
showed low level autofluorescence in both the green and red channels indicating that
the fluorescent signals measured were specific for CLU-OVA and the early endosomes
(Figure 4.5).
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Figure 4.5 Time course of internalisation of CLU-OVA into bone marrow derived
macrophages and co-localisation with early endosomes as detected by confocal microscopy.
Bone marrow derived macrophages were incubated with CLU-OVA, and samples taken at
15 min, 30 min and 1 h, washed immediately to remove any non-bound ligand, then fixed
and permeabilised to allow staining of the early endosomes with αEEA1 antibody. The
negative control had no added protein but was fixed and permeabilised followed by staining
with an isotype control antibody and indicates autofluorescence under the conditions used.
The differential interference contrast (DIC) image, early endosomes (αEEA1), CLU-OVA
and fluorescence overlays are shown. Yellow scale bars at the bottom right of the far right
image in each row represent 10 µm and indicate the scale of all images in that row. Images
shown are representative of between 50 and 100 cells examined in each case.

108

Chapter 4: Binding and Internalisation of CLU and CLU-OVA

Internalisation of CLU-OVA into bone marrow derived macrophages and
subsequent co-localisation with lysosomes were examined (Figure 4.6). Again
CLU-OVA appeared to be taken up into bone marrow derived macrophages very
rapidly with intracellular CLU-OVA detected at 15 min (Figure 4.6). At all time points
tested some, but not all, CLU-OVA appeared to co-localise with lysosomes, as detected
in the overlay images by yellow punctate bodies (Figure 4.6). There is clearly
intracellular CLU-OVA not contained within lysosomes, and lysosomes not containing
CLU-OVA, indicated by green and red punctate bodies respectively (Figure 4.6). The
negative control showed very low levels of autofluorescence in both the green and red
channels indicating that the results obtained were CLU-OVA and lysosome specific
(Figure 4.6).
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One-way ANOVA testing showed a significant difference in the extent of inhibition of
CLU-OVA binding between the inhibitors tested (p = 0.000, f = 48.16). Both fucoidan
(p < 0.0001) and polyI (p < 0.0001) significantly inhibited binding (Figure 4.7) as
assessed by an un-paired student’s t-test. This suggests that scavenger receptors are
involved in the binding of CLU-OVA to bone marrow derived macrophages.

70
60

AFU

50
40
30
20
10

*

*

0

Figure 4.7 Inhibition of CLU-OVA binding to bone marrow derived macrophages. CytoD,
EIPA, fucoidan, GST-RAP, mannan, mβCD and polyI were used as inhibitors of a variety
of receptors and cellular uptake mechanisms. Binding reported as reported in arbitrary
fluorescence units (AFU; mean ± standard deviation; n = 4. Combined results from
duplicate experiments). * Significantly higher inhibition than the no inhibitor control at
(p < 0.0001), as determined by un-paired student’s t-test.

To investigate whether circulating white blood cells could bind CLU and CLU-OVA,
human white blood cells were analysed for binding of CLU, CLU-OVA, OVA, HSA
and BSA after gating based on forward and side scatter (Figure 4.8a). CD14 expression
was also tested to confirm the monocyte population (Figure 4.8b). Lymphocytes which
mainly consist of natural killer cells, T cells and B cells have medium size and low
granularity when assessed by flow cytometry (Kersey and Gajl-Peczalska 1975;
Trinchieri 1989). Monocytes are larger in size and slightly higher in granularity; they
also express a high level of CD14. Granulocytes which consist of neutrophils,
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lymphocytes, and 3.5 and 6.77 times lower to monocytes, respectively). A significant
difference in the levels of ligand binding to lymphocytes was detected by one-way
ANOVA (p = 0.000, f = 153.5). CLU-OVA and CLU showed significantly greater
binding to lymphocytes compared to OVA, HSA or BSA (p < 0.02). There was also a
significant difference between binding of ligands to monocytes as assessed by one-way
ANOVA (p = 0.000, f = 237.8) and post-hoc un-paired student’s t-testing showed that
both CLU-OVA and CLU bound significantly more to monocytes than OVA, HSA or
BSA (p < 0.01).
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Figure 4.9 Binding of ligands to granulocytes, lymphocytes and monocytes as assessed by
flow cytometry and reported in arbitrary fluorescence units (AFU; mean ± standard
deviation; n = 3). * Significantly higher than OVA, HSA or BSA at (p < 0.02), as
determined by un-paired student’s t-test.

Inhibition of binding to white blood cells was analysed with blood obtained from two
individuals. As there were slight differences between the results obtained for the two
individuals, both sets of results are shown (Figure 4.10). Fucoidan and polyI showed the
greatest inhibition of CLU-OVA binding for both samples and to all cell types,
implicating scavenger receptors in the binding of CLU-OVA (Figure 4.10). In the
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granulocyte population EIPA and mβCD showed the next highest level of inhibition,
inhibiting less than 30% of the binding (Figure 4.10). Binding to lymphocytes was not
inhibited to as great an extent by fucoidan and polyI compared to the other cell
populations (Figure 4.10). Similar to the results obtained for the granulocyte population
(Figure 4.10), polyI and fucoidan showed the greatest inhibition of binding to the
monocytes, followed by EIPA and mβCD (Figure 4.10).
Inhibition of binding to white blood cell populations was only conducted in triplicate for
one person (person 2) though similar trends were seen for both people (as described
above). Therefore statistical analysis could only be undertaken on the results found for
person 2 (Table 4.2). For the granulocyte population, one-way ANOVA testing showed
a significant difference in binding inhibition between the inhibitors tested (p = 0.000,
f = 47.51). Post-hoc un-paired student’s t-test analysis showed that fucoidan, polyI and
EIPA significantly inhibited CLU-OVA binding to granulocytes, compared to the no
inhibitor control (p = 0.0004, p = 0.0004 and p = 0.026, respectively; Table 4.2).
For the lymphocyte population, one-way ANOVA testing showed a significant
difference between the inhibitors tested (p = 0.000, f = 22.44). Post-hoc un-paired
student’s t-test analysis showed that fucoidan, GST-RAP, mannan, mβCD and polyI all
significantly inhibited the binding of CLU-OVA to lymphocytes (Table 4.2).
For the monocyte population, one-way ANOVA showed a significant difference
between the inhibitors tested (p = 0.000, f = 63.7). Post-hoc un-paired student’s t-test
analysis showed that fucoidan, and polyI significantly inhibited the binding of
CLU-OVA to monocytes; EIPA, mannan, and mβCD also significantly inhibited the
binding of CLU-OVA to monocytes compared to the no inhibitor control (Table 4.2).
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Figure 4.10 Inhibition of CLU-OVA binding to white blood cells including granulocytes,
lymphocytes and monocytes, showing results for blood cells obtained from two individuals
(Person 1: mean ± ½ range; n = 2. Person 2: mean ± standard deviation; n = 3). CytoD,
EIPA, GST-RAP, mannan, mβCD and polyI were used as inhibitors of a variety of
receptors and cellular uptake mechanisms. Binding reported in arbitrary fluorescence units
(AFU).
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Table 4.2 Statistical significance of the inhibition of CLU-OVA binding to white blood
cell populations (un-paired student’s t-test). P-values are reported and p < 0.05 indicates a
significant difference. Any p-values > 0.05 are indicated by ‘NS’ for not significant.
cytoD

EIPA Fucoidan

GSTRAP

Mannan

mβCD

PolyI

Granulocytes NS

0.026

0.0004

NS

NS

NS

0.0004

Lymphocytes NS

NS

0.0046

0.0041

0.022

0.0029

< 0.0001

0.036

< 0.0001

NS

0.043

0.0007

< 0.0001

Monocytes

NS
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4.4

Discussion

The binding and internalisation of CLU-OVA conjugate into APCs was studied as part
of an examination of the potential of CLU to modulate immune responses. Murine
macrophages were the APC chosen because; (i) antigen presentation (Unanue 1984;
Lanzavecchia 1990; Itano and Jenkins 2003) and cross-presentation (Debrick et al.
1991; Kovacsovics-Bankowski et al. 1993; Bellone et al. 1997; Pozzi et al. 2005) have
been reported to occur in macrophages; (ii) macrophages are known to express
scavenger receptors (Gough and Gordon 2000) which are thought to play a role in the
binding of CLU, other chaperones and chaperone complexes; (iii) the immortalised
mouse leukaemic monocyte macrophage cell line RAW 264.7 was available; and
(iv) we had access to mice (no longer required for other experimentation) to produce
bone marrow derived macrophages, which are relatively easy to work with in culture.
Binding of CLU-OVA to human white blood cells was also investigated, to determine
which type(s) of circulating human cells may bind CLU-OVA.
Binding and internalisation of CLU, CLU-OVA, OVA and control proteins by
RAW 264.7 cells was first investigated. A cell line was first used due to ready
availability, the ease of production of large cell numbers, and to limit the number
of animals used in this study. CLU and CLU-OVA both bound significantly more to
RAW 264.7 cells than OVA, BSA or HSA (Figure 4.1). CLU and CLU-OVA showed
similar binding to the surface of RAW 264.7 cells after 15 min incubation at 37 °C
(Figure 4.2). By 1 h both CLU and CLU-OVA appeared to be internalised, though
binding on the surface was still apparent. At earlier time points OVA showed low level
binding to the surface of these cells, though as time progressed the internalisation of
OVA was evident. At all time points tested the binding and internalisation of BSA and
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HSA was lower than that of the other proteins and the pattern of distribution of the
internalised material was a mixture of both diffuse and punctate. The confocal
microscopy analyses suggest that CLU, CLU-OVA and OVA are internalised by RAW
264.7 cells, typically within 30 min (Figure 4.2).
As a first step towards examining the mechanism of binding of CLU-OVA to
RAW 264.7 cells, the concentration dependence of binding was assessed in a
preliminary study. Saturation of binding was not reached at the concentrations tested
(20 - 225 µg/mL; data not shown), suggesting that the binding of CLU-OVA to
RAW 264.7 cells was dominated by a receptor-independent process. The effects of a
range of inhibitors on the binding and internalisation of CLU-OVA by RAW 264.7 cells
were also tested. None of the reagents tested inhibited the binding (Figure 4.3a).
However, mβCD significantly inhibited internalisation, measured as total cell associated
CLU-OVA, although the extent of inhibition was relatively low (< 20%; Figure 4.3b).
mβCD is a cyclic oligosaccharide that sequesters cholesterol to deplete membrane
cholesterol and therefore disrupt lipid rafts (Kilsdonk et al. 1995), and may also inhibit
the formation of clathrin-coated endocytic vesicles (Rodal et al. 1999) (Table 4.1).
Clathrin coated vesicles are associated with receptor mediated endocytosis (Mellman
1996; Santini et al. 1998; Mousavi et al. 2004) and can work in co-operation with lipid
rafts to internalise prion proteins, some integral membrane proteins and tetanus toxin
(Deinhardt et al. 2006; Taylor and Hooper 2006; Rollason et al. 2007; Sarnataro et al.
2009). This indicates that in RAW 264.7 cells, lipid rafts and/or clathrin-mediated
endocytosis may play a minor role in the internalisation of CLU-OVA. Unlabelled
CLU, fucoidan, polyI and GST-RAP did not inhibit the binding or internalisation of
CLU-OVA into RAW 264.7 cells, suggesting that CLU-OVA may be taken up by a
receptor-independent route (Table 4.1). Previous work undertaken by our lab and our
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French collaborators has implicated scavenger receptors in the internalisation of CLU
and CLU complexes by peripheral human monocytes, rat hepatocytes, and human
monocyte derived macrophages and dendritic cells (Wyatt et al. 2011). Thus the results
were expected to implicate scavenger receptors in the uptake of CLU-OVA by RAW
264.7 cells, but this proved not to be the case. It is possible that the RAW 264.7 cell line
had lost the ability to express functional receptors during culture; however, this was not
directly tested. To avoid potential artifacts sometimes associated with immortalised cell
lines, the binding and internalisation of CLU and CLU-OVA by primary murine bone
marrow derived macrophages was subsequently investigated.
CLU and CLU-OVA showed significantly higher levels of binding to bone marrow
derived macrophages relative to OVA, BSA or HSA. CLU-OVA showed two-fold
greater binding compared to CLU (Figure 4.4). This is consistent with previously
published results obtained for HSP70 which showed increased binding of HSP70-OVA
peptide complexes to macrophages and dendritic cells compared to OVA alone (HSP70
alone was not tested) (Tobian et al. 2004).
Unlike the binding of CLU-OVA to RAW 264.7 cells, its binding to bone marrow
derived macrophages was inhibited by ~ 80% by both fucoidan and polyI (Figure 4.7).
This is similar to the level of fucoidan-mediated inhibition of gp96 binding to peritoneal
macrophages found by Berwin et al. (2003). Fucoidan is a ligand for class A, C, E, F
and H scavenger receptors which include SR-AI, SR-AII (Platt et al. 1996), LOX-1
(Oka et al. 1998), SREC-1 (Berwin et al. 2004), and FEEL-1 (Tamura et al. 2003) but
not class B scavenger receptors (Acton et al. 1994; Fluiter and van Berkel 1997; Gough
and Gordon 2000). PolyI is a non-specific inhibitor of scavenger receptors and TLR3,
though it is also reported not to bind to class B scavenger receptors, (Brown et al. 1980;
Pearson et al. 1993; Fluiter and van Berkel 1997; Peiser and Gordon 2001; Marshall119
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Clarke et al. 2007). The high levels of inhibition of CLU-OVA binding by
fucoidan and polyI provide strong evidence for the involvement of scavenger receptors
(Table 4.1) in its uptake into bone marrow derived macrophages. Most scavenger
receptors are expressed by macrophages (Table 4.3) including all listed above.
Scavenger receptors have been implicated in the binding of many intracellular
chaperones and chaperone-peptide complexes when they are present in the extracellular
space, including SR-AI (Berwin et al. 2003; Berwin et al. 2004), SREC-1 (Berwin et al.
2004; Thériault et al. 2006; Calderwood et al. 2007b; Gong et al. 2008; Gong et al.
2009a; Murshid et al. 2010), LOX-1 (Delneste et al. 2002; Thériault et al. 2005) and
FEEL-1 (Thériault et al. 2006), so it is not surprising that CLU-OVA complexes are
also internalised by these rather promiscuous receptors (Krieger 1992; Seong and
Matzinger 2004).
LRP1 has also been implicated in the binding of intracellular chaperone-peptide
complexes and α2m-peptide complexes (Binder et al. 2000b; Basu et al. 2001; Binder et
al. 2001b; Binder et al. 2002; Binder and Srivastava 2004; Bowers et al. 2009). RAP is
an inhibitor of LRP1, LRP2 and VLDLR (Kasza et al. 1997; Marino et al. 1999;
Andersen et al. 2000; Herz and Strickland 2001; Yakovlev et al. 2012) (Table 4.1).
GST-RAP was, however, unable to significantly inhibit the binding of CLU-OVA to
bone marrow derived macrophages, thus it is unlikely that LRP1/2 or VLDLR plays a
role in the binding and internalisation of CLU-OVA by these cells.
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Table 4.3 The major scavenger receptors, their expression profiles, whether they have been
reported to bind chaperones, play a role in cross-presentation, and whether polyI and
fucoidan have been reported to inhibit them.
Class

Scavenger
receptor

A

SR-AI/II

Expression
profile

Dendritic cells
Endothelial
cells
Macrophages
Mast cells
Monocytes
Smooth muscle
cells

Binding of
chaperones and
roles in crosspresentation
Gp96 and
calreticulin are
internalised by
SR-AI

Do polyI
and
fucoidan
inhibit?

References

Yes

(Hughes et al.
1995; de
Winther et al.
2000; Berwin et
al. 2003;
Berwin et al.
2004; Delneste
et al. 2007;
Greaves and
Gordon 2009;
Stephen et al.
2010)

HSP70 does not
bind SR-AI

* Not
expressed by
neutrophils
A

MARCO

B cells
Dendritic cells
Macrophages
Microglia

HSP70 does not
bind

Yes

(Granucci et al.
2003; Delneste
et al. 2007; Zhu
et al. 2009;
Stephen et al.
2010)

B

SR-B1

Adipocytes
B cells
Hepatocytes
Macrophages
Monocytes

HSP70 does not
bind

No

(Fluiter and van
Berkel 1997;
van Oosten et
al. 1998;
Delneste et al.
2007; Zhu et al.
2009; Stephen
et al. 2010)

B

CD36

Adipocytes
B cells
Dendritic cells
Epithelial cells
Endothelial
cells
Macrophages
Monocytes
Platelets

HSP70 does not
bind

No

(Fluiter and van
Berkel 1997;
Panjwani et al.
2000; Radsak et
al. 2003;
Berwin et al.
2004; Delneste
et al. 2007; Zhu
et al. 2009;
Fischer et al.
2010)

Conflicting
evidence regarding
binding of gp96

* Not
expressed by
neutrophils
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E

LOX-1

B cells
Endothelial
cells
Macrophages
Neutrophils
Platelets
Smooth muscle
cells
* Not
expressed by
monocytes

F

SREC-1

Endothelial
cells
Macrophages
* Not
expressed by
monocytes

Binds calreticulin

Yes

(Moriwaki et
al. 1998;
Yoshida et al.
1998; Delneste
et al. 2002;
Thériault et al.
2006;
Schaeffer et al.
2009; Fischer et
al. 2010;
Matsutake et al.
2010; Stephen
et al. 2010; Xie
et al. 2010;
Yoshimoto et
al. 2011;
Stephen and
Ponnambalam
2012)

Yes

(Adachi et al.
1997; Berwin et
al. 2004;
Thériault et al.
2006;
Calderwood et
al. 2007b;
Gong et al.
2008; Gong et
al. 2009a;
Fischer et al.
2010; Murshid
et al. 2010;
Stephen et al.
2010)

polyI

(Shimaoka et
al. 2000;
Berwin et al.
2004; Stephen
et al. 2010)

Binds HSP60 and
HSP70 to facilitate
cross-presentation
and anti-tumour
immunity
Internalises gp96peptide complexes
into dendritic cells
and B cells to
potentiate a
MHC I and
MHC II response
to chaperoned
peptides

Binds calreticulin
Mediates
HSP70-peptide
immunity
Mediates
HSP90-OVA
cross-presentation
Facilitates the
uptakes of
chaperone-peptide
complexes into the
MHC II pathway

G

SR-PSOX

None reported
B cells
Dendritic cells
Endothelial
cells
Macrophages
Smooth muscle
cells
T cells

H

FEEL-1

Endothelial
cells
Macrophages
Monocytes

Internalises HSP70 Yes
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Confocal analysis showed that within 15 min there was a strong uptake of CLU-OVA
by bone marrow derived macrophages, indicated by green fluorescent punctate
bodies within the cells, and little cell surface associated fluorescence (Figure 4.5 and
Figure 4.6); this was faster than the internalisation of CLU-OVA by RAW 264.7 cells
(Figure 4.2). This may be due to uptake via scavenger receptors into bone marrow
derived macrophages rather than a non-specific uptake mechanism into RAW 264.7
cells. Scavenger receptors have been shown to internalise gp96 in as little as 10 min at
37 °C (Berwin et al. 2003).
Following internalisation by bone marrow derived macrophages, the majority of
CLU-OVA appeared to be contained within early endosomes; however, some appeared
to be distinct from early endosomes (Figure 4.5). CLU-OVA also appeared to
co-localise with lysosomes (Figure 4.6). Ideally 3 colour analyses would have been
undertaken on these cells to determine if CLU-OVA not contained within early
endosomes was in fact contained within the lysosomes of these same cells, or in other
cellular compartments. Unfortunately this was not possible, due to detection limitations
imposed by the presence of brightly autofluorescent structures in both RAW 264.7 cells
and bone marrow derived macrophages, and the configuration of the confocal system
available. RAW 264.7 cells have been shown to phagocytose neutral red (Beutler et al.
1985) and upon further investigation of the literature, RAW 264.7 cells and
macrophages are often cultured in phenol red free medium when measuring endocytosis
(Popov et al. 2002; Pollock et al. 2010). Phenol red is excited at 488 nm and detected
between 550 and 650 nm (Benson et al. 1979) which is one of the ranges where brightly
autofluorescent structures were detected. Therefore it is possible that the
“autofluorescent” structures contain phagocytosed phenol red from the culture medium.
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This could be confirmed by comparing the autofluorescence of these cells to ones
cultured in phenol red free medium.
Gp96 has been shown to bind to human monocytes and murine dendritic cells and
macrophages, with internalisation into murine dendritic cells and macrophages resulting
in fast (< 15 min) co-localisation with early endosomes. Within these compartments
gp96 co-localised with recycling MHC class I and class II molecules (Wassenberg et al.
1999; Singh-Jasuja et al. 2000b). Internalisation of HSP90-peptide complexes into bone
marrow derived dendritic cells resulted in co-localisation with early endosomes and
direct loading of the peptides onto MHC I molecules to generate a peptide specific CTL
response (Kurotaki et al. 2007). Another study showed that following APC
internalisation of HSP90 bound to OVA peptides, the peptides (that did not require
proteolytic processing) were loaded directly onto MHC I molecules in endosomes.
However, if HSP90 bound to full length OVA was internalised, the OVA required
processing into peptides by the proteasome in the cytosol prior to loading on MHC I
molecules (Murshid et al. 2010). The mechanism by which chaperoned peptides or
proteins are diverted from the endocytic pathway into the cytosol is not fully
understood, but once in the cytosol proteins/peptides can be processed by the traditional
MHC I pathway (Heath and Carbone 2001; Rock and Shen 2005; Burgdorf et al. 2008).
The chaperoned protein/peptide may also be loaded onto MHC II molecules within the
phagolysosome

(Cresswell

1994a;

Cresswell

1994b).

The

partitioning

of

proteins/peptides into the MHC class I or class II pathway is also not understood
(Murshid et al. 2012). These studies taken together show that localisation into
intracellular compartments may depend on cell type, method of internalisation, and size
of the chaperoned antigen. As our knowledge in this area grows it is likely that we will
be able to more completely understand the role CLU can play in modulation of the
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immune system. Due to the observed co-localisation of CLU-OVA with early
endosomes, it is likely that CLU acts to load OVA peptides onto recycling MHC I or
MHC II molecules contained within these compartments (Figure 4.11), similar to gp96
and HSP90 (Wassenberg et al. 1999; Singh-Jasuja et al. 2000b; Kurotaki et al. 2007;
Murshid et al. 2010). It is also possible that CLU may direct full length OVA to
(i) processing via the phagolysosome for subsequent presentation with MHC class II
molecules, or (ii) the cytosol for proteolysis by the proteasome prior to loading onto
MHC class I molecules, via the traditional MHC class I antigen loading pathway (see
section 1.4, Figure 1.5 and Figure 4.11).

Figure 4.11 Routes by which chaperones in the extracellular space may direct bound
proteins and peptides for cross-presentation onto MHC class I molecules or presentation
onto MHC class II molecules in APCs. Internalised chaperone-peptide complexes may
co-localise with recycling MHC I and MHC II molecules within early endosomes to directly
load the peptide onto these molecules for cross-presentation and presentation respectively.
Internalised chaperones bound to full length protein (chaperone-protein) may direct
the bound protein into the cytosol, by an as yet undetermined mechanism (red arrow),
for digestion in the proteasome followed by association with MHC I molecules and
cross-presentation on the surface of APCs. Internalised chaperone-protein may also direct
the protein for processing in the phagolysosome for subsequent association with MHC II
molecules and presentation on the surface of APCs.
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Human white blood cell populations were successfully identified by flow cytometry
based on their size, granularity and CD14 expression (Figure 4.8). Binding of all ligands
was highest to granulocytes followed by monocytes then lymphocytes (Figure 4.9).
Similar to the results found for the bone marrow derived macrophages, CLU-OVA
showed the greatest level of binding, followed by CLU alone. All white blood cell
populations bound significantly more CLU-OVA and CLU than OVA, HSA or BSA.
Neutrophils are the most abundant granulocyte, accounting for ~ 70% of the human
granulocyte population, (Amulic et al. 2012) and express scavenger receptors. Although
most scavenger receptors expressed on neutrophils have not yet been characterised, it is
known that they express LOX-1 (Stephen and Ponnambalam 2012) but not SR-AI
(Hughes et al. 1995) both of which bind fucoidan and polyI (Table 4.3). Neutrophils
also express numerous TLRs but not TLR3 (Sabroe et al. 2005; Amulic et al. 2012).
Eosinophils play an important role in allergic diseases, tissue injury and host defence
against parasitic infections. They express IgE, IgG, complement and many TLRs
including TLR3 which binds polyI (Kulczycki 1984; Capron 1989; Rothenberg and
Hogan 2006; Kvarnhammar and Cardell 2012). Basophils are the least abundant
granulocyte, and express TLR2, TLR4 and IgE receptors (Stone et al. 2010). Neither
basophils nor eosinophils are known to express scavenger receptors. Fucoidan and polyI
inhibited ~ 80% of CLU-OVA binding to granulocytes (Figure 4.10), implicating
scavenger receptors and potentially TLR3 in the uptake of CLU-OVA into granulocytes
(Table 4.1). Only single peak flow cytometry profiles were seen (data not shown)
indicating that only one type of cell was involved in the binding of CLU-OVA. Taken
together with the known receptor expression profiles of different types of granulocytes,
and the abundance of neutrophils within the granulocyte population, it is likely that
neutrophils are the granulocyte responsible for mediating the binding and internalisation
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of CLU-OVA. Neutrophils have also been shown to bind gp96 in a fucoidan-inhibitable
manner; this binding activates the neutrophils which increases phagocytosis (Radsak et
al. 2003). Neutrophils have recently been shown to play a role in antigen cross-priming
via MHC I (Beauvillain et al. 2007), and are also capable of expressing MHC II
molecules under conditions of inflammation (Gosselin et al. 1993; Mudzinski et al.
1995) to present internalised antigen to CD4+ T cells in vitro (Radsak et al. 2000;
Culshaw et al. 2008). EIPA also significantly inhibited CLU-OVA binding to
granulocytes (by ~ 30%; Figure 4.10). This suggests that macropinocytosis, which is
inhibited by EIPA (Table 4.1) (Koivusalo et al. 2010; Hussain et al. 2011), may play a
minor role in the uptake of CLU-OVA by granulocytes. Preliminary studies have also
demonstrated the binding of α2m and α2m-client protein complexes to granulocytes
(French 2005). Binding of α2m alone was inhibitable by RAP, although the binding of
α2m-client protein complexes was not, implicating the LRP1 receptor in the binding of
α2m alone but not α2m-client protein complexes (French 2008).
Binding of CLU-OVA to lymphocytes was low compared to the binding to granulocytes
and monocytes; although the binding of CLU and CLU-OVA was still significantly
higher than OVA, HSA or BSA (Figure 4.9). For all inhibitors tested, the extent of
inhibition of CLU-OVA binding to lymphocytes was also lower than that obtained for
granulocytes and monocytes (Figure 4.10). T cells account for between 61 and 85% of
the total lymphocyte population (Reichert et al. 1991) and express LRP1 (Spijkers et al.
2005), TLRs (Funderburg et al. 2008) and SR-PSOX (Shashkin et al. 2003; Tabata et
al. 2005). B cells account for between 7 and 23% of total lymphocyte population
(Reichert et al. 1991), are activated by mannan (Mangeney et al. 1989), express LRP1
(Spijkers et al. 2005) and the scavenger receptors MARCO, SR-B1, CD36, LOX-1 and
SR-PSOX (Zhu et al. 2009; Matsutake et al. 2010; Jordo et al. 2011). Natural killer
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cells comprise up to 15% of the peripheral blood lymphocytes (Whiteside and
Herberman 1994) and express LRP1 (Spijkers et al. 2005).
Binding of CLU-OVA to lymphocytes was significantly inhibited by 5 of the
7 inhibitors tested (Table 4.1), suggesting that a broad range of binding mechanisms
may be used by these cells. This may be because there are many subsets of B and
T cells, which may express different receptors and bind and internalise ligands via
different mechanisms (Mosmann and Sad 1996; Allman and Pillai 2008; Jackson et al.
2008; Kitagishi et al. 2012). PolyI and fucoidan inhibited ~ 40% and ~ 30% of
CLU-OVA binding, respectively, implicating scavenger receptors and potentially
TLR3 in the binding of CLU-OVA to lymphocytes. mβCD inhibited ~ 20% of the
binding of CLU-OVA to lymphocytes, potentially implicating lipid rafts (Kilsdonk et
al. 1995) and clathrin mediated endocytosis (Rodal et al. 1999) in its uptake by
lymphocytes. GST-RAP and mannan also inhibited ~ 10% of CLU-OVA binding
potentially implicating a minor role for LRP1/2 or VLDLR and mannose receptors in
the binding of CLU-OVA (Kery et al. 1992; Willnow et al. 1996; Andersen et al. 2000;
Sheng et al. 2006).
CLU-OVA and CLU showed significantly greater binding to monocytes than OVA,
HSA or BSA (Figure 4.9), although this binding was less than that to granulocytes.
Fucoidan and polyI inhibited between 60 and 90% of the binding of CLU-OVA
to monocytes (Figure 4.10), which are known to express SR-AI, SR-B1, CD36 and
FEEL-1 but not LOX-1 and SREC-1 (Table 4.3). Of the scavenger receptors expressed
by monocytes, polyI and fucoidan only inhibit SR-AI and FEEL-1, implicating one or
both of these receptors in the binding of CLU-OVA to monocytes. LRP1 is expressed
by monocytes (Fischer et al. 2010); however, the fact that GST-RAP did not inhibit

128

Chapter 4: Binding and Internalisation of CLU and CLU-OVA

CLU-OVA binding to this cell type suggests that LRP1/2 and VLDLR are not involved
in the binding of CLU-OVA to monocytes. EIPA, mannan and mβCD showed low
(< 40%) but significant (Table 4.2) inhibition of CLU-OVA binding to monocytes
(Figure 4.9); implicating multiple mechanisms (Table 4.1) in the lower levels of binding
of CLU-OVA to monocytes. Monocytes are not known to express mannose receptors
(of which mannan is an inhibitor) or to perform macropinocytosis (of which EIPA is an
inhibitor) until differentiated into macrophages or dendritic cells (Sallusto et al. 1995;
Egan et al. 1999), therefore the reason(s) for EIPA and mannan inhibiting CLU-OVA
binding/internalisation in this study is uncertain. Preliminary studies have shown that
proteolytically activated α2m binds to monocytes (French 2005). Monocytes also bind
gp96 via a fucoidan inhibitable mechanism (Radsak et al. 2003) and are able to
internalise HSP70-peptide complexes via LRP1 and scavenger receptors, to generate a
bound peptide-specific MHC II response resulting in the production of antigen specific
CD4+ T cells (Fischer et al. 2010).
As binding of CLU-OVA to bone marrow derived macrophages, human granulocytes,
lymphocytes and monocytes was inhibited by fucoidan and polyI, it is likely that
RAW 264.7 cells were not an appropriate model. RAW 264.7 cells have been reported
to express scavenger receptors (de Vries et al. 1999; Fitzgerald et al. 2000; Coller and
Paulnock 2001; Harb et al. 2009) which is why they were chosen as a starting point for
this study, however, expression of scavenger receptors under our culture conditions was
not tested. If the cultured RAW 264.7 cells were no longer expressing scavenger
receptors this may account for the results.
This study showed that binding of CLU and CLU-OVA to bone marrow
derived macrophages, human granulocytes, lymphocytes and monocytes was
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significantly greater than that of OVA, BSA or HSA. Depending on the individual cell
type, different binding mechanisms were implicated. It is likely that the route
of uptake into cells, the cell type involved and the antigen itself may influence
the immune response generated (Castellino et al. 2000; Murshid et al. 2010). Many
of the cell types investigated in this study are involved in generating an immune
response either by stimulating other immune cells, by presenting antigen to CD4+
T cells or cross-presenting antigen to CD8+ T cells. As CLU-OVA shows enhanced
binding/uptake into monocytes, granulocytes, and macrophages this suggests that
similar to other chaperones, CLU may direct bound antigen for the generation of a
specific immune response to the bound antigen (Figure 4.11). Further work to elucidate
the mechanism by which CLU directs bound antigen to either MHC I or MHC II
molecules will aid in our understanding of how CLU functions as an immune modulator
(as examined in the next chapter).
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5 Immune Modulatory Effects of CLU
5.1

Introduction

Almost all studies of the immunomodulatory effects of chaperones have assessed
cross-presentation and subsequent priming of the immune system to generate a CTL
response (see section 1.4 for details). Little research has been carried out to examine the
role of chaperones in eliciting a MHC II directed CD4+ T cell response. Most of the
previous work in this area has focussed on potential roles of intracellular chaperones in
the extracellular space (Srivastava et al. 1998; Binder 2006; Calderwood et al. 2007a;
Binder 2008; Calderwood and Ciocca 2008; Pockley et al. 2008; Henderson et al.
2010). In contrast, with the notable exception of α2m (Binder et al. 2000b; Binder et al.
2001b; Binder 2004; Bowers et al. 2009), the roles that ECs may play has received very
little attention.
CTL responses are thought to be essential for the generation of anti-tumour
immunity as well as for the effective treatment and prevention of a number of human
diseases including viral infections and intracellular pathogens (Binder 2008). Therefore
the development of effective adjuvants that mediate a CTL response with minimal
side effects are critical to improve our ability to fight these diseases. CTL responses
are typically harder to elicit than humoral immune responses and so the ability
of chaperones to direct antigens to a cross-priming (generation of a CTL response
to exogenously derived antigen presented on MHC class I molecules) pathway is of
great interest. Currently there are only a very few adjuvants clinically approved for
human use, none of which are able to stimulate a CTL response (Marrack et al. 2009;
Mbow et al. 2010; Wang et al. 2012). Therefore there is still a need to develop
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adjuvants that can stimulate both arms of the immune system and can be used in a
clinical setting.
HSP-antigen vaccines have been used in animal studies for a number of diseases;
including cancer (Udono and Srivastava 1993; Udono et al. 1994; Udono and Srivastava
1994; Blachere et al. 1997; Suzue et al. 1997; Tamura et al. 1997; Srivastava 2000), a
variety of viral infections (Suzue and Young 1996; Heikema et al. 1997; Ciupitu et al.
1998; Anthony et al. 1999; Brenner and Wainberg 2001; Navaratnam et al. 2001; Li et
al. 2005a; Gong et al. 2009b), malaria (Perraut et al. 1993), and intracellular bacterial
infections (Finelli et al. 1999; Sponaas et al. 2001; Zugel et al. 2001; Rapp and
Kaufmann 2004; Hosseini Jazani et al. 2010). HSP-antigen vaccines have also been
used in a number of clinical cancer trials (Janetzki et al. 2000; Castelli et al. 2004;
Parmiani et al. 2004; Binder 2006; Parmiani et al. 2006; Srivastava 2006; Binder 2008;
Srivastava et al. 2009; Randazzo et al. 2012), including melanoma (Belli et al. 2002;
Pilla et al. 2006; Testori et al. 2008; Tosti et al. 2009; Eton et al. 2010; di Pietro et al.
2011), glioblastoma (See et al. 2011), renal cell carcinoma (Cohen et al. 2002; Wood et
al. 2008; Yang 2008), cervical neoplasia (Einstein et al. 2007; Roman et al. 2007),
colorectal carcinoma (Mazzaferro et al. 2003; Rivoltini et al. 2003), chronic myeloid
leukaemia (Li et al. 2005b) and pancreatic adenocarcinoma (Maki et al. 2007), and in a
clinical trial against herpes simplex virus (Koelle et al. 2008). In all clinical trials the
vaccines were reported to be well tolerated with minimal side effects.
One of the limiting factors regarding the currently used chaperone-peptide vaccines
is the limiting amount of vaccine available (Binder 2006; Srivastava 2006; Srivastava et
al. 2009). Currently all chaperone vaccines in clinical trials are tumour
derived, meaning the tumour is excised, homogenised and the chaperone-peptide
complexes purified from the homogenate to form the chaperone vaccine. Due to the
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intracellular location of the chaperones, the tumour size largely dictates the amount of
chaperone-peptide vaccine that can be produced (Binder 2006). Considering vaccine
efficacy has been shown to improve with 10 or more injections (Gordon and Clark
2004; Richards et al. 2006; Binder 2008; Testori et al. 2008; Srivastava et al. 2009) the
limited quantities of tumour derived (intracellular chaperone based) vaccine available
has serious limitations. As CLU is readily purified in milligram amounts from a
standard 400 mL blood donation, this provides a more readily available source of
chaperone to generate a vaccine. CLU can also bind to a wide variety of protein clients
to form complexes with them (Humphreys et al. 1999; Poon et al. 2000; Carver et al.
2003; Wyatt and Wilson 2010), making it very suitable for the development of
chaperone-peptide vaccines.
This study investigated the ability of CLU to act as an adjuvant of both arms of
the immune system, to generate both CTL and humoral immune responses through
cross-presentation of antigen on MHC class I, and antigen presentation on MHC class II
molecules, respectively. Murine models were used to assess these responses. To study
cross-presentation and to determine whether a cross-priming or cross-tolerance response
(see section 1.4 for definitions) to a model antigen (OVA) was induced, mice were
immunised with CLU-OVA conjugate or a variety of control proteins and then
challenged with OVA in the presence of a strong adjuvant. IL-2 and IFNγ responses
were measured to determine whether proliferation of immune cells occurred and
whether these cells gained effector function. This was undertaken during a working visit
to our collaborators laboratory in Angers, France (P. Jeannin at INSERM).
To study the generation of a humoral immune response, mice underwent a series of
immunisations with CLU-OVA (chemically linked), CLU/OVA (complexed utilising
the chaperone action of CLU), or a series of control proteins to determine if an OVA
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specific antibody response could be generated, and if so what immunoglobulin isotypes
made up this response.

134

Chapter 5: Immune Modulatory Effects of Clusterin

5.2

Methods

5.2.1

CrossPresentation of OVA In Vivo

5.2.1.1

Immunisation Schedule

To determine whether CLU could mediate cross-priming or cross-tolerance in vivo,
OT-1 (CD45.2) CD8+ T cells (2 x 106) were intravenously injected into C57BL/6
(CD45.1) mice (5 mice/group), this was performed by Céline Beauvillain (INSERM,
Angers, France). OT-1 CD8+ T cells were purified from OT-I transgenic mice (Charles
River Laboratories, L’Arbresle, France). These mice carry a transgenic CD8+ T cell
receptor for the MHC class I - restricted OVA peptide amino acids 257 - 264
(SIINFEKL). To purify these cells, mice were sacrificed by cervical dislocation and the
draining lymph nodes and spleen were harvested and placed into separate tubes
containing RPMI. The organs were homogenised separately on blutex nylon mesh
(Tissages Tissues Techniques, Paris, France) using a 2 mL syringe plunger in RPMI and
filtered through blutex into a 15 mL tube on ice. Cells were pelleted at 300 x g for
10 min and the supernatants removed. Contaminating red blood cells in the spleen
sample were removed by osmotic lysis. Cells were resuspended in 3 mL 0.2% NaCl for
30 s followed by the addition of 3 mL 1.6% NaCl to return the solution to an isotonic
state. Tubes were then topped up with RPMI and centrifuged as above. The cells
obtained from the spleen after red blood cell lysis and the draining lymph nodes were
then pooled prior to purification using a CD8a+ T cell isolation kit (Miltenyi Biotec,
Bergish Gladbach, Germany) following the manufacturer’s protocol. CD11c+ cells
(dendritic cells) were then depleted from the sample using CD11c microbeads (Miltenyi
Biotec).
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After 24 h, mice were intraperitoneally injected with 160 µg OVA with and without
CFA, 160 µg CLU-OVA with and without CFA, or 160 µg HSA-OVA. At day 12, mice
were challenged with 50 µg OVA + CFA via an intraperitoneal route. On day 15, mice
were sacrificed via cervical dislocation and used for an in vivo cytolysis assay (section
5.2.2.2), the intracellular measurement of cytokines (section 5.2.2.3), and measurements
of cytokines secreted from cells isolated from the spleen and draining lymph nodes
(section 5.2.2.4).

5.2.1.2

In Vivo Cytolysis Assay

On day 14 spleen cells were harvested (as described in section 5.2.1.1) by Mari Scotet
(INSERM, Angers, France) and plated at 3 x 106 cells per well in duplicate for each
mouse to be injected (2 mice per group). On day 15, one well of spleen cells previously
prepared from each mouse was pulsed with 2 µg/mL SIINFEKL peptide for 20 min at
37 °C. Pulsed and un-pulsed cells were labelled by incubation with CFDA-SE at 10 µM
(CFSEhigh) or 1 µM (CFSElow), respectively, in 100 mM sodium bicarbonate, pH 8.3.
The cells were washed, combined at a 1:1 ratio and intravenously injected into 2 mice
per treatment group (this was performed by Céline Beauvillain). This allows for the
detection of specific killing of OVA pulsed cells (CFSEhigh) compared to the
non-specific killing of un-pulsed cells (CFSElow) by CTLs. Four hours later mice were
sacrificed by cervical dislocation and the spleen cells harvested (as per section 5.2.1.1)
prior to analysis for CFSE expression by flow cytometry using a FACScalibur
cytofluorometer (BD Biosciences). Specific killing was measured as a reduction in the
ratio of antigen-pulsed (CFSEhigh) cells to un-pulsed (CFSElow) cells.
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5.2.1.3

Measurement of Intracellular Cytokines

Mice were sacrificed by cervical dislocation (3 per treatment group), the spleen and
draining lymph nodes harvested (as per section 5.2.1.1), and the cells combined (spleen
and draining lymph node cells kept separate). Cells were added to a 96 well plate
at 2 x 106 cells/well in complete RPMI 1640 medium (cRPMI; RPMI 1640 medium
supplemented with 5 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential
amino acids, 10 mM Hepes, 100 U/mL penicillin, 100 µg/mL streptomycin)
supplemented with 10% (v/v) FCS, 2 µg/mL SIINFEKL peptide, 10 µg/mL brefeldin A,
and incubated for 4 h under standard conditions. The addition of brefeldin A enhances
the amount of cytokine retained within the cell by blocking transport processes, and is
commonly used when detecting intracellular cytokines. These cells were washed in
1% BSA/PBS by centrifugation for 5 min at 300 x g and 4 °C and split in half to allow
staining with both specific and isotype control antibodies. Cells were incubated in
FcBlock for 10 min at 4 °C prior to the addition of either biotinylated rat-anti-mouse
CD45.2 or biotinylated (isotype control) rat IgG2b for 15 min at 4 °C. Cells were
washed in 1% BSA/PBS as above, prior to the addition of 10 µg/mL SA-ALEXA488
for 20 min at 4 °C. Cells were then washed three times in 1% BSA/PBS as above
prior to fixation in 4% (w/v) PFA in PBS for 15 min at room temperature before
washing again in PBS and permeabilising in 0.1% (w/v) saponin/0.1% BSA/PBS
for 20 min at room temperature. Intracellular cytokine staining was performed
by incubating cells for 30 min at 4 °C with 5 µg/mL PE-labelled rat anti-IFNγ
and 5 µg/mL allophycocyanin-labelled rat anti-IL-2, or 5 µg/mL of the isotype control
antibodies (PE-labelled rat IgG1 and allophycocyanin-labelled rat IgG2b) in
0.1% saponin/0.1% BSA/PBS. Cells were washed three times in PBS as above prior to
flow cytometry analysis.
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5.2.1.4

Measurement of Cytokines Secreted from Cells Taken
from the Spleen and Draining Lymph Nodes of
Immunised Mice

Cells obtained from draining lymph nodes and the spleen were added separately in
quadruplicate to a 96 well plate (2 x 105 cells/well in 200 µL cRPMI supplemented with
10% (v/v) FCS) and stimulated or not (in duplicate) with SIINFEKL peptide. Cells were
incubated under standard conditions for 48 h prior to aspiration of the supernatant,
which was frozen at - 20 °C for short term storage prior to the measurement of IFNγ and
IL-2 in the supernatant by ELISA. Mouse IFNγ or mouse IL-2 ELISA kits (both from
BD Biosciences) were used to detect IFNγ and IL-2 respectively, in the tissue culture
supernatants following the manufacturer’s protocols. If any sample values were lower
than that obtained for the 0 pg/mL IL-2 or IFNγ standards, they were corrected to zero.

5.2.2

Measuring the Humoral Immune Response

5.2.2.1

Immunisation, Blood Sampling and Sacrifice

Mice were injected intraperitoneally with 200 µg of either: CLU, OVA,
CLU-OVA (chemically linked as described in section 2.9), OVA mixed in a 1:1 ratio
with ALUM (Aluminium Phosphate Gel Adjuvant; AlPO4 content 2%; Accurate
Chemical and Scientific Corp, Westbury, NY, USA). Preliminary results established
that CLU was able to stimulate an OVA specific immune response when chemically
linked to OVA; therefore, a subsequent experiment was undertaken to include
additional controls. This involved the intraperitoneal injection of 200 µg OVA,
CLU/OVA complexes (formed using the chaperone action of CLU as described in
section 2.10), OVA mixed in a 1:1 ratio with ALUM, or HSA, MSA, HSA-OVA or
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MSA-OVA (the latter two conjugates generated with the same chemistry used to
produce CLU-OVA; section 2.9).
Injections were performed on days 1, 15, 29 and 40 and immune responses were
monitored over a period of 6 weeks by performing tail bleeds. In both experiments
naive plasma samples were taken on day 0. In the first experiment, samples were also
taken on days 14 and 28 as well as the final day (day 43) to determine if isotype
switching occurred during the maturation of the immune response. No changes were
seen and so for the second experiment only naive and final day plasma was taken. To
perform tail bleeds, the tails of mice were placed in warm water to increase vasodilation
before 1 - 2 mm was removed from the tip of the tail using a sharp scalpel. Tails were
milked into a 1.5 mL tube ensuring at least 10 µL of blood was collected, which was
subsequently placed on ice. Plasma samples were prepared by centrifuging the blood
samples at 10,000 x g for 15 min, the plasma was then removed, diluted 1:100 in
1% BSA/PBS/0.01% (w/v) thimerosal, and stored at 4 °C until required. On day 43,
mice were sacrificed by CO2 asphyxiation and the blood collected by cutting the heart
and collecting the blood from the thoracic cavity with a sterile syringe; plasma samples
were prepared as above.

5.2.2.2

Measuring Immunoglobulin Responses by ELISA

ELISA was used to monitor the OVA specific immune responses generated
in vivo, including isotype-specific responses. To ensure that the titres of anti-OVA
antibodies of different isotypes (IgA, IgE, IgG1, IgG2a, IgG2b, IgG3 and IgM) could
be detected and compared, the dilution used for each isotype-specific secondary
antibody was selected by performing an ELISA in which purified isotype control
antibodies were used to coat ELISA plates at an equal concentration (10 µg/mL), and
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the isotype-specific secondary antibodies titrated across the plate. A dilution of each
isotype-specific detection antibody was then chosen that yielded approximately the
same arbitrary absorbance value (~ 1.0), and this dilution (Table 2.3) was used in all
subsequent assays. All isotype-specific antibodies had no known cross-reactivity with
other immunoglobulin isotypes. Assays were performed in high binding 384 well
ELISA plates (Greiner Bio-One) rather than 96 well plates to minimise the amount of
sample used and to increase the number of samples that could be simultaneously
processed.
Non-isotype specific anti-OVA titre was calculated by coating ELISA plates with
10 µg/mL OVA in PBS (20 µL/well) for either 1 h at 37 °C or overnight at 4 °C, plates
were washed 6X in PBS and subsequently blocked with HDC (defined in section 2.4;
50 µL/well) overnight at 4 °C. Large batches of plates were coated and blocked at once
and stored (sealed, containing HDC blocking solution) at 4 °C until required. Plasma
samples from the mice (pre-diluted 1 in 100; 20 µL/well, in triplicate) were diluted
in binary steps across the plate in HDC, incubated at 37 °C for 1 h before the plates
were washed 6X in PBS. Goat-anti-mouse Ig-HRP antibody (1:1,000 in HDC;
20 µL/well) was added and incubated at 37 °C for 1 h before the plates were again
washed 6X in PBS. Developing solution (2.5 mg/mL OPD, in 0.03% w/v H2O2, 0.05 M
citric acid, 0.1 M Na2HPO4, pH 5) was added (50 µL/well) and the plates incubated
at room temperature until adequate colour had developed. The reaction was stopped by
the addition of 1 M HCl (20 µL/well) and the absorbance at 492 nm measured in a
Spectra-Max Plus 384 plate reader.
OVA specific IgG1 antibodies were detected using a goat-anti-mouse IgG1 (1:5,000 in
HDC; 20 µL/well) incubated for 1 h at 37 °C. Plates were washed as above before
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adding mouse-anti-goat Ig-HRP (1:30,000 in HDC; 20 µL/well) for 1 h at 37 °C,
followed by washing and detection as described above.
For all other isotypes, a streptavidin/biotin amplification system was applied to increase
the signal. Coating, blocking, sample application, addition of isotype-specific antibodies
and washing were carried out as above. Biotinylated rabbit-anti-goat IgG (1:20,000 in
HDC; 20 µL/well) was then added to the plate for 1 h at 37 °C and the plates washed as
above. Streptavidin (2.5 µg/mL) and bHRP (2.5 µg/mL) were pre-mixed in HDC and
added to the plate (20 µL/well) for 1 h at 37 °C, the plates washed and detection
performed as above.
A sample of plasma from mice immunised with OVA-ALUM (diluted at 1:100) was
added to 8 wells on each plate and the mean absorbance value obtained from these
wells. The plate with the highest mean absorbance value was used as a “maximum” and
all plates normalised to this, to allow comparison between plates. Samples were also
background corrected by subtracting the mean absorbance value (n = 8) for wells where
HDC rather than plasma was used as the sample (all other steps were the same). Titres
were calculated using an arbitrary absorbance value of 0.2 as the “cut-off”. Titres were
calculated for each of the plasma samples (which were in triplicate on the plate) and
compared to that calculated for mice immunised with OVA, using an un-paired
student’s t-test to determine significance (p < 0.05).
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5.3

Results

The successful chemical conjugation of CLU to OVA (to form CLU-OVA) was
assessed by SDS-PAGE analysis of the reaction compared to a mock reaction (where
a sample of the reaction mixture was taken immediately after the addition of
SMCC-derivatised CLU to reduced OVA, and the reaction halted by the addition of
excess free cysteine). Western blot analysis was undertaken to confirm the presence of
both CLU and OVA in the CLU-OVA sample (after removal of free OVA by SEC)
(Figure 5.1). Using anti-CLU antibodies, CLU was detected in the CLU sample (Figure
5.1a, lane 2) but not the OVA sample (Figure 5.1a, lane 3); CLU was detected as a main
band at ~ 75 kDa with another band at > 130 kDa probably representing SDS-resistant
CLU oligomers (Figure 5.1a, lane 2). Western blotting using anti-CLU antibodies
detected HMW bands at > 100 kDa in the CLU-OVA sample (Figure 5.1a, lane 4),
corresponding to the conjugate. Using anti-OVA antibodies, OVA was detected in the
OVA sample (Figure 5.1a, lane 2) but not the CLU sample (Figure 5.1a, lane 3). OVA
was detected as a large smear most likely due to overloading of the gel, with main bands
at 35 - 55 kDa and ~ 100 kDa (Figure 5.1b, lane 2). Western blotting using anti-OVA
antibodies also detected HMW bands at > 100 kDa (Figure 5.2a, lane 4), corresponding
to the conjugate. The detection of HMW material containing both CLU and OVA in the
CLU-OVA sample confirmed that the two proteins had been successfully conjugated.
Similarly, the successful formation of HMW CLU/OVA complexes was confirmed by
SEC and subsequent Western blot analysis (data not shown).
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The proliferation of cells was monitored by measuring IL-2 both contained within
CD8+ T cells (Figure 5.2a) and in the supernatant of cells obtained from the
draining lymph nodes or spleen (pulsed or not with SIINFEKL peptide; Figure 5.2b).
Of CD8+ T cells isolated from the draining lymph nodes, mice immunised with
CLU-OVA + CFA showed the strongest IL-2 response, followed by mice immunised
with CLU-OVA alone. Mice immunised with OVA or OVA + CFA had lower,
comparable levels of intracellular IL-2 and mice immunised with HSA-OVA showed
similar low levels (Figure 5.2a). Overall the CD8+ T cells isolated from the spleen
had lower levels of intracellular IL-2, although again mice immunised with
CLU-OVA and CLU-OVA + CFA showed the strongest response (Figure 5.2a). When
cells were isolated from the draining lymph nodes or spleen, only mice that had been
immunised with CLU-OVA + CFA showed a strong IL-2 response when the cells were
stimulated with SIINFEKL peptide (Figure 5.2b).
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Figure 5.2 a) Intracellular IL-2 detected by flow cytometry. Results displayed as a
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tissue culture supernatant of cells stimulated or not with SIINFEKL peptide (values plotted
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The gain of cellular effector function was monitored by measuring IFNγ contained
within CD8+ T cells (Figure 5.3a) and in the supernatant of cells obtained from
the draining lymph nodes or spleen (pulsed or not with SIINFEKL peptide; Figure
5.3b). With respect to CD8+ T cells isolated from the draining lymph nodes, mice
immunised with CLU-OVA + CFA showed the strongest IFNγ response, followed by
mice immunised with CLU-OVA. Mice immunised with OVA, OVA + CFA or
HSA-OVA contained comparable levels of intracellular IFNγ, with HSA-OVA being
the lowest (Figure 5.3a), these results were similar to those obtained for IL-2 (Figure
5.2a). When cells were isolated from the draining lymph nodes and stimulated or not
with SIINFEKL peptide in vitro, only mice that had been immunised with CLU-OVA
+ CFA showed a strong IFNγ response when their cells were stimulated (Figure 5.3b).
In all other treatment groups, stimulation with SIINFEKL did not result in the secretion
of IFNγ (Figure 5.3b). Although much less IFNγ was secreted from cells isolated from
the spleen, a similar trend to that observed for the draining lymph nodes was seen; mice
that had been immunised with CLU-OVA + CFA showed a stronger IFNγ response
when their cells were stimulated (Figure 5.3b). In all other treatment groups, stimulation
with SIINFEKL did not result in the secretion of IFNγ (Figure 5.3b).
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The in vivo cytolysis assay measures the CTL response against targets pulsed with the
OVA antigen SIINFEKL (and labelled with a high level of CFDA-SE; CFSEhigh)
compared to lysis of non-pulsed targets (labelled with a low amount of CFDA-SE;
CFSElow). CLU-OVA and to a slightly lesser extent CLU-OVA + CFA showed an
increase in the specific, CTL-mediated lysis of SIINFEKL pulsed targets when
compared to mice treated with PBS or OVA (Figure 5.4). All mice, regardless of
treatment group, were injected with OVA + CFA 3 days prior to final experimentation;
if a cross-tolerance response was elicited, the mouse immune system would not respond
to this challenge resulting in no lysis of the SIINFEKL pulsed targets. The mice in
groups immunised with OVA, OVA + CFA and HSA-OVA showed slightly lower
specific lysis than the PBS treatment group (Figure 5.4), though due to the low sample
size (n = 2), the significance of these results could not be determined.
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Figure 5.4 In vivo cytolysis assay to measure cytotoxic T lymphocyte (CTL) response.
Specific cytolysis (as a percent) was determined by the equation: 100 – [(number of
peptide-pulsed cells (CFSEhigh) / number of un-pulsed cells (CFSElow)) x 100] (values
plotted are means ± ½ range; n = 2).
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5.3.2

Measuring the Humoral Immune Response

The following experiments were carried out in two parts, therefore direct comparisons
could not be made between them, and hence the results are presented separately. In both
experiments OVA + ALUM was used as the positive control and OVA alone was used
as a baseline comparison. Unless otherwise specified any statistically significant
differences are based on comparisons with the OVA alone treatment group.
The initial experiment sought to establish whether CLU could enhance the humoral
immune response against a chemically conjugated antigen (OVA). This experiment
involved mice immunised with CLU-OVA, OVA + ALUM, CLU alone, OVA alone
and PBS as a negative control. Once it was established that CLU could act as an
adjuvant of the humoral immune system, a second experiment was performed to include
additional controls, to confirm that the adjuvant effect was CLU specific. Immunisation
with HSA-OVA, and HSA alone, were used to control for the introduction of a human
plasma protein into a murine system. Immunisation with MSA alone was used to
control for the introduction of a protein of a similar size to CLU, which should not
be recognised by the immune system (as it is a murine protein). Immunisation with
MSA-OVA was used to determine whether the chemistry involved in the conjugation
affects the immune response to OVA. CLU/OVA complexes were also generated by
exploiting the chaperone action of CLU. OVA is a very stable protein and very harsh
conditions were required to destabilise it in order to make these complexes. This may
have had unknown effects on the antigenicity of peptides contained within OVA, and it
was also possible that the antigenic peptides may have been masked when destabilised
OVA was bound to CLU.
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Initially, to confirm that an immune response had been raised against OVA, the total
OVA-specific Ig titre was measured. These results showed similar trends to those
obtained for the specific IgG1 isotype anti-OVA response (total Ig titre data not shown).

5.3.2.1

Antibody Responses as a Function of Time

In the first experiment, the antibody responses were tested over the course of the
immunisation schedule. At all time points tested, plasma from mice immunised with
CLU, and in the PBS control group, contained negligible OVA-specific IgM antibodies
(Figure 5.5). Naive plasma from all treatment groups lacked any specific IgM anti-OVA
antibodies (Figure 5.5a). By week 2, plasma from mice immunised with OVA + ALUM
contained more OVA-specific IgM antibodies than the other groups; these antibodies
were also detected at a lower level in the CLU-OVA and OVA treatment groups at this
time point (Figure 5.5b). This response was marginally stronger at week 4 (Figure 5.5c)
and increased further by the final bleed (week 6; Figure 5.5d). At all time points the
positive control group (mice immunised with OVA + ALUM) contained the highest
levels of OVA-specific IgM antibodies, followed by plasma from mice immunised with
CLU-OVA; both of these groups had higher antibody levels than mice immunised with
OVA alone (Figure 5.5).
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Figure 5.5 ELISA measurements of IgM anti-OVA antibodies at all time points (mean
± SE; n = 9 - 12). a) Naive sample (day 0). b) Week 2 sample (day 14). c) Week 4 sample
(day 28). d) Final time point (week 6, day 43).

Both naive plasma, and plasma from the CLU and PBS control groups (at all time
points tested), contained no detectable IgG1 anti-OVA antibodies (Figure 5.5). By week
2, the plasma from mice immunised with OVA + ALUM contained more OVA-specific
IgG1 antibodies than the other groups; these antibodies were also detected at a lower
level in the CLU-OVA treatment group at this time point (Figure 5.5b). By week 4,
plasma from the OVA + ALUM, CLU-OVA and OVA treatment groups all contained
OVA-specific IgG1 antibodies (Figure 5.5c) which increased in titre by the final bleed
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(week 6; Figure 5.5d). At all time points the positive control group (mice immunised
with OVA + ALUM) showed the strongest OVA-specific antibody response followed
by plasma from mice immunised with CLU-OVA; both of these groups had a higher
antibody response than mice immunised with OVA alone (Figure 5.5).
For mice immunised with CLU-OVA or OVA, the OVA-specific IgM antibody
response was seen earlier (week 2) than the corresponding IgG1 response (Figure 5.5b
and Figure 5.6b). Both IgM and IgG1 responses, however, increased with time (Figure
5.5 and Figure 5.6).
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Figure 5.6 ELISA measurements of IgG1 anti-OVA antibodies at all time points (mean
± SE; n = 9 - 12). a) Naive sample (day 0). b) Week 2 sample (day 14). c) Week 4 sample
(day 28). d) Final time point (week 6, day 43).
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5.3.2.2

IgM OVASpecific Immune Response

The positive control samples (mice immunised with OVA + ALUM) were screened for
anti-OVA antibodies of all isotypes using a streptavidin/biotin amplification system
(except IgG1, as this showed a strong response without amplification). As only the IgM
isotype yielded an absorbance value greater than 0.2 (the nominal cut-off for calculation
of titre), the anti-OVA antibody titres were only calculated for the IgM and IgG1
isotypes.
Plasma from mice immunised with CLU-OVA or OVA + ALUM showed higher levels
of OVA-specific IgM antibodies at all dilutions tested compared to mice immunised
with OVA alone (Figure 5.7a). Mice in the PBS and CLU control groups showed no
IgM-specific anti-OVA antibodies (Figure 5.7), while those immunised with CLU-OVA
or OVA + ALUM showed a significantly higher titre than mice immunised with OVA
alone (p = 0.0052 and p < 0.0001, respectively; Figure 5.7b).
In the second experiment, at the lower dilutions tested, plasma from mice immunised
with OVA + ALUM gave lower absorbance values compared to plasma from mice
immunised with OVA alone. However, at higher dilutions (above 1 in 1,600), the
absorbance values did not decrease as rapidly compared to the other treatment groups
(including OVA; Figure 5.8a); thus mice immunised with OVA + ALUM had a
significantly higher titre compared to those immunised with OVA alone (p = 0.015;
Figure 5.8b). Mice in the MSA and HSA control groups showed no detectable specific
IgM anti-OVA immune response; hence no titre could be calculated for these treatment
groups (Figure 5.8). Mice immunised with CLU/OVA showed a significantly higher
titre than mice immunised with OVA alone (p = 0.0003). Mice immunised with
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HSA-OVA and MSA-OVA had significantly lower titres than mice immunised with
OVA alone (p < 0.0001 in both cases; Figure 5.8b).
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Figure 5.7 Calculated IgM anti-OVA titres. a) ELISA data for antibody titres of plasma
from different mouse treatment groups (see key). b) Titre values for mice immunised with
CLU-OVA, OVA or OVA + ALUM. In both plots, data shown represent means ± SE;
n = 10 – 15. Significantly higher titre than OVA at ** (p < 0.001) or * (p < 0.05), as
determined by un-paired student’s t-test.
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CLU/OVA, OVA, MSA-OVA, HSA-OVA or OVA + ALUM. In both plots, data shown
represent means ± SE; n = 11 - 12. Significantly higher titre than OVA at ** (p < 0.001) or
* (p < 0.05), ŧŧ significantly lower than OVA response (p < 0.001), as determined by
un-paired student’s t-test.
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5.3.2.3

IgG1 OVASpecific Immune Response

In the first experiment, plasma from mice immunised with CLU-OVA or OVA
+ ALUM showed a significantly higher IgG1 anti-OVA titres than plasma from mice
immunised with OVA alone (p = 0.036 and p <0.0001, respectively; Figure 5.9b).
Similar to the IgM anti-OVA response, there were no detectable IgG1 anti-OVA
antibodies in plasma from mice in the PBS and CLU control groups (Figure 5.9) or, in
the second experiment, in plasma from mice in the MSA and HSA control groups
(Figure 5.10). In the second experiment, plasma from mice immunised with OVA
+ ALUM, CLU/OVA or MSA-OVA showed significantly higher IgG1 anti-OVA titres
than plasma from mice immunised with OVA alone, while plasma from mice
immunised with HSA-OVA had a significantly lower titre than mice immunised with
OVA alone (p = 0.0003, p < 0.0001, p = 0.02, and p = 0.0008, respectively; Figure
5.10).
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Figure 5.9 Calculated IgG1 anti-OVA titres. a) ELISA data for antibody titres of plasma
from different mouse treatment groups (see key). b) Titre values for mice immunised
with CLU-OVA, OVA or OVA + ALUM. In both plots, data shown represent means
± SE; n = 10 - 15. Significantly higher titre than OVA at ** (p < 0.001) or * (p < 0.05), as
determined by un-paired student’s t-test.
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Figure 5.10 Calculated IgG1 anti-OVA titres. a) ELISA data for antibody titres of plasma
from different mouse treatment groups (see key). b) Titre values for mice immunised with
CLU/OVA, OVA, MSA-OVA, HSA-OVA or OVA + ALUM. In both plots, data shown
represent means ± SE; n = 10 - 12. Significantly higher titre than OVA at ** (p < 0.001) or
* (p < 0.05), ŧŧ significantly lower than OVA response (p < 0.001), as determined by
un-paired student’s t-test.
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5.4

Discussion

The role that chaperone proteins play in immune modulation has been of interest
since the early 1990s after Srivastava et al. discovered that gp96 was able to induce a
cross-priming response specific to the peptides it was chaperoning (Srivastava et al.
1986; Srivastava et al. 1994). Since then, most of the research has focussed on
intracellular chaperones and the role they may play after being released from cells into
the extracellular space (Basu and Srivastava 2000; Srivastava 2002b; Srivastava 2002a;
Parmiani et al. 2004; Nishikawa et al. 2008). The only extracellular chaperone that has
been investigated for its role in immune modulation is α2m (Binder et al. 2000b; Binder
et al. 2001b; Binder 2004), however, when these studies were undertaken, it was not
known that α2m is a chaperone (French et al. 2008). This study investigated whether
CLU could potentiate an immune response to OVA when chemically linked to OVA or
complexed with it using the chaperone action of CLU.
Preliminary studies in mice were undertaken to establish whether CLU is able to
potentiate a CTL response to OVA when the two proteins are chemically linked.
This response was monitored by (a) determining intracellular levels of IL-2 and IFNγ
in the CD8+ T cell population isolated from either the spleen or the draining lymph
nodes, (b) measuring the amount of IL-2 and IFNγ secreted by cells obtained from the
spleen and draining lymph nodes, and (c) determining whether a cross-tolerance or
cross-priming response was generated when mice were challenged with OVA in the
presence of a strong adjuvant after immunisation with CLU-OVA or a number of
controls.
Under normal conditions IL-2 is predominantly produced by CD4+ T helper cells and to
a lesser extent by CD8+ T cells, natural killer cells and natural killer T cells (Malek
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2008; Boyman and Sprent 2012). Following antigen activation of the immune system,
IL-2 production by CD4+ and CD8+ T cells is rapidly and strongly induced and remains
elevated for a number of days in the draining lymph nodes and spleen (Kalia et al.
2010) and is associated with proliferation of these cells (Boyman and Sprent 2012).
Under normal conditions IFNγ is produced by CD4+ T helper cells, CD8+ CTLs,
natural killer cells, natural killer T cells, B cells and professional APCs (Young 1996;
Bach et al. 1997; Schroder et al. 2004). Following antigen stimulation of the immune
system, activated CD4+ T cells and CD8+ CTLs become the predominant source of
IFNγ (Frucht et al. 2001; Sen 2001; Schoenborn and Wilson 2007) and consequently
the production of IFNγ is often used as a marker for cross-priming (Bonifaz et al. 2002;
Matsutake et al. 2010). IFNγ is not produced immediately after antigen stimulation as
the differentiation of naive CD4+ and CD8+ into activated, mature effector cells
requires several rounds of cell division (Reiner 2001; Schoenborn and Wilson 2007).
IFNγ is essential for immunity against intracellular pathogens and tumours (Ikeda et al.
2002; Schoenborn and Wilson 2007).
Measurement of intracellular IL-2 and IFNγ within CD8+ T cells suggests that
the CD8+ T cells obtained from the draining lymph nodes of mice immunised with
CLU-OVA + CFA were undergoing the greatest proliferation and had the highest gain
of effector (CTL) function. This was followed by mice immunised with CLU-OVA
alone (Figure 5.2a and 5.3a). CFA is a strong adjuvant of the immune system and
contains killed Mycobacterium tuberculosis in an oil and water emulsion. It acts to
provide a continuous release of antigen so a strong and persistent immune response is
generated (Freund and McDermott 1942; Freund 1947; Billiau and Matthys 2001).
Therefore it is expected that CFA would enhance the immune response to any antigen it
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is administered with. Although the amount of intracellular IL-2 and IFNγ within CD8+
T cells obtained from the spleen was lower than in those obtained from the draining
lymph nodes a similar trend was seen for both in that, regardless of their tissue source,
CD8+ T cells obtained from mice immunised with CLU-OVA + CFA and CLU-OVA
showed the highest amount of intracellular IL-2 and IFNγ (Figure 5.2a and Figure 5.3a).
Draining lymph nodes are the first tissue where antigen specific CD8+ T cells are
detected following stimulation of the immune response (Wu et al. 2011), which may
explain why higher levels of CTL (IFNγ containing CD8+ T cells) were seen in the
draining lymph nodes compared to the spleen. In CD8+ T cells obtained from both the
draining lymph nodes and spleen, similar levels of both IL-2 and IFNγ were detected in
mice immunised with OVA and OVA + CFA, and mice immunised with HSA-OVA
showed slightly lower levels (Figure 5.2a and Figure 5.3a). It is unclear why CFA in
this case did not enhance the immune response to OVA, but as there is a small sample
size (n = 2) this experiment should be repeated to verify these results. As HSA
chemically linked to OVA did not enhance the IL-2 or IFNγ response of CD8+ T cells
to OVA challenge, this suggests that the enhancement of the OVA specific immune
response was CLU specific.
The amount of IL-2 and IFNγ secreted by all the cells (excluding the red blood cells)
isolated from the draining lymph nodes and spleen was also measured. This
measurement is less specific than the intracellular cytokine measurement as more than
one cell type is present in the cell suspensions. Therefore this is not a direct
measurement of the gain of CTL function but rather is indicative of the OVA specific
response of all cells contained within these organs. Secreted IL-2 was only detected for
cells obtained from mice immunised with CLU-OVA + CFA (Figure 5.2b). It is likely
that the amount of IL-2 in the other samples was below the detection limit of the
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ELISA. As cells that express IL-2 make up approximately 2% of the total cell
population of the spleen (Yui et al. 2001; Yui et al. 2004) this may explain why such
low levels were detected in the in vitro assay, at least for this organ. Naive CD8+ T cells
secrete IL-2 whilst undergoing division and typically lose the ability to produce IL-2
after differentiation into effector T cells. Effector T cells are then able to produce IFNγ
and have cytolytic activity (Aruga et al. 1997; Cheng et al. 2002).
It has previously been shown that splenocytes obtained from mice immunised with
HSP70-OVA and stimulated with SIINFEKL release IFNγ (Suzue et al. 1997).
Therefore the ability of CLU to stimulate a similar response was measured. When either
draining lymph node or spleen derived cells were stimulated with SIINFEKL peptide
in vitro only cells obtained from mice immunised with CLU-OVA + CFA produced
IFNγ, though there was much less secreted by the spleen derived cells than the draining
lymph node derived cells (Figure 5.3b). Even though the CD8+ T cell population from
mice immunised with CLU-OVA showed an increase in intracellular IFNγ compared to
mice immunised with OVA, secreted IFNγ was not detected in the supernatant of the
cells derived from the draining lymph nodes and the spleen of mice immunised with
CLU-OVA when stimulated with SIINFEKL peptide (Figure 5.3). When testing for
secreted IFNγ there were multiple cell types present, some of which may not express
IFNγ. However, as IFNγ was detected in the CD8+ T cell population, this indicates that
these cells display effector (CTL) function.
The direct measurement of OVA specific in vivo cytolysis showed that mice immunised
with CLU-OVA and CLU-OVA + CFA had increased specific cytolysis compared to
both the PBS and OVA treatment groups (Figure 5.4), suggesting that a mature CTL
response had been generated in these mice (Bonifaz et al. 2002). Mice immunised with
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PBS, OVA, OVA + CFA or HSA-OVA all showed similar responses (no cytolytic
activity detected) indicating that the enhancement of the OVA specific immune
response was due to CLU.
Taken together, the results from the cross-presentation in vivo experiment suggest that
immunisation with CLU-OVA + CFA (and potentially CLU-OVA alone) induced the
proliferation of CD8+ T cells and subsequent differentiation into effector T cells
(indicated by the presence of IFNγ and cytolytic activity). This supports the role of CLU
in cross-priming, akin to the responses elicited by a number of other chaperones (Basu
and Srivastava 2000; Srivastava 2002b; Srivastava 2002a; Parmiani et al. 2004;
Nishikawa et al. 2008). However, as indicated earlier, this experiment was preliminary
and had a low sample size so statistical significances could not be determined.
Therefore these results are suggestive only and need to be reproduced to confirm their
validity.
Although little research has been undertaken to investigate the role chaperones may play
in stimulating a humoral immune response, we investigated the ability of CLU to
potentiate the humoral response to OVA, by immunising with a chemically linked
conjugate (CLU-OVA), or a CLU/OVA complex formed using the chaperone activity
of CLU. OVA is a very stable protein and requires heating to > 90 °C (Wilson, M. R.
personal communication) or the addition of 400 mM DTT at 37 °C to induce it to unfold
and precipitate from solution. The chemical linkage of OVA to proteins has been used
in previous immunological presentation studies (Bonifaz et al. 2002). HSA-OVA and
MSA-OVA were produced using the same chemical linkage to act as controls.
OVA + ALUM was used as a positive control in the humoral immune response
experiments as this has previously been shown to elicit a significant increase in OVA

163

Chapter 5: Immune Modulatory Effects of Clusterin

specific antibody production compared to OVA administered alone (Wang et al. 2012).
As expected, the use of ALUM as an adjuvant in this study elicited very strong antibody
responses and showed the strongest titre in all experiments. PBS, CLU, HSA and MSA
were all used as negative control proteins and as expected no OVA specific immune
response was detected (Figure 5.5 - Figure 5.10).
Mice immunised with OVA + ALUM showed the development of both an IgM and
IgG1 isotype specific immune response to OVA after 2 weeks. At this same time point a
weaker IgM immune response to OVA was detected in mice immunised with either
OVA or CLU-OVA (Figure 5.5). IgM is the first immunoglobulin to be produced by
immature B cells when they are stimulated with antigen (Schroeder and Cavacini 2010),
therefore, it follows that an OVA-specific IgM response would be detected first. It was
expected that as the immune response matured, isotype switching to IgG1 would occur
(Huston 1997; Chaplin 2003). The level of OVA-specific IgG1 increased with the
number of injections (Figure 5.6); IgG1 is the most abundant antibody isotype in
blood and signifies that a mature immune response has been generated (Chaplin 2003;
Schroeder and Cavacini 2010). As both OVA-specific IgM and IgG1 levels in the blood
increased over time the remaining data analysis were conducted at the final time point.
The IgG subclasses are numbered in order of their abundance in the blood of healthy
subjects (IgG1 > IgG2 > IgG3). Mouse IgG1 is generally induced as a result of
immunisation with protein antigens, whereas, IgG2 and IgG3 responses generally result
from infection with viruses or immunisation with polysaccharides (Perlmutter et al.
1978; Coutelier et al. 1987; Markine-Goriaynoff et al. 2000; Schroeder and Cavacini
2010); as we were using protein antigens in this study, this may explain why only low
levels of IgG2 and IgG3 were seen. IgA responses are important in mucosal immunity
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(Macpherson et al. 2008); as the antigens in this study were injected into mice via an
intraperitoneal route, this may be why an IgA response was not mounted against OVA.
IgE is associated with allergic reactions (Gould and Sutton 2008); the fact that
OVA-specific IgE was not detected in this study suggests that the mice did not
experience a hypersensitivity or allergic reaction to OVA.
When mice were immunised with CLU-OVA, significantly higher IgG1 anti-OVA and
IgM anti-OVA immune responses were generated compared to mice immunised with
OVA alone, though the response was predominantly of an IgG1 isotype (Figure 5.7
and Figure 5.9). Immunisation with CLU/OVA generated significantly higher IgG1
anti-OVA and IgM anti-OVA titres compared to mice immunised with OVA alone,
though again the IgG1 response predominated (Figure 5.8 and Figure 5.10). Chemically
linked HSA-OVA and MSA-OVA failed to elicit a specific anti-OVA IgM titre (Figure
5.8). A significantly lower anti-OVA IgG1 response was induced when mice were
immunised with HSA-OVA compared to those immunised with OVA alone (Figure
5.10). Compared to mice immunised with OVA alone, immunisation with MSA-OVA
produced a significantly greater specific anti-OVA IgG1 response (p = 0.02). However,
immunisation with CLU/OVA gave a 1.4 fold higher titre than mice immunised with
MSA-OVA (Figure 5.10). A direct comparison can not be made between the
OVA-specific IgG1 titres generated for mice immunised with CLU-OVA and
MSA-OVA as these immunisations were not undertaken in the same experiment.
However, immunisation with CLU-OVA stimulated a 7.7 fold higher titre compared to
OVA (Figure 5.9), CLU/OVA elicited a 3.5 fold higher titre than OVA and MSA-OVA
elicited a 2.5 fold higher titre than OVA (Figure 5.10). These results suggest that
immunisation with the chemically linked conjugate (CLU-OVA) can produce a higher
anti-OVA titre than either CLU non-covalently complexed with OVA via the chaperone
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action of the former (i.e. CLU/OVA) or MSA-OVA. These results could arise from the
very harsh conditions used to destabilise OVA (400 mM DTT, at 37 °C) when
generating CLU/OVA; this may structurally compromise some antigenic OVA epitopes
resulting in lower titres. MSA (in MSA-OVA) was used a control protein and was not
expected to act as an adjuvant. Ideally these comparisons would be made within the one
experiment to allow stronger conclusions about the relative immunogenicity of the
different molecular species to be drawn.
These results taken together show that CLU is able to potentiate an antibody response to
OVA when they are either chemically conjugated (CLU-OVA) or complexed using the
chaperone action of CLU (CLU/OVA). It might also be of interest in the future to see if
the addition of ALUM to either CLU-OVA or CLU/OVA further enhances the response
caused by CLU, to yield a stronger response than OVA + ALUM. The combination of
adjuvants (CLU and ALUM) may enable the production of highly efficacious
therapeutics, with enhanced responses compared to therapeutics which only utilise
individual adjuvants. There are various possible mechanisms by which CLU enhances
the humoral immune response to OVA, including stimulation of APCs, activation of
naive CD4+ T cells or a T helper cell co-stimulatory function (Gong et al. 2009b).
IgG1 is able to fix complement to play a role in complement mediated cytolysis
(Bruggemann et al. 1987) and binds to cells such as macrophages, monocytes and
neutrophils through Fc receptors. When bound to antigen this facilitates more efficient
uptake into APCs and other phagocytic cells (Hazenbos et al. 1998), the release of
inflammatory cytokines and antibody dependent cell mediated cytotoxicity (Ravetch
and Kinet 1991; Hulett and Hogarth 1994). This can result in anti-tumour immunity if
the antigen is tumour-derived (Eisenthal et al. 1987; Hearing et al. 1991; Ravetch and
Kinet 1991) or if parasite-derived IgG1 antibodies can mediate the effective killing of
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immature parasites such as schistosomula (Horowitz et al. 1983) both in the intra- or
extracellular space (Lopez et al. 1983). The ability of an adjuvant to stimulate an IgG1
isotype response to antigen may be favourable as it appears that IgG1 is able to more
efficiently facilitate both complement mediated cytolysis and antibody dependent cell
mediated cytotoxicity (Bruggemann et al. 1987). IgM, however, also plays a role in
fixing complement and the opsonisation of antigen (Schroeder and Cavacini 2010).
In the last 100 years there has been the worldwide implementation of vaccines against a
wide range of human and animal pathogens. This has lead to the decreased prevalence
of infectious diseases such as mumps and rubella where there has been widespread
routine vaccination of children against these diseases, for example in the United States
of America (Centers for Disease Control and Prevention, 2012). One of the great
successes of worldwide vaccination schemes is the eradication of smallpox in 1980
(Strassburg 1982). However there are still many widely prevalent infectious diseases
against which we currently unable to vaccinate, and there is a need to develop cheaper,
long lasting, efficacious vaccines that can not only be used in the developed world but
in impoverished countries. Worldwide, HIV/AIDS and tuberculosis still remain leading
causes of death, and in low income countries, infectious disease accounts for ~ 40% of
deaths each year (World Health Organisation, 2011).
When using vaccines, the importance of producing a sustained humoral immune
response is widely recognised and the generation and maintenance of prolonged
antibody responses is essential to provide protective immunity against a wide variety of
pathogens (Amanna et al. 2007). The generation of an antibody response is especially
important for vaccination against extracellular pathogens, and protective immunity
against some microorganisms such as tetanus and diphtheria relies on the presence of
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pre-existing antibodies in the body to neutralise the exotoxins produced by these
pathogens (Janeway Jr et al. 2001).
As CLU is able to enhance both IgM and IgG1 specific responses against attached
antigen, this suggests that CLU may not only provide an ideal target for the
development of anti-cancer vaccines but may also be suitable as an adjuvant for the
production of vaccines against pathogens such as malaria, tuberculosis and HIV.
Future work should seek to determine how prolonged the induced immune response is.
Determining if the response declines or remains strong over time, gives an indication as
to whether the development of CLU-antigen as a therapeutic will require ongoing
“booster” shots, or if a limited initial course of immunisations will establish long-term
immunity to the bound antigen. It would also be of interest to determine whether
antigen-specific memory B cells are produced. If they are this would enable rapid and
strong immune responses upon subsequent antigen challenge, either due to a “booster”
immunisation or following exposure to the antigen during infection or tumour growth.
Previous work has shown that chaperone rich cell lysates are capable of eliciting both a
tumour-specific T cell response as well as eliciting humoral immunity, which resulted in
a significant delay in the growth of established tumours (Graner et al. 2000; Graner et
al. 2003; Li et al. 2008). It would be interesting to see if CLU is able to delay the
growth of established tumours, or prevent the establishment of new tumours. Other
studies have shown that chaperones can mediate anti-viral CTL and antibody immunity
(Navaratnam et al. 2001) and may act as good vaccine targets for HIV and other viral
infections that are best treated by the generation of both CTL and antibody immunity
(SenGupta et al. 2004).
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If CLU is able to activate both arms of the immune system to potentiate both CTL and
antibody responses against bound antigen, this indicates that CLU may provide a viable
vaccine adjuvant to overcome the current limitations of chaperone-peptide vaccines as
outlined in the introduction, or for the development of vaccines against numerous
pathogens. In the in vivo experiments, mice showed no adverse side effects and it is
likely that this would also be the case in humans if CLU-antigen vaccines were
developed for clinical use, especially as all chaperone-antigen vaccines that have been
used in clinical trials have been well tolerated (Srivastava et al. 2009; Tosti et al. 2009;
di Pietro et al. 2011).
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6 Discussion and Conclusions
The role that CLU plays as an adjuvant of the immune response has not been previously
studied. Thus far, together with our collaborators, we are the only researchers
worldwide to examine this phenomenon. Using CLU as a modulator of the immune
response may overcome current problems associated with the use of intracellular
chaperones in the production of vaccines. Due to the abundance of CLU in human
plasma, it is more readily purified in larger quantities than endogenous intracellular
chaperones complexed with antigens purified from tumour lysates, potentially
increasing the quantity of personalised chaperone-antigen vaccine that can be produced,
and thereby increasing vaccine efficacy. Furthermore the successful production of rCLU
also provides an alternative theoretically unlimited source of CLU for the production of
CLU based therapeutics.
The specific aims of this study were to (i) produce a chaperone active form of rCLU,
(ii) test the binding of CLU and CLU-OVA to a variety of cells (and their subsequent
internalisation), to elucidate potential receptors involved, and (iii) study the ability of
CLU to stimulate both a CTL and humoral immune response against the model antigen
OVA in a mouse model. These aims were addressed in chapters 3, 4 and 5 respectively.
In our laboratory and others, there have been many previous attempts to produce a pure
form of rCLU. Of the published and commercially available sources of human rCLU
(Table 3.1), none have been tested for chaperone activity and these products are
typically poorly characterised. In those cases where rCLU has been characterised, it is
often of low purity, and not correctly glycosylated or proteolytically processed into
α- and β-chains; in some cases the produced rCLU contained a variety of truncation
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products (Dawes 2002; Lakins et al. 2002; Stewart 2007). Therefore the production of a
correctly folded, chaperone active form of rCLU was a primary aim of this study. The
initial plan was to produce rCLU and then determine if it behaved similarly to wtCLU
with respect to cell binding, internalisation and modulation of the immune response.
However, producing rCLU proved to be very difficult and many different expression
systems and purification protocols were developed (detailed in chapter 3) before success
was achieved. This was not accomplished until after aims 2 and 3 had been effectively
completed. Nevertheless, the chaperone activity of m-rCLU was verified as similar to
that of wtCLU.
To date there has been very little structural analysis of CLU, with the exception of
inferences drawn from CD spectroscopy about its secondary structure content. Ideally,
x-ray crystallography would be undertaken on CLU to definitively elucidate its
structure. This has, however, proved to be very difficult due to CLU being inherently
flexible and heavily glycosylated, and the fact that it forms heterogeneous oligomers in
solution. One rationale to express CLU in bacteria was the possibility that it might yield
an abundant source of a non-glycosylated CLU suitable for x-ray crystallographic
studies. Unfortunately this was unsuccessful, rCLU was contained within inclusion
bodies and it was not possible to refold it into a form with chaperone activity, despite
many refolding methods trialled. The requirement to correctly form 5 intra-molecular
disulphide bonds makes prokaryotic expression of CLU a challenge. It also remains
uncertain whether proteolytic cleavage of CLU into an α- and β-chain (only performed
by eukaryotes) is required for the correct structure and function of CLU.
After many systematic modifications were made to the expression protocol a pure form
of m-rCLU was successful produced using HEK293 cells. The product appeared to be
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correctly folded and post-translationally modified, although it appeared to have less
glycosylation than wtCLU. Chaperone assays using three client proteins confirmed the
chaperone function of m-rCLU, and in future will enable mutagenesis studies to
determine the functional residues and regions within CLU. Currently m-rCLU does not
provide any advantages when compared with wtCLU for the determination of structure
by x-ray crystallography. However, although it is unlikely, if in future a reliable method
for crystallising oligomeric and heavily glycosylated proteins is found, then we could
also test rCLU mutants produced using this expression system for changes in structure.
With collaborators, our laboratory is currently undertaking an x-ray crystallography
study on enzymatically deglycosylated wtCLU. If this proves successful then rCLU
mutants could be prepared in a similar way to determine what residues or regions within
CLU are important for correct structure.
In previous studies of the role of CLU in extracellular proteostasis, complexing CLU to
chaperone client proteins has been shown to enhance the uptake and degradation of the
client protein compared to either CLU or the client protein alone. This has been shown
both in vitro and in vivo (Wyatt 2009; Wyatt et al. 2011). This led us to propose a
model for extracellular proteostasis whereby CLU (and other extracellular chaperones)
are able to bind to and stabilise misfolded extracellular client proteins, and then direct
them for uptake and subsequent degradation by cells (Yerbury et al. 2005b; Wyatt et al.
2009a; Wyatt et al. 2012; Dabbs et al. 2013). Following uptake, CLU may (i) direct the
bound client protein to an intracellular degradation pathway, or (ii) act as an adjuvant to
stimulate an immune response. It is likely that the cell type, the client protein/antigen,
the route of internalisation, and the presence of other stimulatory molecules may all
influence which pathway the CLU-bound protein is directed to. It is also possible that
these pathways may not be mutually exclusive and depending on the local environment
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the CLU-bound protein may be directed to both of these pathways within the cell. Many
cell types have been shown to bind and internalise CLU-client protein complexes
including both APCs and non-APCs (e.g. hepatocytes, monocytes, granulocytes,
macrophages and dendritic cells), although the clearance of CLU-client protein
complexes from the blood is largely performed by the liver in rat models (Wyatt 2009;
Wyatt et al. 2011).
Binding of CLU-OVA to murine bone marrow derived macrophages, human
granulocytes, monocytes and lymphocytes was higher than binding of either CLU or
OVA alone; suggesting that when CLU is associated with another protein, the complex
is more efficiently bound and internalised by receptors. This is further supported by the
studies of Wyatt (2009) which showed that HMW complexes formed between CLU and
GST or fibrinogen were bound to a greater extent by monocytes and granulocytes than
the individual constituent proteins. Complexes formed between CLU and a range of
client proteins were cleared more efficiently from the bloodstream of rats than CLU or
the client proteins alone (Wyatt 2009; Wyatt et al. 2011). This current study, along with
that of Wyatt (2009), implicated scavenger receptors in the binding and internalisation
of CLU-OVA or other CLU complexes. Scavenger receptors are rather promiscuous and
are able to recognise a variety of damaged and modified ligands (Murphy et al. 2005;
Pluddemann et al. 2007). Therefore they may play a role in extracellular proteostasis by
facilitating uptake of a broad range of ligands (including misfolded proteins and
chaperone-protein complexes) into a variety of cells.
The results from chapter 4 of this study suggest that scavenger receptors mediate
the majority of CLU-OVA uptake by bone marrow derived macrophages,
granulocytes, monocytes and to lesser extent lymphocytes. These cell types each
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express a unique repertoire of receptors, including many types of scavenger receptor
(Table 4.5). Scavenger receptors have been reported to play an essential role in the
cross-presentation of intracellular chaperone bound antigen (Delneste et al. 2002; Gong
et al. 2009a; Murshid et al. 2010; Xie et al. 2010). Therefore, it is likely that uptake of
CLU-OVA into APCs via scavenger receptors can also facilitate cross-presentation.
In murine bone marrow derived macrophages, internalised CLU-OVA was found
co-localised with the early endosome compartment; this is similar to the results
found for FITC-labelled-gp96 uptake into murine dendritic cells (Wassenberg et al.
1999; Singh-Jasuja et al. 2000b). The early endosome compartment is known to contain
recycling MHC class I and class II molecules, meaning that the chaperone bound
antigen may be directly loaded onto these molecules within this compartment,
to result in either cross presentation or presentation, respectively (Singh-Jasuja et al.
2000b). Internalised CLU-OVA was also found co-localised with lysosomes of bone
marrow derived macrophages, akin to previously published results which showed that
CLU-client protein complexes co-localised with lysosomes in hepatocytes (Wyatt
2009).
Aim 3 of this thesis studied the immune modulatory potential of CLU, and mainly
focussed on the potential of CLU to mediate a humoral immune response specific to
bound antigen. I also undertook preliminary work with our French collaborators which
suggests that, similar to the effects of some intracellular chaperones, CLU is able to
direct bound antigen to the cross-presentation pathway to stimulate a CTL response;
these experiments need to be repeated, however, to confirm this interpretation.
CLU was able to significantly enhance the humoral immune response to OVA when
they were either chemically linked using an SMCC cross-linker (CLU-OVA) or
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complexed using the chaperone action of CLU (CLU/OVA). In both cases CLU
potentiated a significant OVA-specific IgM and IgG1 isotype immune response in mice.
IgM antibodies play a role in fixing complement and opsonising antigen and are
typically associated with immature immune responses or those mounted against highly
repetitive structures (e.g. carbohydrates) (Heimburg-Molinaro and Rittenhouse-Olson
2009; Schroeder and Cavacini 2010). The production of an IgG response generally
occurs after secondary immunisation with antigen and is associated with a more mature
immune response (Nezlin 1998; Chaplin 2003). Development of an IgG response
enables the immune system to efficiently undertake complement mediated cytolysis and
antibody dependent cell mediated cytotoxicity (Bruggemann et al. 1987). This can
mediate anti-tumour immunity if the antigen is tumour derived (Eisenthal et al. 1987;
Hearing et al. 1991; Ravetch and Kinet 1991), or killing of both intracellular and
extracellular pathogens if the antigen is pathogen derived (Horowitz et al. 1983; Lopez
et al. 1983). The development of a sustained antibody response upon immunisation is
also important for efficacious vaccination against many pathogens including those that
cause tetanus, diphtheria, and tuberculosis (Janeway Jr et al. 2001; Amanna et al. 2007).
Immunisation of mice with a fusion protein between HSP70 and a cancer antigen
resulted in the generation of an antigen specific IgG response ~ 4.5 fold higher than
immunisation with the cancer antigen alone (Ma et al. 2005). In the current study,
immunisation with CLU-OVA or CLU/OVA resulted in significantly higher
OVA-specific IgG1 titres compared to mice immunised with OVA alone (7.7 and 3.5
fold higher, respectively); suggesting that physical association between CLU and the
antigen is able to stimulate an antigen-specific immune response.
The primary focus of the current literature in this area is on the ability of intracellular
chaperones to mediate cross-priming to generate a CTL response specific to the
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chaperone-bound antigen (Basu and Srivastava 2000; Srivastava 2002b; Parmiani et al.
2004; Srivastava 2006). One of the reasons for this focus is that CTL responses are
typically harder to elicit than humoral immune responses and are likely to be important
in killing tumours. There are currently only a few adjuvants approved for clinical use in
humans and these are unable to stimulate a CTL response (Khurana et al. 2010; Mbow
et al. 2010; Garcon et al. 2012; Gruber 2012). Therefore the ability of chaperones to
potentiate both a CTL response and a humoral response to bound antigen is of great
interest. By activating both arms of the immune system, a broader response would be
mounted against the antigen, maximising the effectiveness of the vaccine.
Currently all chaperone vaccines in clinical trials are tumour derived; this limits the
amount of chaperone-peptide vaccine that can be produced (Binder 2006). Considering
vaccine efficacy has been shown to improve with 10 or more injections (Gordon and
Clark 2004; Richards et al. 2006; Binder 2008; Testori et al. 2008; Srivastava et al.
2009), the ability to produce larger amounts of vaccine would be advantageous. Due to
the abundance of CLU in human plasma, it may provide a more readily available source
of chaperone for the development of chaperone-peptide vaccines. Alternatively the
m-rCLU produced in this study may provide an alternative, theoretically unlimited
source of CLU for the development of therapeutics, once its immune stimulatory
efficacy, and the ability to scale up production has been determined.
The injection of mice with CLU, CLU-OVA and CLU/OVA did not produce any
adverse side effects. Clinical trials of intracellular chaperone vaccines have also shown
minimal side effects and are well tolerated overall (Srivastava et al. 2009; Tosti et al.
2009; di Pietro et al. 2011), suggesting that if CLU based vaccines are developed for
use in a clinical setting, they will also be well tolerated. It will be important in future
work to firmly establish whether CLU can potentiate both CTL and antibody responses
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to bound antigen. Once this is done, the path is open to develop CLU as a superior
option for chaperone-peptide based clinical vaccines.
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